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The Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid 
Dependence review the use of medicines such as methadone, buprenorphine, naltrexone 
and clonidine in combination with psychosocial support in the treatment of people 
dependent on heroin or other opioids. Based on systematic reviews of the literature and 
using the GRADE approach to determining evidence quality, the guidelines contain specific 
recommendations on the range of issues faced in organizing treatment systems, managing 
treatment programmes and in treating people dependent on opioids. 
Developed in collaboration with internationally acclaimed experts from the different 
regions of the globe, the Guidelines for the Psychosocially Assisted Pharmacological 
Treatment of Opioid Dependence should be of interest to policy makers, programme 
managers, and clinicians everywhere who seek to alleviate the burden of opioid 
dependence.
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BACKGROUnD TO THe DeVelOPMenT OF THeSe 
GUIDelIneS
These guidelines were developed in response to a 
resolution from the United Nations Economic and Social 
Council (ECOSOC), which invited the World Health 
Organization (WHO), in collaboration with the United 
Nations Office on Drugs and Crime (UNODC), “to develop 
and publish minimum requirements and international 
guidelines on psychosocially assisted pharmacological 
treatment of persons dependent on opioids”[1]. In 
accordance with WHO policy, the recommendations 
in these guidelines are based on systematic reviews of 
the available literature and consultation with a range 
of experts from different regions of the world. The 
GRADE evidence tables summarizing these reviews are 
contained in Annex 1 of this document.
InTenDeD ReADeRSHIP OF THeSe GUIDelIneS
These guidelines are intended to be read by those involved 
in providing psychosocially assisted pharmacological 
treatments at any level. The readership falls into three 
broad groups:
 policy makers and administrators who make •	
decisions on the availability of medicines and the 
structure and funding of services in countries or in 
subnational health administrative regions
 managers and clinical leaders responsible for the •	
organization of specific health-care services, and 
for the clinical care those services provide
 health-care workers treating patients within the •	
health-care system.
ePIDeMIOlOGY OF OPIOID DePenDenCe
UNODC estimates that there are 25 million problem 
drug users in world, of whom 15.6 are problem opioid 
users and 11.1 problem heroin users (approximately 
0.3% of the global population)[2].1
The global epidemic of HIV and acquired immune 
deficiency syndrome (AIDS) is often fuelled and 
maintained by unsafe injection practices, with an 
1 The category of "problem drug user" is generally defined to 
include both dependent users and non dependent drug injectors.
estimated 30% of new cases of HIV outside sub-
Saharan Africa due to unsafe injecting,[5] particularly 
unsafe opioid injecting. The cost of this epidemic is 
counted in the millions of lives lost each year and the 
billions of dollars spent[6]. A comprehensive package of 
interventions to prevent the transmission of HIV must 
include measures to reduce unsafe injecting of opioids, 
including the treatment of opioid dependence[7,11].
As with other chronic conditions, opioid dependence 
tends mostly to follow a relapsing and remitting 
course.
PSYCHOSOCIAllY ASSISTeD PHARMACOlOGICAl 
TReATMenTS
Psychosocially assisted pharmacological treatment refers 
to the combination of specific pharmacological and 
psychosocial measures used to reduce both illicit opioid 
use and harms related to opioid use and improve quality 
of life. While the psychosocial measures are varied, only 
a few specific medications are used for the treatment of 
opioid dependence. 
Opioid agonist maintenance treatment is defined as 
the administration of thoroughly evaluated opioid 
agonists, by accredited professionals, in the framework 
of recognized medical practice, to people with opioid 
dependence, for achieving defined treatment aims[8,9,10. 
Both methadone and buprenorphine are sufficiently 
long acting to be taken once daily under supervision, 
if necessary. When taken on a daily basis they do not 
produce the cycles of intoxication and withdrawal 
seen with shorter acting opioids, such as heroin. Both 
methadone and buprenorphine can also be used in 
reducing doses to assist in withdrawal from opioids, 
a process also referred to as opioid detoxification. 
Methadone and buprenorphine have a strong evidence 
base for their use, and have been placed on the WHO 
model list of essential medicines[8].
A different approach is that of assisting people dependent 
on opioids to withdraw from opioids completely, a 
process also referred to as opioid detoxification. Both 
methadone and buprenorphine can also be used in 
reducing doses to assist in withdrawal from opioids. 
Executive summary
xiExecutive summary
Alpha-2 adrenergic agonists – such as clonidine – can 
also be used for opioid detoxification, to reduce the 
severity of opioid withdrawal symptoms. 
Following detoxification, the long-acting opioid 
antagonist naltrexone can be used to prevent relapse 
to opioids. Naltrexone produces no opioid effects itself, 
and blocks the effects of opioids for 24–48 hours. 
The short-acting opioid antagonist naloxone can be used 
to reverse the effects of opioid intoxication and overdose.
SUMMARY OF eVIDenCe AnD ReCOMMenDATIOnS OF 
THeSe GUIDelIneS
Opioid agonist maintenance treatment
Of the treatment options examined, opioid agonist 
maintenance treatment, combined with psychosocial 
assistance, was found to be the most effective. 
Oral methadone liquid and sublingual buprenorphine 
tablets are the medications most widely used for opioid 
agonist maintenance treatment. In the context of 
high-quality, supervised and well-organized treatment 
services, these medications interrupt the cycle of 
intoxication and withdrawal, greatly reducing heroin 
and other illicit opioid use, crime and the risk of death 
through overdose.
Compared to detoxification or no treatment, methadone 
maintenance treatment (using mostly supervised 
administration of the liquid methadone formulation) 
significantly reduces opioid and other drug use, criminal 
activity, HIV risk behaviours and transmission, opioid 
overdose and all-cause mortality; it also helps to retain 
people in treatment.
Compared to detoxification or no treatment, 
buprenorphine also significantly reduces drug use and 
improves treatment retention.
Methadone compared to buprenorphine for 
opioid agonist maintenance treatment
Comparing the evidence from clinical trials on the 
effectiveness of methadone and buprenorphine 
for opioid agonist maintenance treatment, both 
medications provide good outcomes in most cases. 
In general, methadone is recommended over 
buprenorphine, because it is more effective and 
costs less. However, buprenorphine has a slightly 
different pharmacological action; thus, making both 
medications available may attract greater numbers 
of people to treatment and may improve treatment 
matching.
Use of methadone in maintenance treatment 
The initial methadone dose should be 20mg or less, 
depending on the level of opioid tolerance, allowing a 
high margin of safety to reduce inadvertent overdose. 
The dosage should be then quickly adjusted upwards 
if there are ongoing opioid withdrawal symptoms 
and downwards if there is any sedation. From there, 
the dose should be gradually increased to the point 
where illicit opioid use ceases; this is likely to be in the 
range of 60–120 mg methadone per day. Methadone 
use should be supervised initially. The degree of 
supervision should be individually tailored, and in 
accordance with local regulations; it should balance 
the benefits of reduced dosing frequency in stable 
patients with the risks of injection and diversion of 
methadone to the illicit drug market. Patients should 
be monitored with clinical assessment and drug 
testing. Psychosocial assistance should be offered to 
all patients.
Use of buprenorphine in maintenance 
treatment 
Buprenorphine maintenance treatment should 
commence with a dose that is tailored to the pattern of 
opioid use, including the level of tolerance, the duration 
of action of opioids used and the timing of most recent 
opioid use (usually 4mg). From there, the dose should 
be rapidly increased (i.e. over days) to one that produces 
stable effects for 24 hours; this is generally in the 
range of 8–24 mg buprenorphine per day. Generally, 
if there is continuing opioid use, the dose should be 
increased. Dosing supervision and other aspects of 
treatment should be determined on an individual basis, 
using the same criteria as for methadone maintenance 
treatment. 
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Treatment for withdrawal and prevention of 
relapse
Opioid withdrawal (rather than maintenance treatment) 
results in poor outcomes in the long term; however, 
patients should be helped to withdraw from opioids if 
it is their informed choice to do so. Withdrawal from 
opioids can be conducted either on an outpatient or 
an inpatient basis, using reducing doses of methadone 
or buprenorphine, or alpha-2 agonists. Methadone and 
buprenorphine are the preferred treatments for opioid 
withdrawal, because they are effective and can be used 
in a supervised fashion in both inpatient and outpatient 
settings. Inpatient treatment is more effective, but it 
is also more expensive and is recommended only for 
a minority of patients (e.g. those with polysubstance 
dependence, or medical or psychiatric comorbidity). 
Accelerated withdrawal techniques using opioid 
antagonists in combination with heavy sedation are not 
recommended because of safety concerns.
Use of naltrexone to prevent relapse 
Naltrexone can be useful in preventing relapse in those 
who have withdrawn from opioids, particularly in those 
who are already motivated to abstain from opioid 
use. Following opioid withdrawal, patients who are 
motivated to abstain from opioid use should be advised 
to consider naltrexone to prevent relapse.
PSYCHOSOCIAl TReATMenT
Psychosocial interventions – including cognitive and 
behavioural approaches and contingency management 
techniques – can add to the effectiveness of treatment, 
if combined with agonist maintenance treatment 
and medications for assisting opioid withdrawal. 
Psychosocial services should be made available to 
all patients, although those who do not take up the 
offer should not be denied effective pharmacological 
treatment.
TReATMenT SYSTeMS
In planning treatment systems, resources should be 
distributed in a way that delivers effective treatment to 
as many people as possible. Opioid agonist maintenance 
treatment appears to be the most cost-effective 
treatment, and should therefore form the backbone 
of the treatment system for opioid dependence. 
Countries with established opioid agonist maintenance 
programmes usually attract 40–50% of dependent 
opioid users into such programmes, with higher rates 
in some urban environments. Because of their cost, 
inpatient facilities should be reserved for those with 
specific needs, and most patients wanting to withdraw 
from opioids should be encouraged to attempt opioid 
withdrawal as outpatients. 
eTHICAl PRInCIPleS OF CARe
When treating people with opioid dependence, ethical 
principles should be considered, together with evidence 
from clinical trials; the human rights of opioid-dependent 
individuals should always be respected. Treatment 
decisions should be based on standard principles of 
medical-care ethics – providing equitable access to 
treatment and psychosocial support that best meets 
the needs of the individual patient. Treatment should 
respect and validate the autonomy of the individual, 
with patients being fully informed about the risks and 
benefits of treatment choices. Furthermore, programmes 
should create supportive environments and relationships 
to facilitate treatment, provide coordinated treatment 
of comorbid mental and physical disorders, and address 
relevant psychosocial factors.
ReCOMMenDATIOnS
This section lists all the recommendations contained in 
these guidelines.
Recommendations for action at policy or health-system 
levels are marked as either marked “minimal” or “best 
practice”:
 •	 minimal recommendations are suggested for 
adoption in all settings as a minimum standard; 
these should be considered the minimal 
requirements for the provision of treatment of 
opioid dependence
 •	 best practice recommendations represent preferred 
strategies for achieving the optimal public health 
benefit in the provision of treatment for opioid 
dependence.
xiiiExecutive summary
The document contains recommendations based on 
evidence from systematic reviews and meta-analyses, 
taking into consideration evidence from other sources, 
technical considerations, resource implications and 
the risks and benefits of different alternatives. As 
recommended in the GRADE system, recommendations 
were divided into two strengths, here termed as 
“strong” or “standard” recommendations.
 •	 strong recommendations are those for which:
 most individuals should receive the intervention,  
assuming that they have been informed about 
and understand its benefits, harms and burdens
 most individuals would want the recommended  
course of action and only a small proportion 
would not
 the recommendation could unequivocally be  
used for policy making
 •	 standard recommendations are those for which:
 most individuals would want the suggested  
course of action, but an appreciable proportion 
would not
 values and preferences vary widely 
 policy making will require extensive debates and •	
involvement of many stakeholders.
Some recommendations do not include an indication 
of strength – this means that the recommendation was 
ungraded.
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Summary of recommendations
Recommendations for health systems at national and subnational levels
Minimal requirements Best practice
Treatment 
strategy
A strategy document should be produced outlining 
the government policy on the treatment of opioid 
dependence. The strategy should aim for adequate 
coverage, quality and safety of treatment.
Legal 
framework
Psychosocially assisted pharmacological treatment should not 
be compulsory.
Treatment 
funding and 
availability 
Treatment should be accessible to disadvantaged populations. 
Pharmacological treatment of opioid dependence should be 
widely accessible; this might include treatment delivery in 
primary care settings.  Patients with comorbidities can be 
treated in primary health-care settings if there is access to 
specialist consultation when necessary. 
At the time of commencement of a treatment service, there 
should be a realistic prospect of that service being financially 
viable.
essential pharmacological treatment options should consist 
of opioid agonist maintenance treatment and services for the 
management of opioid withdrawal. At a minimum, this would 
include either methadone or buprenorphine for opioid agonist 
maintenance and outpatient withdrawal management.
To achieve optimal coverage and treatment outcomes, 
treatment of opioid dependence should be provided free 
of charge, or covered by public health-care insurance.
Pharmacological treatment of opioid dependence should 
be accessible to all those in need, including those in 
prison and other closed settings. 
Pharmacological treatment options should consist of 
both methadone and buprenorphine for opioid agonist 
maintenance and opioid withdrawal, alpha-2 adrenergic 
agonists for opioid withdrawal, naltrexone for relapse 
prevention, and naloxone for the treatment of overdose.
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Recommendations for treatment programmes
Minimal requirements Best practice
Clinical governance Treatment services should have a system of clinical 
governance, with a chain of clinical accountability within 
the health-care system, to ensure that the minimal 
standards for provision of opioid dependence treatment 
are being met.
A process of clinical governance should be 
established to ensure that treatments for opioid 
dependence are both safe and effective. The 
process should be transparent and outlined in a 
clinical governance document.
Treatment of opioid dependence should be 
provided within the health-care system.
Consent to treatment Patients must give informed consent for treatment.
Training of staff Treatment of opioid dependence should be carried out 
by trained health-care personnel. The level of training 
for specific tasks should be determined by the level of 
responsibility and national regulations.
Health authorities should ensure that treatment 
providers have sufficient skills and qualifications 
to use controlled substances appropriately. These 
requirements may include postgraduate training 
and certification, continuing education and 
licensing, and the setting aside of funding for 
monitoring and evaluation.
Medical records Up-to-date medical records should be kept for all 
patients. These should include, as a minimum, the history, 
clinical examination, investigations, diagnosis, health 
and social status, treatment plans and their revisions, 
referrals, evidence of consent, prescribed drugs and other 
interventions received.
Confidentiality of patient records should be ensured.
Health-care providers involved in the treatment of 
an individual should have access to patient data in 
accordance with national regulations, as should patients 
themselves. 
Health-care providers or other personnel involved in 
patient treatment should not share information about 
patients with police and other law enforcement authorities 
unless a patient approves, or unless required by law.
Patients treated with opioid agonists should be 
identifiable to treating staff.
Pharmacy records Documented processes should be established to ensure 
the safe and legal procurement, storage, dispensing 
and dosing of medicines, particularly of methadone and 
buprenorphine.
Clinical guidelines Clinical guidelines for the treatment of opioid dependence 
should be available to clinical staff.
Clinical guidelines should be detailed, 
comprehensive, evidence based and developed 
at a country level or lower, to reflect local laws, 
policies and conditions.
Opioid agonist 
maintenance dosing 
policies
To maximize the safety and effectiveness of agonist 
maintenance treatment programmes, policies and 
regulations should encourage flexible dosing structures, 
with low starting doses and high maintenance doses, 
and without placing restrictions on dose levels and the 
duration of treatment.
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Recommendations for treatment programmes
Minimal requirements Best practice
Detoxification 
services
Opioid withdrawal services should be structured 
such that withdrawal is not a stand-alone service 
but is integrated with ongoing treatment options.
Take home doses Take-home doses can be recommended when the 
dose and social situation are stable, and when 
there is a low risk of diversion for illegitimate 
purposes.
Involuntary discharge Involuntary discharge from treatment is justified 
to ensure the safety of staff and other patients, 
but noncompliance with programme rules alone 
should not generally be a reason for involuntary 
discharge. Before involuntary discharge, 
reasonable measures to improve the situation 
should be taken, including re-evaluation of the 
treatment approach used.
Assessment and 
choice of treatment
A detailed individual assessment should be conducted 
which includes: history (past treatment experiences; 
medical and psychiatric history; living conditions; legal 
issues; occupational situation; and social and cultural 
factors, that may influence substance use); clinical 
examination (assessment of intoxication / withdrawal, 
injection marks); and, if necessary, investigations (such as 
urine drug screen, HIV, Hep C, Hep B, TB, liver function). 
Urine drug testing should be available for use at initial 
assessment when a recent history of opioid use cannot 
be verified by other means (e.g. evidence of opioid 
withdrawal or intoxication).
The choice of treatment for an individual should be 
based on a detailed assessment of the treatment 
needs, appropriateness of treatment to meet those 
needs (assessment of appropriateness should be 
evidence based), patient acceptance and treatment 
availability.
Screening for psychiatric and somatic comorbidity 
should form part of the initial assessment.  
Voluntary testing for HIV and common infectious 
diseases should be available as part of an 
individual assessment, accompanied by counselling 
before and after testing.
Ideally, all patients should be tested at initial 
assessment for recent drug use.
Treatment plans should take a long-term 
perspective.
Opioid withdrawal should be planned in 
conjunction with ongoing treatment.
Range of services to 
be offered
essential pharmacological treatment options should 
consist of opioid agonist maintenance treatment and 
services for the management of opioid withdrawal.
naloxone should be available for treating opioid 
overdose.
Pharmacological treatment options should consist 
of both methadone and buprenorphine for opioid 
agonist maintenance and opioid withdrawal, 
alpha-2 adrenergic agonists for opioid withdrawal, 
naltrexone for relapse prevention, and naloxone 
for the treatment of overdose.
Psychosocial support 
availability
Psychosocial support should be available to all opioid-
dependent patients, in association with pharmacological 
treatments of opioid dependence. At a minimum, this 
should include assessment of psychosocial needs, 
supportive counselling and links to existing family and 
community services.
A variety of structured psychosocial interventions 
should be available, according to the needs of the 
patients. Such interventions may include - but are 
not limited to - different forms of counselling and  
psychotherapy, and assistance with social needs 
such as housing, employment, education, welfare 
and legal problems.
xviiExecutive summary
Recommendations for treatment programmes
Minimal requirements Best practice
Onsite psychosocial and psychiatric treatment 
should be provided for patients with psychiatric 
comorbidity.
Availability of 
treatment for 
comorbid medical 
conditions
links to HIV, hepatitis and TB treatment services (where 
they exist) should be provided.
Where there are significant numbers of opioid-
dependent patients with either HIV, hepatitis 
or TB, treatment of opioid dependence should 
be integrated with medical services for these 
conditions.
For patients with TB, hepatitis or HIV and 
opioid dependence, opioid agonists should 
be administered in conjunction with medical 
treatment; there is no need to wait for abstinence 
from opioids to commence either anti-TB 
medication, treatment for hepatitis or antiretroviral 
medication.
Opioid-dependent patients with TB, hepatitis or 
HIV should have equitable access to treatment for 
TB, hepatitis, HIV and opioid dependence.
Availability of 
hepatitis B vaccine
Treatment services should offer hepatitis B 
vaccination to all opioid-dependent patients.
Treatment evaluation There should be a system for monitoring the safety of 
the treatment service, including the extent of medication 
diversion.
There should be intermittent or ongoing evaluation 
of both the process and outcomes of the treatment 
provided.
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Recommendations for treatment of the individual patient
Strength of 
recommendation
Quality of 
evidence
Choice of 
treatment
For the pharmacological treatment of opioid dependence, clinicians should 
offer opioid withdrawal, opioid agonist maintenance and opioid antagonist 
(naltrexone) treatment, but most patients should be advised to use opioid 
agonist maintenance treatment.
Strong low to moderate
For opioid-dependent patients not commencing opioid agonist maintenance 
treatment, consider antagonist pharmacotherapy using naltrexone following 
the completion of opioid withdrawal.
Standard low
Opioid agonist 
maintenance 
treatment
For opioid agonist maintenance treatment, most patients should be advised 
to use methadone in adequate doses in preference to buprenorphine.
Strong High
During methadone induction, the initial daily dose should depend on the 
level of neuroadaptation; it should generally not be more than 20 mg, and 
certainly not more than 30mg.
Strong Very low
On average, methadone maintenance doses should be in the range of 
60–120 mg per day.
Strong low
Average buprenorphine maintenance doses should be at least 8 mg per day. Standard Very low
Methadone and buprenorphine doses should be directly supervised in the 
early phase of treatment.
Strong Very low
Take-away doses may be provided for patients when the benefits of reduced 
frequency of attendance are considered to outweigh the risk of diversion, 
subject to regular review.
Standard Very low
Psychosocial support should be offered routinely in association with 
pharmacological treatment for opioid dependence.
Strong High 
Management 
of opioid 
withdrawal 
For the management of opioid withdrawal, tapered doses of opioid agonists 
should generally be used, although alpha-2 adrenergic agonists may also be 
used.
Standard Moderate
Clinicians should not routinely use the combination of opioid antagonists 
and minimal sedation in the management of opioid withdrawal.
Standard Very low
Clinicians should not use the combination of opioid antagonists with heavy 
sedation in the management of opioid withdrawal.
Strong low
Psychosocial services should be routinely offered in combination with 
pharmacological treatment of opioid withdrawal.
Standard Moderate
Pregnancy Opioid agonist maintenance treatment should be used for the treatment of 
opioid dependence in pregnancy.
Strong Very low
Methadone maintenance should be used in pregnancy in preference to 
buprenorphine maintenance for the treatment of opioid dependence; 
although there is less evidence about the safety of buprenorphine, it might 
also be offered.
Standard Very low
1Scope and purpose
These guidelines have been developed in response to 
the resolution Guidelines for psychosocially assisted 
pharmacological treatment of persons dependent on 
opioids of the United Nations Economic and Social 
Council (ECOSOC). The resolution invited the World 
Health Organization (WHO), in collaboration with 
United Nations Office on Drugs and Crime (UNODC), 
“to develop and publish minimum requirements and 
international guidelines on psychosocially assisted 
pharmacological treatment of persons dependent on 
opioids, taking into account regional developments 
in the field, in order to assist the member states 
concerned”[1].
These guidelines are intended to be read by those involved 
in providing psychosocially assisted pharmacological 
treatment  of opioid dependence at any level. Chapter 2 
explains how the guidelines were formulated, and 
Chapter 3 provides background information on opioid 
dependence. Chapters 4–6 are directed, respectively, 
at the three broad groups for whom this document is 
intended:
policy makers and administrators who make •	
decisions on the availability of medicines, and on 
the structure and funding of services in countries or 
in subnational health administrative regions
managers and clinical leaders responsible for the •	
organization of specific health-care services, and 
for the clinical care those services provide
health-care workers treating patients within the •	
health-care system.
National and regional programmes, and treatment 
guideline groups may wish to use this document to 
assist in the development of locally adapted guidelines.
The clinical questions addressed by these guidelines were 
developed in consultation with clinicians and academics 
from various countries involved in the management of 
opioid dependence. The questions addressed by these 
guidelines can be summarized briefly as:
What medications should be used for the •	
management of opioid dependence and withdrawal? 
Further questions related to this issue are: 
Should preference be given to opioid agonist  
maintenance treatment, detoxification or 
antagonist treatment? 
Which medications should be used for each  
approach? 
 How should medications be administered  
(optimal dose, level of dosing supervision, etc.)?
What level and type of psychosocial support should •	
be provided to opioid-dependent patients?
What specific treatment should be offered •	
to specific groups (e.g. people with human 
immunodeficiency virus (HIV) and pregnant 
women)?
What are the minimal standards for provision of •	
treatment for opioid dependence?
The recommendations in the guidelines operate at three 
levels:
treatment systems at national and subnational •	
levels (policy, legislation, funding, regional and 
country planning) (see Chapter 4)
treatment programmes (methods of organization •	
and provision of care) (see Chapter 5)
treatment of the individual patient (see Chapter 6).•	
Recommendations made at the level of the individual 
patient are based on systematic reviews of clinical trials, 
summarized in Annex 1. Recommendations at the other 
two levels are based on a range of evidence, including 
extrapolation of clinical trial data by experts in the 
guidelines development group, epidemiological studies 
and the principles of medical ethics.
The medications considered in these guidelines are 
methadone, buprenorphine, naltrexone and adrenergic 
alpha-2 agonists (clonidine, lofexidine and guanfacine). 
Although other medications show promise in the 
treatment of opioid dependence, they have not been 
included in these guidelines because there is insufficient 
evidence to make a full analysis of their effectiveness; 
thus, including them would significantly increase the 
complexity of the guidelines. A brief description of 
the pharmacology of these medications is included in 
Annex 4.
The aims of these guidelines are to:
reduce global barriers to the effective treatment of •	
opioid dependence
contribute to the development of evidence-•	
based and ethical treatment policies for opioid 
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dependence
contribute to improvement of the quality of •	
pharmacological treatment of opioid dependence
facilitate implementation of effective treatment •	
policies and programmes for opioid dependence.
The guidelines are not:
a comprehensive guide to opioid dependence or its •	
treatment
a replacement for clinical judgement•	
a description of local regulations for the provision •	
of opioid dependence treatment.
The guidelines cover not only opioid dependence, 
but also treatment of opioid overdose and opioid 
withdrawal.
3Method of formulation of recommendations
The WHO Guidelines for the Psychosocially Assisted 
Pharmacological Treatment of Opioid Dependence were 
prepared according to the WHO Guidelines for WHO 
Guidelines (2003)[12], modified as necessary to provide 
advice:
on many complex clinical questions for which •	
evidence is lacking
even in the absence of high-quality evidence.•	
A group of technical experts – international scientists 
with expertise in opioid dependence and clinical 
guidelines development – was convened in 2005, and 
again in 2006 and 2007. The membership of this group 
is detailed in the acknowledgements section. In their 
first meeting, the group defined the key questions to 
be addressed by the guidelines. For each key clinical 
question, the literature was searched for recent 
systematic reviews on the topic. Where a Cochrane 
review2 existed, that review was used in preference 
to other reviews. Where no suitable systematic review 
existed, a review was conducted.
At its meeting in 2006, the group assessed the evidence 
and formulated recommendations. The quality of the 
evidence was assessed according to the methodology 
described by the GRADE working group[13]. This 
approach involves assessing the quality of evidence 
on a particular question, taking into consideration the 
magnitude of the effect, the relevance of the data to 
the clinical question being asked, the sample size in the 
relevant trials, the methodology of the trials and the 
consistency of the findings. At the start of this process, 
each health outcome was rated from 1 to 9, according 
to its importance. The GRADE convention on the rating 
of outcomes is as follows:
ratings of 7–9 are for critical health outcomes•	
ratings of 4–6 are for outcomes that are considered •	
important but not critical to the decision; they 
should be used in judgements about tradeoffs 
and recommendations, but not in judgements 
about the overall quality of evidence across critical 
outcomes
ratings of 1–3 are generally removed from •	
the evidence profile and are not considered in 
2  http://www.cochrane.org/
judgements about the overall quality of evidence, 
tradeoffs or recommendations.
In some instances, additional meta-analyses were 
conducted from the systematic review data:
to exclude non-randomized controlled trials (non-•	
RCTs) (where Cochrane reviews had included non-
randomized trials)
to reverse some outcomes and thus maintain •	
outcome consistency (e.g. using “drop out” as the 
primary outcome measure of retention rather than 
“still in treatment”)
to reverse the order of the comparisons, where •	
necessary (e.g. methadone versus buprenorphine 
instead of buprenorphine versus methadone).
to examine an additional outcome of interest (e.g. •	
the addition of seroconversion as an outcome 
measure in the review of opioid agonist treatment 
and HIV). 
In the GRADE system, evidence is classified as “high”, 
“moderate”, “low” or “very low”. Definitions are as 
follows:
High•	  – Further research is very unlikely to change 
confidence in the estimate of effect.
Moderate•	  – Further research is likely to have an 
important impact on confidence in the estimate of 
effect and may change the estimate.
Low•	  – Further research is very likely to have  
an important impact on confidence in the  
estimate of effect and is likely to change the 
estimate.
Very low•	  – Any estimate of effect is very uncertain.
The resulting evidence profiles are listed in Annex 1.
To produce a series of recommendations, the technical 
experts considered the evidence from these reviews 
and meta-analyses, taking into consideration evidence 
from other sources, technical considerations, resource 
implications and the risks and benefits of different 
alternatives.
The strength of each recommendation is based on 
considerations of the effectiveness of the intervention, 
the strength of the evidence, the resource implications, 
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the balance between benefits and harms, and a 
consideration of ethical implications. As recommended 
in the GRADE system, recommendations are divided into 
two strengths, here termed as “strong” or “standard” 
recommendations. 
“Strong” recommendations can be interpreted as 
follows:
Most individuals should receive the intervention, •	
assuming that they have been informed about and 
understand its benefits, harms and burdens.
Most individuals would want the recommended •	
course of action and only a small proportion would 
not.
The recommendation could unequivocally be used •	
for policy making.
“Standard” recommendations can be interpreted as 
follows:
Most individuals would want the suggested course •	
of action, but an appreciable proportion would not.
Values and preferences vary widely.•	
Policy making will require extensive debates and •	
involvement of many stakeholders.
Some recommendations do not include an indication 
of strength – this means that the recommendation is 
ungraded.
A draft of the guidelines was circulated for feedback in 
July 2007 to selected organizations, WHO departments 
and regional offices, and WHO collaborating centres; it 
was also provided to individuals on request. This draft, 
along with received submissions, was considered at the 
third meeting in September 2007. 
These guidelines are likely to require updating in the 
near future, given the pace of research in this field, the 
multitude of alternative treatments not considered here 
and the relatively scant published experience to date 
in less resourced countries. The recommendations are 
therefore expected to remain valid for the next three 
years only.
The WHO Department of Mental Health and Substance 
Abuse will take responsibility for updating these 
guidelines. 
Policy and programme-level recommendations are based 
on the evidence from the GRADE process, combined 
with other evidence not reviewed systematically, 
including the opinion of the members of the technical 
expert group. Consequently, there are no GRADE 
tables corresponding to the recommendations in these 
sections.
2.1 Conventions for reporting clinical 
trial data
Clinical trial data are summarized in these guidelines. 
When comparing outcomes classed as categorical 
variables (e.g. mortality, retention in treatment or 
abstinence from opioids), the relative risk is used 
(RR). The relative risk is the ratio of the probability of 
a particular outcome in the population exposed to a 
particular intervention or risk factor, compared to the 
probability of that outcome occurring without exposure 
to the risk factor or intervention. For example, if an RCT 
compared a group of heroin users on methadone with a 
group assigned to detoxification, and found that those 
in the methadone group had a relative risk of heroin use 
of 0.32, this would mean that, on average, people with 
opioid dependence are approximately one third as likely 
to be using heroin if they are treated with methadone 
than if they undergo opioid detoxification.
For continuous variables (e.g. the severity of opioid 
withdrawal, or the number of opioid-positive urine 
tests for each study participant), the standardized 
mean difference (SMD) or weighted mean difference 
is used with a meta-analysis. The standardised mean 
difference, used for non-comparable scales, is the 
difference between two means, divided by an estimate 
of the within-group standard deviation. The weighted 
mean difference is used for comparable scales.
The 95% confidence interval (CI) for a relative risk or 
mean difference expresses the range that is highly likely 
(i.e. 19 times out of 20) to contain the true relative risk 
or mean difference, based on the data available. For 
example, the 95% confidence interval for the relative 
risk of dying in the follow-up period if randomly 
allocated to methadone compared to detoxification is 
0.29 to 0.48; this implies that there is a 95% chance 
that the true relative risk lies in this range.
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3.1 Opioid dependence
Opioid dependence is characterized by a cluster of 
cognitive, behavioural and physiological features. The 
International Classification of Diseases, 10th edition 
(ICD-10)[14] identifies six such features: 
a strong desire or sense of compulsion to take •	
opioids
difficulties in controlling opioid use•	
a physiological withdrawal state•	
tolerance•	
progressive neglect of alternative pleasures or •	
interests because of opioid use
persisting with opioid use despite clear evidence of •	
overtly harmful consequences.
ICD-10 defines opioid dependence as the “presence of 
three of more [of these features] present simultaneously 
at any one time in the preceding year” (see Annex 3 for 
more details).
Opioid dependence does not develop without a period 
of regular use, although regular use alone is not 
sufficient to induce dependence.
3.2 Neurobiological aspects of opioid 
dependence
Repeated opioid use induces a series of 
neuroadaptations in various neuronal circuits in 
the brain that are involved in motivation, memory, 
behaviour control and disinhibition. The result is an 
increased and long-lasting reward value associated 
with the use of opioids and the environmental cues 
associated with such use, and a decreased reward 
value associated with natural reinforcers encountered 
in everyday life events[15].
Recent decades have seen a substantial increase in 
our understanding of the neurobiological aspects 
of substance dependence[9]. We now know that 
certain parts of the brain have an important role 
in regulating pleasurable behaviours, and that 
neuronal pathways to and from these areas form 
so-called “reward circuits”. They are located within 
the mesocorticolimbic dopamine systems originating 
in the ventral tegmental area, projecting to the 
nucleus accumbens, amygdala, and prefrontal cortex 
area[16].
In the 1970s and 1980s, the existence of multiple opioid 
receptors was reported, and further pharmacological 
research suggested the classification of opioid binding 
sites into three receptor classes, referred to as mu, delta 
and kappa receptors[17, 18]. Since then, our understanding 
has further developed and we now know that opioid 
receptors belong to the family of G-protein coupled 
receptors, and that each receptor class has several 
subtypes[19].
The opioid effects of analgesia, euphoria and sedation 
are mediated primarily by the mu receptor. Opioids 
induce dopamine release indirectly by decreasing 
gamma-aminobutyric acid (GABA) inhibition via mu 
receptors in the ventral tegmental area[20, 21, 22]. They also 
induce dopamine release directly, by interacting with 
opioid receptors in the nucleus accumbens[23, 24].
The effect of chronic opioid exposure on opioid receptor 
levels has not been well defined in humans. Tolerance 
develops through multiple mechanisms, including an 
acute desensitization of the opioid receptor (which 
develops within minutes of opioid use and resolves 
within hours after use), and a long-term desensitization 
of the opioid receptor (which persists for several days 
after removal of opioid agonists). Changes also occur 
in the number of opioid receptors[25], and there is 
compensatory up-regulation of the cyclic adenosine 
monophosphate (cAMP) producing enzymes. When 
the opioid is withdrawn, the cAMP cascade becomes 
overactive, leading to the “noradrenergic storm” seen 
clinically as opioid withdrawal, which may create a drive 
to reinstate substance use. The intensely dysphoric 
withdrawal syndrome is characterized by watery eyes, 
runny nose, yawning, sweating, restlessness, irritability, 
tremor, nausea, vomiting, diarrhoea, increased blood 
pressure, chills, cramps and muscles aches; it can last 
seven days or even longer.
Long-term changes in neuronal circuitry, similar to 
those seen in learning and memory, can occur as a 
result of repeated opioid use. This effect creates a high 
risk of relapse to opioid use even after long periods of 
abstinence[26].
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3.3 Epidemiology of illicit opioid use 
and dependence
Opioid dependence is a worldwide health problem that 
has enormous economic, personal and public health 
consequences. There are an estimated 15.6 million 
illicit opioid users in the world, of whom 11 million use 
heroin[2]. Opioids are the main drugs of abuse in Asia, 
Europe and much of Oceania, and it is estimated that 
globally the consumption of the opioid class of drugs is 
increasing[2].
3.4 Harms associated with opioid use
Injecting drug use has been strongly associated with 
HIV, accounting for 30% of HIV infections outside 
sub-Saharan Africa, and up to 80% of cases in some 
countries in eastern Europe and central Asia[5]. Once 
it enters a drug-using population, HIV can spread 
rapidly, and new epidemics of HIV infection mediated 
by intravenous drug use are occurring in sub-Saharan 
Africa[2]. Despite this situation, measures that prevent 
the spread of HIV in IDU, including opioid agonist 
maintenance treatment, have less than 5% coverage 
worldwide[27].
Unsafe injecting practices associated with injecting drug 
use have also led to a global epidemic of hepatitis C. 
An estimated 130 million people are infected with 
hepatitis C, with 3–4 million people newly infected each 
year[28]. Unsafe injection practices are the main route of 
transmission, accounting for an estimated 90% of new 
hepatitis C infections.
In countries with a low prevalence of HIV, opioid-
dependent individuals have been found to have an 
annual mortality of 2–4% per annum, or 13 times that 
of their peers[29]. This increased mortality is primarily 
due to overdoses, violence, suicide, and smoking and 
alcohol-related causes[30, 31, 32]. In countries with high HIV 
prevalence, acquired immunodeficiency syndrome (AIDS) 
also makes a significant contribution to mortality[33].
Opioid dependence per se is associated with a significant 
reduction in quality of life as meaningful activities 
become replaced by time spent intoxicated or seeking 
opioids[34]. In addition to medical comorbidity associated 
with injecting drug use and violence, illicit opioid users 
have high rates of psychiatric comorbidity – in particular, 
depression and post-traumatic stress disorder[35].
3.5 Economic consequences of opioid 
use
Opioid dependence imposes a significant economic 
burden on society, not only in terms of directly 
attributable health-care costs (e.g. treatment and 
prevention services, and other health-care use), but 
also in terms of its impact on other budgets (notably 
social welfare and criminal justice services). Opioid 
dependence also has an effect on productivity, due to 
unemployment, absenteeism, and premature mortality.
Studies in industrialized countries have attempted to 
place an economic value on the aggregate impact of 
these consequences, with findings of from 0.2 to 2% of 
a country’s gross domestic product (GDP)[36, 37, 38]. 
3.6 Natural history of opioid 
dependence
Cohort studies of dependent illicit opioid users show 
that although a significant proportion (10–40%) are 
abstinent at follow-up, most continue to use illicit 
opioids[39, 40, 41, 42]. Contact with treatment is one factor 
associated with recovery from opioid dependence; other 
factors include personal motivation, religion, spirituality, 
family and employment[41].
3.7 Opioid dependence as a medical 
condition
Historically, opioid dependence was often seen as a 
disorder of willpower, reflecting poorly on the character 
of an individual. However, with recent advances in the 
understanding of the biological mechanism behind 
dependence and its implications, it has now been widely 
accepted that, regardless of the reasons for opioid 
use, the neurological changes that occur with opioid 
dependence constitute a brain disorder. Therefore, 
opioid dependence can be considered as a medical 
condition, with complex sociological and individual 
determinants. Opioid dependence is characterized by 
a series of symptoms that have long-term prognostic 
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implications, and for which treatment options now 
exist[9]. 
3.8 Treatment of opioid dependence
Treatment of opioid dependence is a set of 
pharmacological and psychosocial interventions aimed 
at:
reducing or ceasing opioid use•	
preventing future harms associated with opioid use•	
improving quality of life and well-being of the •	
opioid-dependent patient.
Treatment of drug dependence can serve a multitude of 
purposes. Beyond reductions in drug usage, it can help 
the drug user to see his or her problems from a different 
perspective, improve self-reliance, and empower the 
individual to seek and effect changes in their life; it can 
even confer self-esteem and give hope. At the same 
time, it can provide access to physical and psychiatric 
care and social assistance, and provide for the needs of 
the patient’s family as well as those of the patient.
In most cases, treatment will be required in the long term 
or even throughout life. The aim of treatment services 
in such instances is not only to reduce or stop opioid 
use, but also to improve health and social functioning, 
and to help patients avoid some of the more serious 
consequences of drug use. Such long-term treatment, 
common for many medical conditions, should not be 
seen as treatment failure, but rather as a cost-effective 
way of prolonging life and improving quality of life, 
supporting the natural and long-term process of change 
and recovery.
Broadly speaking, there are two pharmacological 
approaches to opioid dependence treatment – those 
based on opioid withdrawal and those based on agonist 
maintenance.
3.8.1 MAnAGeMenT OF OPIOID WITHDRAWAl
Pharmacological management of opioid withdrawal is 
usually by one of the following:
gradual cessation of an opioid agonist (i.e. •	
methadone)
short-term use of a partial agonist (i.e. •	
buprenorphine)
sudden opioid cessation and use of alpha-2 •	
adrenergic agonists to relieve withdrawal 
symptoms. 
In practice, most patients resume opioid use within six 
months of commencing opioid withdrawal[43, 44]; the 
implication being that a single detoxification episode 
should not be promoted as effective treatment. 
3.8.2 AGOnIST MAInTenAnCe TReATMenT
Agonist maintenance treatment usually consists of daily 
administration of an opioid agonist (e.g. methadone) 
or a partial agonist (e.g. buprenorphine). The resulting 
stable level of opioid effect is experienced by the 
dependent user as neither intoxication nor withdrawal, 
but more as “normal”. The aims of agonist maintenance 
treatment include:
reduction or cessation of illicit opioids•	
reduction or cessation of injecting and associated •	
risk of bloodborne virus transmission 
reduction of overdose risk•	
reduction of criminal activity •	
improvement in psychological and physical health. •	
In practice, most patients commencing opioid agonist 
treatment will cease heroin or use it infrequently, with 
only 20–30% reporting ongoing regular heroin use[43, 45]. 
However, relapse to heroin use following the cessation 
of agonist maintenance treatment is common[46, 47, 48]and 
research is lacking on when, who and how to withdraw 
from opioid agonist maintenance treatment.
3.8.4 PSYCHOSOCIAl ASSISTAnCe
Psychosocial assistance in the treatment of opioid 
dependence refers to the many ways in which 
professional and non-professional members of society 
can support the psychological health and the social 
environment of the opioid user, to help improve both 
the quality and duration of life. Assistance can range 
from the simple (e.g. provision of food and shelter) to 
the complex (e.g. structured psychotherapy); this topic 
is discussed in Chapter 6.
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The WHO constitution[49] defines health as “a state of 
complete physical, mental and social well-being and 
not merely the absence of disease or infirmity”. It goes 
on to state that the enjoyment of the highest attainable 
standard of health is one of the fundamental rights 
of every human being, without distinction of race, 
religion, political belief, economic or social condition. 
The constitution also states that the health of all 
peoples is fundamental to the attainment of peace and 
security, and is dependent upon the fullest cooperation 
of individuals and states. Similarly, the Ottawa charter[50] 
outlines the link between health and broader social 
policy and health systems, highlighting the importance 
of actions at the health-system level.
These guidelines contain two levels of recommendations 
for action at the health-system level – “minimal” and 
“optimal”. Recommendations marked “minimal” are 
suggested for adoption in all settings as a minimum 
standard; they should be considered the minimal 
requirements for the provision of treatment of opioid 
dependence. Recommendations marked “optimal” 
represent best practice strategies for achieving the 
maximal public health benefit in the provision of 
treatment for opioid dependence.
4.1 International regulations
Nations operate within an international regulatory 
framework; and methadone and buprenorphine are 
medicines under international control. The Single 
Convention on Narcotic Drugs, 1961 (as revised by the 
1972 protocol) and the Convention on Psychotropic 
Substances, 1971, outline specific control requirements 
for those substances (details of requirements of these 
conventions are given in Annex 7). The conventions also 
include the requirement to make treatment available 
for people who are dependent upon narcotic drugs 
or psychotropic substances. The two main objectives 
of these conventions are to make narcotic drugs and 
psychotropic substances (including opioids) available 
for medical and scientific purposes, and to prevent their 
diversion for other purposes. 
Responsible authorities should familiarise themselves 
with the international and legal regulations for the 
procurement, distribution, storage and prescription 
of opioids. If a country does not have regulations 
concerning the dispensing of agonist maintenance 
medications and provision of interventions, then 
these should be developed in accordance with the 
relevant conventions. The laws and regulations should 
enable prescribed methadone and buprenorphine to 
be dispensed – either under supervision or as take-
home doses – from accessible dispensing points, while 
preventing diversion for non-medical use.
Treatment providers should familiarize themselves with 
the national and subnational requirements, and ensure 
that the treatment provided is consistent with relevant 
laws and regulations.
International agreements that outline responsibilities 
for the protection of human rights are also relevant to 
opioid treatment (see ethical issues, below).
4.2 Opioid dependence as a health-
care issue
Substance dependence per se should be regarded as a 
health problem and not a legal one. Given the multiple 
medical problems associated with opioid dependence 
and the nature of pharmacological treatment, provision 
of pharmacological treatment for opioid dependence 
should be a health-care priority. This is encouraged in 
the Single Convention on Narcotic Drugs, 1961, which 
encourages parties to give special attention to, and 
take all practicable measures for, the prevention and 
treatment of the abuse of narcotic drugs. The convention 
also stipulates that treatment may be made available 
as an alternative to conviction or punishment (or in 
addition to them) to those people with substance-use 
disorders who have committed punishable offences.
4.3 National treatment policy
When a treatment system is developed in any country, 
it should be planned as part of the community’s 
overall resources for dealing with health and 
social problems (WHO Expert Committee 30th 
Report).[10, 50]
The policy should outline the approach to preventing 
and treating the problems of opioid dependence. It 
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should be based on epidemiological data, the evidence 
for effectiveness of interventions, the resources of the 
country and the values of the society.
Estimating treatment need is important for 
planning treatment services, and for reviewing 
the accessibility of services to different population 
groups. Estimating the number of opioid-dependent 
people in a population from household surveys is 
difficult due to their under representation in large-
scale epidemiological surveys. Alternative techniques 
that can be more effective are capture–recapture, 
back projection and multiplier methods[51]. WHO has 
produced guidance on how to estimate the number 
of opioid-dependent people[52].
Treatment need can also be estimated using systems 
that monitor treatment, including the demand for 
first-time treatment. However, some populations may 
be underrepresented in estimates of those seeking 
treatment; such groups include women, the young, 
street children, refugees, the poor and minority ethnic 
and religious groups.
Collecting data on the number of patients treated 
with each type of treatment can be useful. Data on 
numbers in opioid agonist maintenance treatment can 
be gathered from treatment centres or pharmacies 
dispensing methadone and buprenorphine, either in 
real time or on an intermittent basis. Gathering data 
on numbers of people treated for opioid withdrawal is 
more difficult, and requires coordination of data from 
residential facilities, outpatient specialist services and 
primary care. A relatively inexpensive way to evaluate 
long-term outcomes is to link data records with 
population registries (mortality).
A needs assessment is a formal systematic attempt to 
determine important gaps between what services are 
needed and those that are currently being provided. 
The assessment involves documenting important gaps 
between current and desired outcomes, and then 
deciding in which order those gaps should be closed.
When planning and developing pharmacological 
treatment for people with opioid dependence, the 
scope of present and potential public health problems 
associated with opioid dependence and current 
treatment coverage should be considered.
Recommendation (Best Practice)
A strategy document should be produced outlining the 
government policy on the treatment of opioid dependence. 
The strategy should aim for adequate coverage, quality and 
safety of treatment.
4.4 Ethical issues
4.4.1 COMPUlSORY AnD COeRCeD TReATMenT
In line with the principle of autonomy, patients 
should be free to choose whether to participate in 
treatment, unless another ethical principle overrides 
this. The principle of autonomy may be overridden, 
for example, when a person is incapacitated by a 
mental illness and can no longer care for themselves, 
or when a person poses a risk to others. Most 
countries have mental health legislation to this 
effect, which can be applied to patients with opioid 
dependence if necessary. However, in most cases, 
those who have lost control over opioid use are not 
necessarily considered to have lost the ability to care 
for themselves in other ways.
In situations where opioid-dependent individuals are 
convicted of crimes related to their opioid use, they 
may be offered treatment for their opioid dependence 
as an alternative to a penal sanction. Such treatment 
would not be considered compulsory unless the 
punishment for refusing or failing treatment were 
more severe than the penal sanction it replaced. 
Similarly, legal proceedings can be a delayed until after 
a period of treatment, so that the effects of treatment 
can be taken into account. Such programmes, which 
divert opioid-dependent patients away from the 
criminal justice system, can also be implemented 
on arrest or before trial. These programmes are 
sometimes called diversion programmes (the use of 
the term “diversion” here should not be confused 
with its use in “diversion of treatment medication”, 
which is described elsewhere). Evaluations of diversion 
programmes show high rates of successful treatment 
and low rates of recidivism[53, 54].
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Recommendation (Minimum standard) 
Psychosocially assisted pharmacological treatment should 
not be compulsory.
4.4.2 CenTRAl ReGISTRATIOn OF PATIenTS
Patients should have the right to privacy. Confidentiality 
should be considered when contemplating setting 
up systems of central registration of patients. Central 
registration has advantages, in that it:
prevents patients from receiving methadone or •	
buprenorphine from more than one source
can be used to limit access to other controlled •	
medicines requiring central approval, such as other 
opioids
can provide more accurate data on treatment •	
numbers than situations where central registration 
is not used. 
However, central registration can facilitate breaches of 
privacy, and this may deter some patients from entering 
treatment. It can also delay the commencement of 
treatment.
Safe and effective treatment of opioid dependence can 
be achieved without central registration. Because such 
registration could cause harm if privacy is breached, 
it should only be used if government agencies have 
effective systems for maintaining privacy. 
4.5 Funding
In each national situation, funding and equitable access 
to treatment should be assured for the treatment 
approaches that are appropriate. In general, this means 
making the most cost-effective treatment widely 
available and accessible.
The cost to patients of treatment for opioid dependence 
also influences the outcomes of treatment. If costs 
are excessive, treatment will not be accessible to 
disadvantaged populations. Many opioid-dependent 
patients have difficulty paying for treatment and are 
not covered by health-insurance schemes. Where 
patients have to pay for treatment, retention rates and 
health outcomes are worse than where treatment is 
free[55]. Even small financial costs for treatment can be a 
significant disincentive. 
Costing mechanisms for treatment can have unintended 
consequences. For example, if higher doses of 
methadone and buprenorphine cost more than lower 
doses, patients may opt for too low a dose, resulting in 
poorer outcomes. In contrast, if patients pay the same 
price regardless of the dose, they may overstate their 
needs and sell their excess supply, which in turn  may 
make staff reluctant to increase the medication dose 
when patients request it. 
The cost of dispensing the medication is also relevant. 
If patients pay a dispensing fee to a pharmacist or clinic 
each time they collect their medication, they may collect 
their medication less frequently. 
Although it is impossible to avoid all perverse incentives 
(i.e. those that have unintended and undesirable 
effects), making treatment both free and accessible will 
minimize them.
Where a country has a public universal health-care 
system, this should include access to opioid dependence 
treatment. Where a country has an insurance system, 
this should again include access to opioid dependence 
treatment, recognizing that long-term treatment will be 
needed in many cases.
Another aspect of treatment funding is sustainability. In 
many cases, pilot funding is used to launch treatment 
of opioid dependence. However, it is not appropriate 
to use short-term funding for long-term agonist 
maintenance treatment without a realistic prospect of 
people in treatment being able to access continuing 
pharmacotherapy at the end of the pilot phase.
The development and maintenance of opioid treatment 
services evidently needs to take place within the 
broader system of health-care financing and provision 
in a given country. An understanding of the way that 
health funds are raised and allocated in a country is 
therefore important for the appropriate planning of 
opioid treatment services. One particularly important 
potential barrier to treatment in many countries with 
relatively low resources is the reliance on private, out-
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of-pocket spending by households as the primary 
mechanism for paying for health care. Tax-based public 
health-insurance schemes provide a more equitable 
mechanism for paying for health services, as well as a 
more suitable basis for developing and sustaining opioid 
treatment services at the population level.
Determining the total resources and associated costs 
needed to initiate and maintain a treatment service 
for opioid dependence should be a key element of 
strategic planning. Although cost estimates have been 
produced for a range of opioid-dependence treatment 
programmes [56, 57, 58, 59, 60, 61, 62, 63], they are largely 
restricted to the context of high-income countries, 
where costs and levels of funding for health may differ 
markedly from those found in low and middle-income 
countries. For example, although estimates of required 
staff will figure prominently in any resource-planning 
exercise, the costs of this labour may not represent 
such a large component of total cost in low and 
middle-income countries (due to lower salary levels); 
in contrast, the costs of purchasing and distributing 
medication, and of fuel, utilities and equipment may 
take up a relatively greater share of costs in such 
countries. WHO has methods and tools that can be 
used to assist such resource planning and programme 
costing at the national level[64].
Recommendation (Minimum standard) 
Treatment should be accessible to disadvantaged 
populations.
Recommendation (Minimum standard) 
At the time of commencement of treatment services, there 
should be a realistic prospect of the service being financially 
viable.
Recommendation (Best Practice)
To achieve optimal coverage and treatment outcomes, 
treatment of opioid dependence should be provided free of 
charge, or covered by public health-care insurance.
4.6 Coverage
Pharmacological treatment of opioid dependence 
should be accessible to all those in need, including those 
in prison (the efficacy of opioid agonist maintenance 
treatment is well documented in this setting) and other 
closed settings[65, 66, 67]. Interruptions to opioid agonist 
maintenance treatment while patients are moving in 
and out of custodial settings should be avoided.
Treatment programmes should be designed to be 
as accessible as possible; for example, programmes 
should be physically accessible, open at convenient 
times, have no undue restrictions on accessibility, and 
have the capacity to be expanded to accommodate 
likely demand. A programme should provide adequate 
facilities and should have opening hours that allow 
staff and patient confidentiality and safety, adequate 
and accessible dispensing facilities, and safe and secure 
storage of medications.
Recommendation (Minimum standard) 
Pharmacological treatment of opioid dependence should be 
widely accessible; this might include treatment delivery in 
primary care settings. Comorbid patients can be treated in 
primary health-care settings if there is access to specialist 
consultation when necessary.
Recommendation (Best Practice)
Pharmacological treatment of opioid dependence should be 
accessible to all those in need, including those in prison and 
other closed settings.
4.6.1 PRIMARY CARe
Integration of opioid dependence treatment into 
primary care is one way to increase accessibility, 
although it may not be possible in all settings. Primary 
care practitioners will usually need support from 
the specialist system, through mentoring, training, 
consultation and referral. With such support, patients 
with quite complex comorbidity can be safely managed 
in primary care.
Opioid agonist maintenance treatment, opioid 
withdrawal services and relapse prevention services can 
all be provided in primary care settings, given the right 
conditions. 
Several clinical trials of opioid agonist maintenance 
treatment have been conducted in primary care 
settings[68, 69, 70]. Use of general practitioners for opioid 
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agonist maintenance treatment significantly increases 
the capacity of the service, and treatment numbers 
have increased rapidly in countries that have adopted 
this approach[71]. Treatment in primary care also has 
the advantage of integrating addiction medical and 
psychiatric services into mainstream services, reducing 
the stigma of addiction and the professional isolation 
of medical staff. Integration also reduces some of the 
problems that clinics can develop when large numbers of 
patients on opioid agonist maintenance are aggregated. 
Within the clinic setting, interaction between patients 
can lead to drug dealing and an antitherapeutic milieu. 
Outside the clinic, the congregation of drug users can 
become a visible target for members of the public 
who do not approve of opioid agonist maintenance 
treatment.
Opioid withdrawal and relapse prevention services can 
also be provided in primary care, with similar efficacy as 
specialist clinics but at lower cost[72, 73].
4.6.2 PRISOnS
Prisoners should not be denied adequate health care 
because of their imprisonment. This would normally 
imply that the treatment options available outside prison 
should also be available in prison. Opioid withdrawal, 
agonist maintenance and naltrexone treatment should 
all be available in prison settings, and prisoners should 
not be forced to accept any particular treatment.
Opioid agonist treatment in prisons
The benefits of opioid agonist maintenance in prisons 
include less injecting drug use while in prison, increase 
in uptake of treatment on leaving prison, and reduction 
of rates of return to prison. Potential harms include 
diversion of medication, and spread of HIV through 
injection of diverted medication using contaminated 
injecting equipment. Because of these potential harms, 
unsupervised doses are generally not appropriate in 
prison settings. Rates of diversion of methadone are 
low, even in prison settings, and can be reduced further 
by diluting the methadone and by keeping methadone 
patients separate from other prisoners for 30 minutes 
after dosing. 
Because it is a sublingual tablet that can take up to 
15 minutes to dissolve, buprenorphine is difficult to 
supervise in prison settings, sometimes resulting in 
pressure on patients from other prisoners to divert their 
medication for injection[74]. Methods to increase the 
effectiveness of supervision include crushing the tablet, 
filming dosing, ensuring the hands remain behind 
the back of the patient during dosing and inspecting 
the mouth after dosing. If effective supervision of 
buprenorphine is difficult, it may be better to use 
methadone instead.
Policy makers and prison administrators should ensure 
appropriate links between prison health services and 
agonist maintenance treatment outside prison. Even 
small gaps in the continuity of treatment are distressing 
for the patient and risk the person relapsing to illicit 
opioid use. Therefore, opioid agonist maintenance 
treatment should be continuous on leaving prison. This 
means coordinating the day of discharge from prison 
with the day of commencement of opioid agonist 
treatment outside prison.
Patients not in treatment in prison should be given the 
opportunity to start methadone or buprenorphine in 
prison, even if they have only a short period of their 
sentence left to complete. Commencement of opioid 
agonist maintenance treatment in prison reduces the 
high risk of overdose and death on leaving prison, and 
reduces reincarceration rates.
4.7 What treatments should be 
available?
If countries are able to afford it, it is best to have both 
methadone and buprenorphine available for opioid 
agonist maintenance treatment. Having both treatments 
means that patients who experience adverse effects from 
one of the medications, or fail to respond, can try the 
alternative. This situation may increase the proportion 
of people with opioid dependence staying in opioid 
agonist treatment; it may also increase the effectiveness 
of treatment, through better matching of treatment and 
patient. The additional availability of alpha-2 adrenergic 
agonists for opioid withdrawal increases the options for 
those who wish to withdraw as quickly as possible or 
who wish to commence naltrexone after withdrawal. 
The availability of naltrexone after withdrawal is also a 
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valuable additional option, because it gives a lower rate 
of relapse.
Recommendation (Minimum standard)
Essential pharmacological treatment options should consist 
of opioid agonist maintenance treatment and services for 
the management of opioid withdrawal. At a minimum, 
this would include either methadone or buprenorphine for 
opioid agonist maintenance and outpatient withdrawal 
management.
Recommendation (Best Practice)
Pharmacological treatment options should consist of 
both methadone and buprenorphine for opioid agonist 
maintenance and opioid withdrawal, alpha-2 adrenergic 
agonists for opioid withdrawal, naltrexone for relapse 
prevention , and naloxone for the treatment of overdose.
4.8 Supervision of dosing for 
methadone and buprenorphine 
maintenance 
This section should be read with the section on opioid 
agonist maintenance treatment (Section 6.4). Without 
supervision of dosing, methadone and buprenorphine are 
likely to be diverted for illicit use, giving rise to problems 
of overdose, injection and spread of bloodborne viruses. 
However, supervision of every dose is severely restrictive 
to patients, and limits the acceptability of treatment. 
Supervision of most doses is still onerous for patients, 
but is not necessarily detrimental to the individual in 
treatment; on the contrary, it may be of benefit in the 
early phases of treatment.
Regulations and laws describing the degree of supervision 
of methadone and buprenorphine maintenance should 
be in accordance with the relevant international treaties 
and reflect the balance between treatment acceptability 
and risk of diversion that is acceptable to the community. 
Programmes in which medicine is being diverted to the 
street market are not beneficial to patients and often 
not tolerated outside the health-care sector either. 
With guidance, treatment staff can select patients at 
lower risk of diversion, who can receive a lower level of 
supervision of dosing (Section 4.6).
In most cases, staff training, adequate take-home 
policies and normal legal restrictions on illicitly 
procured opioids can minimize diversion without the 
need for specific legislation. Programmes will be more 
sustainable if there are systems to prevent or minimize 
diversion of pharmacotherapy, and to monitor the 
benefits of treatment. As a minimum, this would 
include systems that monitor the extent of diversion 
(Section 5.7).
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This section is primarily aimed at clinical leaders and 
health administrators responsible for the organization 
and delivery of opioid dependence treatment, and the 
standards of care involved.
5.1 Clinical governance
Clinical governance refers to the mechanism of 
accountability for clinical outcomes. Normally, this role 
falls to a clinical leader or health administrator, or is 
shared by both. Responsibilities include ensuring that:
staff are adequately selected, trained and supervised•	
adequate clinical protocols and procedures are in •	
place for
determining the structure of the treatment service 
developing and maintaining mechanisms of  
quality assessment and improvement
ensuring that practices comply with relevant  
laws and professional requirements.
As a minimum, a process of clinical governance should 
be established to ensure that minimal standards for 
provision of opioid dependence treatment are being 
met. Ideally, the process of clinical governance should 
be well developed, so that treatments for opioid 
dependence are both safe and effective.
Where treatment is delivered outside the health-care 
system (e.g. in prisons) and not primarily under the 
responsibility of health authorities, there should still 
be a documented chain of accountability for health 
outcomes.
It is best to have the primary responsibility for treatment 
within the health-care system, even in diverse settings, 
because clinical accountability is then easier to establish 
and maintain.
Recommendation (Minimum standard) 
Treatment services should have a system of clinical 
governance, with a chain of clinical accountability within the 
health-care system, to ensure that the minimal standards for 
provision of opioid dependence treatment are being met.
Recommendation (Best Practice) 
Treatment of opioid dependence should be provided within 
the health-care system.
Recommendation (Best Practice) 
A process of clinical governance should be established to 
ensure that treatments for opioid dependence are both safe 
and effective. The process should be transparent and outlined 
in a clinical governance document.
5.2 Ethical principles and consent
In line with the rights to autonomy and the highest 
attainable standard of health enshrined in Article 12 
of the International Covenant on Economic, Social 
and Cultural Rights[75], people should be free to chose 
whether or not they participate in treatment. 
The WHO Resource Book on Mental Health, Human 
Rights and Legislation[76] says that, to be valid, consent 
must satisfy the following criteria:
“The person/patient giving consent must be •	
competent to do so, and competence is assumed 
unless there is evidence to the contrary.
Consent must be obtained freely, without threats •	
or improper inducements.
There should be appropriate and adequate •	
disclosure of information. Information must be 
provided on the purpose, method, likely duration 
and expected benefits of the proposed treatment; 
possible pain or discomfort and risks of the 
proposed treatment, and likely side-effects. This 
information should be adequately discussed with 
the patient.
Choices should be offered, if available, in •	
accordance with good clinical practice; alternative 
modes of treatment, especially those that are less 
intrusive, should be discussed and offered to the 
patient.
Information should be provided in a language and •	
form that is understandable to the patient.
The patient should have the right to refuse or stop •	
treatment.
Consequences of refusing treatment, which may •	
include discharge from the hospital, should be 
explained to the patient.
The consent should be documented in the patient’s •	
medical records.
The right to consent to treatment implies also the •	
right to refuse treatment. If a patient is judged as 
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having the capacity to give consent, then refusal of 
such consent must also be respected.”
One of the implications for provision of informed consent 
in opioid-dependent patients is that patients may not 
be in an adequate state to provide informed consent 
when they are intoxicated or in opioid withdrawal. In 
this case, treatment may commence and patients may 
be asked to confirm their consent to treatment after 
treatment has commenced, as soon as the patient 
is neither intoxicated nor in opioid withdrawal. On 
occasion, this may mean a change in treatment direction 
from opioid agonist maintenance to opioid withdrawal, 
or the reverse.
When considering what risks to include in the informed 
consent process for patients commencing opioid agonist 
maintenance treatment, it is important to include the 
increased risk of overdose during the first weeks of 
treatment, and the likely opioid withdrawal symptoms 
that will be experienced when stopping opioid agonist 
treatment. Patients commencing opioid withdrawal 
and abstinence-based treatments should be specifically 
warned about the increased risk of overdose on relapse 
to opioid use compared to opioid agonist maintenance 
treatment.
Recommendation (Minimum standard) 
Patients must give informed consent for treatment.
5.3 Staff and training
The support and training of health-care personnel 
requires a continuous effort, and special attention is 
needed to develop and maintain a competent workforce. 
Training should include (as a minimum) an understanding 
of the nature of opioid dependence, assessment 
and diagnosis, pharmacological and psychosocial 
treatments, and management of intoxication, overdose 
and difficult behaviours.
Recommendation (Minimum standard) 
Treatment of opioid dependence should be carried out by 
trained health-care personnel. The level of training for specific 
tasks should be determined by the level of responsibility and 
national regulations.
Recommendation (Best Practice) 
Health authorities should ensure that treatment providers 
have sufficient skill and qualifications to use controlled 
substances appropriately. These requirements may include 
postgraduate training and certification, continuing education 
and licensing and the setting aside of funding for monitoring 
and evaluation.
5.3.1 MeDICAl STAFF
In most settings, medical staff will be required for 
the treatment of opioid dependence, both for clinical 
assessment and for prescription of pharmacotherapy. In 
some settings, due to a shortage of medical staff, these 
responsibilities may fall on nursing or other health-care 
staff. Also, medical staff may delegate some of their 
responsibilities to nursing and other health-care staff, in 
accordance with local regulations.
In specialist clinics, medical staff should be supervised by 
a physician or psychiatrist specializing in the treatment 
of substance dependence.
In generalist settings, general practitioners and other 
medical staff should have a basic level of training in the 
diagnosis and treatment of opioid dependence. Because 
of the potential for methadone and buprenorphine to do 
harm if prescribed inappropriately, many countries have 
a system of licensing medical staff to prescribe opioid 
agonist maintenance treatment. Each service should 
ensure that its own training programmes incorporate 
local clinical guidelines and regulations.
All medical staff working in the field of substance abuse 
should have some avenue for clinical supervision, be it 
from peers, senior colleagues or professional supervisors. 
This helps to guard against inappropriate prescribing 
and to maintain the professionalism of medical staff in 
their dealings with patients.
5.3.2 PHARMACY STAFF
Staff dispensing methadone and buprenorphine are 
generally pharmacists, although medical and nursing 
staff may also be able to dispense medication, 
depending on national laws. Staff dispensing 
methadone and buprenorphine should have specific 
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training in opioid-dependence treatment. This should 
include the nature of opioid dependence, the goals of 
treatment, therapeutic rapport, recognition of opioid 
withdrawal and intoxication, and responses to difficult 
behaviours. This should include proper storage of 
controlled medicines, the nature of opioid dependence, 
the goals of treatment, therapeutic rapport, recognition 
of opioid withdrawal and intoxication, methods to 
minimize diversion of medication, and responses to 
difficult behaviours.
5.3.3 PSYCHOSOCIAl SUPPORT STAFF
To ensure professionalism and consistency of service 
delivery, basic training in treatment of substance 
dependence is recommended. Further training 
requirements will depend on the nature of the 
psychosocial intervention being offered.
Staff should be provided with supervision, adequate 
support, and standardized operational instructions on 
the management of intoxication, difficult behaviours 
and other emergency conditions.
5.4 Clinical records
Every contact between the health service and the 
patient should be recorded in the medical record. The 
record should be up to date and clearly legible. Each 
entry should be signed and dated.
Sometimes police may ask to see medical records; they 
should not be given access to medical records against 
the wishes of the patient unless appropriate legal 
requirements and procedures have been met.
In some circumstances, professional standards may 
warrant a breach of confidentiality; for example, if the 
safety of a child is at risk. In these situations, professional 
staff should balance the patient’s right to privacy 
against the duty to protect, and should seek advice 
from their professional body if unsure. Such breaches of 
confidentiality are generally allowed under law; indeed, 
in some cases they may be required by law.
As a general rule, patients should have access to their 
own medical records. This may be limited in some 
situations if it is not in the patient’s best interest to view 
all of his or her own records.
If there are national systems of identification, such as 
identity cards, bank cards or social security cards, these 
should be used when necessary to confirm the identity 
of patients. In the absence of such systems, treatment 
providers should find alternative ways to establish 
patient identity. The main reason for this is to avoid giving 
potentially lethal doses of opioids to the wrong patient. 
If there is a system of central registration (Section 4.2), 
the system will require accurate identification of 
participants if it is to be effective.
Recommendation (Minimum standard) 
Up-to-date medical records should be kept for all patients. 
These should include, as a minimum, the history, clinical 
examination, investigations, diagnosis, health and social 
status, treatment plans and their revisions, referrals, evidence 
of consent, prescribed drugs and other interventions received.
Recommendation (Minimum standard) 
Confidentiality of patient records should be ensured.
Recommendation (Minimum standard) 
Health-care providers involved in the treatment of an 
individual should have access to patient data in accordance 
with national regulations, as should patients themselves.
Recommendation (Minimum standard) 
Health-care providers or other personnel involved in patient 
treatment should not share information about patients with 
police and other law enforcement authorities unless a patient 
approves, or unless required by law.
Recommendation (Minimum standard) 
Patients treated with opioid agonists should be identifiable 
to treating staff.
5.5 Medication safety
Most countries have regulations that govern the 
procurement, storage, dispensing and dosing of 
medicines, and these often contain special provisions 
for opioids and other medications of abuse and 
dependence. The regulations usually stipulate storage 
of methadone and buprenorphine in locked cabinets, 
with two staff members witnessing any movement of 
medication. These measures reduce the risk of theft 
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of medication, particularly the risk of diversion by staff 
members. 
Methadone and buprenorphine can be fatal if the wrong 
dose is dispensed or a dose is dispensed to the wrong 
patient. Various systems can be used to ensure that the 
correct dose is being dispensed to the correct patient. 
Such systems essentially involve checking the identity of 
the patient and ensuring that the prescription is valid. 
They can be low technology – for example, having a 
photo of the patient at the dispensing point and having 
the patient sign for their dose. Alternatively, systems can 
be high-technology – for example, commercial systems 
linking retinal scanning devices to methadone pumps.
Recommendation (Minimum standard) 
Documented processes should be established to ensure the 
safe and legal procurement, storage, dispensing and dosing 
of medicines, particularly of methadone and buprenorphine.
5.6 Treatment provision
5.6.1 ClInICAl GUIDelIneS
Clinical guidelines are one mechanism for improving 
the quality of treatment. Clear, evidence-based clinical 
guidelines for the treatment of opioid dependence are 
available, and at a minimum these should be accessible 
to treatment staff. Ideally, local guidelines should be 
developed at a country or subnational level to reflect 
local laws, policies and conditions. The guidelines will 
be affected by differences in costs and requirements for 
supervision of methadone and buprenorphine. Local 
guidelines should represent the accepted treatment 
standards in the particular location, reflecting to some 
extent the values and mores of the society and its 
professional bodies.
Recommendation (Minimum standard) 
Clinical guidelines for the treatment of opioid dependence 
should be available to clinical staff.
Recommendation (Best Practice)
Clinical guidelines should be detailed, comprehensive, 
evidence based and developed at a country level or lower, to 
reflect local laws, policies and conditions.
5.6.2 TReATMenT POlICIeS
Policies on the objectives, indications, settings, dosage 
schemes and treatment regulations (including reasons 
for treatment termination) should be developed and 
clearly communicated to patients and staff. This applies 
for the management of opioid dependence with 
opioid detoxification, opioid agonist maintenance and 
naltrexone treatment.
Access to and networking with medical, psychiatric, 
social and harm-reduction services is desirable, 
and should be developed when possible; however, 
psychosocial interventions, including counselling, may 
not be necessary onsite.
Men and women can be treated in the same facility, 
providing that culturally appropriate and gender-specific 
needs can be taken care of.
Recommendation (Minimum standard) 
To maximize the safety and effectiveness of agonist 
maintenance treatment programmes, policies and regulations 
should encourage flexible dosing structures, with low 
starting doses and high maintenance doses, without placing 
restrictions on dose levels and the duration of treatment.
Recommendation (Best Practice) 
Opioid withdrawal services should be structured such that 
withdrawal is not a stand-alone service but is integrated with 
ongoing treatment options. 
Recommendation (Best Practice) 
Take-home doses can be recommended when the dose and 
social situation are stable, and when there is a low risk of 
diversion for illegitimate purposes.
Recommendation (Best Practice) 
Involuntary discharge from treatment is justified to ensure 
the safety of staff and other patients, but noncompliance 
with programme rules alone should not generally be a reason 
for involuntary discharge. Before involuntary discharge, 
reasonable measures to improve the situation should be 
taken, including re-evaluation of the treatment approach used.
5.6.3 InVOlUnTARY DISCHARGe AnD OTHeR FORMS OF 
lIMIT SeTTInG
One of the primary responsibilities of a treatment 
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service is to protect its staff and patients from harm. If a 
situation arises in which the past behaviour of a patient 
would indicate that there is a significant risk of harm to 
other patients or staff, the treatment service must act 
to reduce that risk, discharging the patient if necessary. 
Such situations are potentially avoidable if the patient’s 
behaviour is identified and managed at an early stage.
An effective treatment service will have clear boundaries 
on what constitutes acceptable and unacceptable 
behaviour, and the service will apply the limits 
consistently and transparently to all patients (sometimes 
referred to as “limit setting”). To avoid replicating the 
rejection that patients experience from other parts of 
society, limit setting should have a graded response, 
including:
positive feedback for “good” behaviour•	
measured responses for mild breaches of •	
acceptable behaviour (e.g. warnings, fewer take-
home dose privileges, more frequent medical visits, 
refusing or delaying doses if intoxicated)
final responses (e.g. treatment discharge and, if •	
necessary, calling the police) for serious breaches of 
acceptable behaviour. 
Applying excessive responses for minor breaches of rules 
will result in many people being discharged when they 
could have gone on to do well from treatment. At the 
same time, failure to respond to significant breaches of 
rules risks harm to other patients and staff, and will not 
help the patient in question.
Each service will have to decide on its own rules and 
limits; these will depend on cultural norms, the goals 
of treatment in that setting and the policy environment 
that allows the treatment to continue. Treatment rules 
are likely to be very different for a withdrawal facility 
or therapeutic community aimed at abstinence, and 
an opioid agonist maintenance programme aimed at 
reducing the mortality and morbidity associated with 
opioid dependence, and at improving quality of life.
Whatever limits are set, they must be consistently 
applied by all treatment staff. In this way, patients will 
quickly learn and more readily accept the boundaries 
of acceptable behaviour. Some patients will push these 
boundaries when there is a perceived difference in the 
way that staff apply limits. Sometimes called “splitting”, 
this behaviour risks setting treatment staff against each 
other, leading to poor outcomes for patients.
Even if an incident is sufficiently serious to warrant 
abrupt discharge, agencies should use this as an 
occasion to review whether they have done all they 
can to avoid provoking or permitting such behaviour. 
Treatment services should have a mechanism of 
reporting incidents when they occur, including “near 
misses” and unexpected adverse outcomes. The reports 
should be reviewed regularly by a team that includes 
someone responsible for the clinical governance of the 
service.
Initiatives to reduce such incidents might include 
measures to train staff in non-judgemental and non-
confrontational communication strategies, reducing 
waiting time for appointments and medication, 
frequent review of patient treatment, use of family 
and employment-friendly practices, and presence of 
security.
If the situation does not warrant immediate discharge 
for the safety of staff and other patients, then 
attempts should be made to resolve the situation 
without discharge, particularly if discharge implies 
no continuing treatment. Patients should understand 
what is expected of them, and there should be clear 
communication when behaviour crosses the boundaries. 
When alternative options are inappropriate or have 
been exhausted, attempts should be made to transfer 
the patient to another treatment service, because 
outcomes after involuntary discharge from treatment 
are poor, with relapse to heroin use occurring in 75% 
of patients[77].
5.6.4 InDIVIDUAl TReATMenT PlAnS
The first stage in individualized treatment is a thorough 
individual assessment that identifies specific psychosocial 
needs and patient motivations, and confirms the 
diagnosis of opioid dependence and the response to 
previous treatments (Section 6.1). Holistic treatment 
then attempts to meet each of those treatment needs. 
Where possible, interventions to address particular needs 
should be evidence based, incorporating individual 
preferences and past treatment experiences.
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As with other long-term conditions, patients should 
not be assumed to be “cured” with the first round of 
treatment, and provisions should be made for follow-
up. Treatment programmes should be structured in 
such a way that they can support patients in the long 
term.
Recommendation (Minimum standard)
A detailed individual assessment should be conducted 
which includes: history (past treatment experiences; medical 
and psychiatric history; living conditions; legal issues; 
occupational situation; and social and cultural factors, 
that may influence substance use); clinical examination 
(assessment of intoxication / withdrawal, injection marks); 
and, if necessary, investigations (such as urine drug screen, 
HIV, Hep C, Hep B, TB, liver function).
Recommendation (Best Practice) 
Screening for psychiatric and somatic comorbidity should 
form part of the initial assessment.
Recommendation (Best Practice) 
The choice of treatment for an individual should be 
based on a detailed assessment of the treatment needs, 
appropriateness of treatment to meet those needs 
(assessment of appropriateness should be evidence based), 
patient acceptance and treatment availability.
Recommendation (Best Practice) 
Treatment plans should take a long-term perspective.
Recommendation (Best Practice) 
Opioid detoxification should be planned in conjunction with 
ongoing treatment.
5.6.5 RAnGe OF SeRVICeS TO Be PROVIDeD
Although different treatment options may be available 
in different programmes, it is useful for programmes to 
be able to offer a full range of services, so that they can 
tailor the services to the needs of the patients.
Each treatment facility with medical staff should ensure 
that the facility has the capacity to administer the 
opioid antagonist naloxone to treat opioid overdoses. 
This includes procedures for maintaining stock and 
injection equipment. Distribution of naloxone, with 
training on its use in overdose to opioid users and their 
families, has been shown to be a feasible approach to 
reducing overdose mortality in the community[78, 79, 80]. 
It is similar in concept to the distribution of adrenaline 
to patients with severe allergic reactions and their 
families.
Recommendation (Minimum standard) 
Essential pharmacological treatment options should consist 
of opioid agonist maintenance treatment and services for the 
management of opioid withdrawal.
Recommendation (Minimum standard) 
Naloxone should be available for treating opioid overdose.
Recommendation (Best Practice) 
Pharmacological treatment options should consist of 
both methadone and buprenorphine for opioid agonist 
maintenance and opioid withdrawal, alpha-2 adrenergic 
agonists for opioid withdrawal, naltrexone for relapse 
prevention, and naloxone for the treatment of overdose.
5.6.6 TReATMenT OF COMORBID COnDITIOnS
Opioid-dependent patients often also suffer from other 
medical and psychiatric conditions, complicated by 
social problems. The optimal approach is to provide 
integrated holistic care to address current problems and 
prevent further problems. In practice, this means being 
able to detect medical, psychiatric and social issues in 
the assessment process, and having the means onsite 
to attend to the issues simultaneously. This may mean 
having staff with multiple skills, or coordinating the use 
of staff with different skill sets. 
5.6.7 PSYCHOSOCIAl AnD PSYCHIATRIC SUPPORT
Medications are useful in the treatment of opioid 
dependence. However, providing medications without 
offering any psychosocial assistance fails to recognize 
the complex nature of opioid dependence, loses the 
opportunity to provide optimal interventions and 
requires treatment staff to go against their clinical 
inclination to respond to the total needs of their 
patients. Treatment services should aim to offer onsite, 
integrated, comprehensive psychosocial support to 
every patient. However, treatment services should 
not deny effective medication if they are unable to 
provide psychosocial assistance, or if patients refuse 
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it. At a minimum, services should attempt to assess 
the psychosocial needs of patients, provide whatever 
support they can, and refer to outside agencies for 
additional support where necessary.
Recommendation (Minimum standard) 
Psychosocial support should be available to all opioid-
dependent patients, in association with pharmacological 
treatments of opioid dependence. At a minimum, this 
should include assessment of psychosocial needs, supportive 
counselling and links to existing family and community 
services.
Recommendation (Best Practice) 
A variety of structured psychosocial interventions should 
be available, according to the needs of the patients. Such 
interventions may include - but are not limited to - different 
forms of counselling and  psychotherapy, and assistance 
with social needs such as housing, employment, education, 
welfare and legal problems.
Recommendation (Best Practice) 
Onsite psychosocial and psychiatric treatment should be 
provided for patients with psychiatric comorbidity.
5.6.8 TB, HePATITIS AnD HIV
Despite the large number of opioid-dependent people 
living with HIV/AIDS, there is considerable evidence 
that they have less access to antiretroviral medication, 
and to other HIV/AIDS treatment and care than others 
who are not substance dependent. Opioid use has 
been identified as a factor in lack of adherence to 
antiretroviral treatment, risking the development of 
viral drug resistance[81]. 
On the other hand, observational studies suggest that 
the impact of highly active antiretroviral therapy on CD4 
counts in patients still using heroin and other drugs is 
reasonable, and is not too dissimilar to the impact of 
such therapy in patients not using illicit substances[82]. 
Excellent results can be obtained for patients in opioid 
agonist maintenance treatment[83]. 
The issues for TB and hepatitis treatment are similar, 
with the exception that clinics with TB patients need to 
carefully consider the risks of spread of TB from patient 
to patient, particularly where immunocompromised 
patients are mixing with TB patients. Given the 
capacity for overcrowded clinics to spread TB, opioid-
dependence treatment clinics should consider their 
response to the issue of TB in combination with local 
TB experts. Issues of ventilation, overcrowding and 
management of coughing patients may need to be 
considered.
Combined treatment of hepatitis C and opioid 
dependence with  opioid agonist maintenance 
treatment and anti-viral agents can also have excellent 
results[84, 85, 86, 87].
A number of RCTs have demonstrated that substance- 
dependent patients are more likely to attend for 
medical care if the treatment is provided onsite; this 
can be arranged for minimal additional cost[88, 89, 90, 91, 92, 
93]. An alternative approach – providing opioid agonist 
maintenance treatment at medical clinics[94] – has also 
been suggested.
To improve compliance, directly observed treatment of 
HIV and TB should be integrated with opioid agonist 
maintenance treatment, and provided in the same 
location.
There are a number of models for the development of 
such integrated care.
Existing opioid-dependence programmes may start •	
treating medical conditions[84].
Existing medical programmes may start treating •	
opioid dependence[85].
New specialized services for drug users may treat •	
opioid dependence, TB, HIV and hepatitis.
Opioid dependence and HIV/TB can be treated in •	
primary care[87].
According to local conditions, mechanisms for treating 
opioid dependence should be combined with treatment 
for TB, HIV and hepatitis. The simplest way for this to 
happen may be for treatment staff to become skilled 
in treating multiple conditions. Since patients on opioid 
agonist maintenance treatment already attend a clinic 
or dispensary daily, integration with HIV treatment 
provides an efficient mechanism for directly observing 
HIV treatment and achieving high compliance rates. 
Where there is no capacity to provide integrated care, 
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links should be established between services providing 
drug treatment and services providing treatment for 
HIV, TB and hepatitis, to increase the success of referral 
and treatment.
Patients with active TB are highly infective and should be 
kept separate from other patients as much as possible 
in the initial stages of treatment, particularly during the 
first two weeks of anti-TB therapy.
All injecting drug users should have access to measures 
to reduce the spread of HIV, including access to clean 
injecting equipment, condoms, antiretroviral drugs and 
other treatments, psychosocial services and medical 
care. While patients who have ceased heroin use before 
treatment have higher rates of adherence to antiretroviral 
treatment, patients without a drug-free period also 
have acceptable levels of response to treatment, and 
there should be no absolute requirement for patients to 
be drug free before commencing treatment.
Recommendation (Minimum standard) 
Links to HIV, hepatitis and TB treatment services (where they 
exist) should be provided.
Recommendation (Best Practice)
Where there are significant numbers of opioid-dependent 
patients in need of treatment for either HIV, hepatitis or TB, 
treatment of opioid dependence should be integrated with 
medical services for these conditions.
Recommendation (Best Practice) 
For opioid-dependent patients with TB, hepatitis or HIV, opioid 
agonists should be administered in conjunction with other 
medical treatment; there is no need to wait for abstinence 
from opioids to commence either anti-TB medication, 
treatment for hepatitis or antiretroviral medication.
Recommendation (Best Practice) 
Opioid-dependent patients with TB, hepatitis or HIV should 
have equitable access to treatment for TB, hepatitis, HIV and 
opioid dependence.
5.6.9 HePATITIS B VACCInATIOn
Vaccination for hepatitis B is recommended for all 
opioid-dependent patients[95]. Ideally, hepatitis B 
vaccines should be given in three doses at least four 
weeks apart, but other vaccination schedules can also 
provide acceptable protection. Each treatment service 
should establish its own vaccination policy, based on the 
costs of vaccination and serology testing, the ability to 
maintain a cold chain, the prevalence of hepatitis B and 
the likelihood that patients will come back for follow-up 
appointments. Given the difficulty of bringing patients 
back for follow-up appointments and the relatively low 
cost of the Vaccine. vaccinating all patients without 
prior serology testing may be the most effective and 
the most cost-effective approach, even if completion of 
the course is not guaranteed. Some studies have shown 
that provision of free Vaccine. staff training, incentives, 
onsite vaccination and accelerated schedules can result 
in higher vaccination rates in this population[96, 97, 98] 
On the other hand, it is useful to test levels of post-
vaccination anti-hepatitis B antibodies, because 
significant numbers of people do not produce an 
adequate immune response[99, 100, 101]; in these cases, 
additional doses of vaccination should be given. 
Many opioid-dependent patients will also benefit from 
vaccination against hepatitis A[102].
Recommendation (Best Practice) 
Treatment services should offer hepatitis B vaccination to all 
opioid-dependent patients.
5.7 Treatment evaluation
For opioid agonist maintenance treatment programmes, 
monitoring the potential for harm through diversion, 
overdose and other adverse events should be the 
minimum standard of treatment evaluation. Examples 
of simple evaluation techniques that could be used 
to detect diversion of drugs from treatment include 
interviewing key informants about drug diversion 
and testing levels of the main drugs used in patients 
presenting for treatment.
A system of detecting and recording adverse events 
in treatment, followed by regular discussion and 
implementation of necessary changes, will help to 
ensure safety. Following-up patients who drop out of 
treatment is helpful in this regard.
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Optimal treatment evaluation examines safety, 
effectiveness and processes of care. Effectiveness can 
be measured “in house”, through routine collection of 
outcome measures combined with follow-up of those 
who have left the service, or “externally”, with the 
assistance of an external evaluation person or team. 
Further details on evaluation can be found in the 
WHO toolkit on the evaluation of opioid substitution 
programmes[103].
Recommendation (Minimum standard) 
There should be a system for monitoring the safety of 
the treatment service, including the extent of medication 
diversion.
Recommendation (Best Practice) 
There should be intermittent or ongoing evaluation of 
both the process and the outcomes of the treatment 
provided.
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In recent years, the choice of treatment options for 
opioid dependence has expanded. Although opioid 
agonist maintenance treatments (methadone and 
buprenorphine) are increasingly seen as the most 
effective management strategies, other options are 
opioid withdrawal and relapse prevention. In practice, 
different approaches will suit different patients. Many 
patients will undergo several episodes of different 
forms of treatment before finding treatments that 
work for them. The choice between the treatment 
options available should be made jointly by the 
clinician and patient, taking into account the priorities 
of the patient, the principles of medical ethics and the 
evidence for effectiveness of the treatments, as well 
as individual patient factors, such as past treatment 
history.
The three treatment approaches discussed in this section 
are:
opioid agonist maintenance treatment•	
opioid withdrawal•	
opioid withdrawal followed by oral naltrexone.•	
The issues considered in relation to opioid agonist 
maintenance treatment are:
methadone compared to buprenorphine for •	
maintenance treatment
optimal doses of methadone and  •	
buprenorphine
use of adjuvant psychosocial support.•	
The issues considered in relation to opioid withdrawal 
are:
choice of medication - methadone, buprenorphine •	
or alpha-2 adrenergic agonists (e.g. clonidine and 
lofexidine)
use of accelerated opioid withdrawal techniques •	
with opioid antagonists (e.g. naloxone and 
naltrexone) with either minimal or heavy  
sedation
use of oral naltrexone for relapse prevention after •	
opioid withdrawal
use of psychosocial support as an adjuvant to the •	
above therapies
choice between inpatient and outpatient •	
detoxification services.
6.1 Diagnosis and assessment of opioid 
dependence 
Assessment includes establishing a relationship between 
the patient and the treatment staff, based on the free 
exchange of information. Initially, patients may wish to 
share only information required to start the treatment 
process. However, as trust develops between the 
patient and staff, more information may be shared, and 
treatment staff will be better able to tailor responses to 
the individual patient.
Determining the physical, psychological and social 
health-care needs of the patient is an important 
part of assessment. Assessment should also include 
factors that may influence drug use, such as past 
treatment experiences, living conditions, legal issues, 
occupational situation, and social and cultural 
factors.
The clinician should take a substance use history to 
assess:
which psychoactive substances have been used in •	
the past, and which are currently being used 
the pattern of use for each substance, including •	
information on the quantity and frequency of  
use
the current level of neuroadaptation to each •	
substance used
drug induced health and social problems•	
previous responses to treatment and other •	
interventions
whether the criteria for harmful use or dependence •	
are met
how the patient views their substance use •	
the factors that have contributed, and continue •	
to contribute, to the patient’s use of psychoactive 
substances
the short, medium and long-term goals of the •	
patient, and what has brought the patient to the 
treatment facility on this occasion.
Clinicians should differentiate between substance 
dependence and nondependent harmful substance use, 
because these categories have significant implications 
for the appropriate treatment strategy.
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On examination of the patient, the degree of intoxication 
or withdrawal should be interpreted in combination 
with the stated time of last use.1 If there is a history 
of injection, the injection sites should be visible and 
consistent with the stated history (usually both recent 
and old injection marks will be visible). 
6.1.1 URIne DRUG SCReenInG
Where available and affordable, urine (or other biological 
sample) drug screening should be routinely conducted 
at the start of treatment, and should indicate recent 
opioid use if the person is to be eligible for treatment. 
When the cost of urine testing is an issue, urine testing 
should be used at least when a recent history of opioid 
use cannot be verified by other means (e.g. evidence 
of opioid withdrawal or intoxication). A negative urine 
drug screen combined with absence of withdrawal 
symptoms excludes current neuroadaptation to opioids; 
however, it does not exclude dependence on opioids in 
the past 12 months. Thus, dependence should not be 
diagnosed on urine drug screening alone, but a negative 
urine drug screen in the absence withdrawal symptoms 
should prompt caution in the use of opioids and other 
sedative medication. 
Urine testing is also useful, in combination with the 
history, to identify other substances that have recently 
been consumed. 
Entry into appropriate treatment programmes should 
not be delayed by waiting for the result of urine drug 
screening, unless the other findings in the assessment 
raise concern about the diagnosis.
Naloxone challenge testing should not be used routinely 
to confirm the presence of current neuroadaptation, 
because it can induce significant withdrawal effects. 
The same information can normally be gathered 
from the patient’s history, examination of the person 
and interpretation of urine drug test results. Provided 
the patient is informed of the risk of adverse effects, 
naloxone challenge testing can be used as an alternative 
to urine drug screening, to confirm the absence of 
current neuroadaptation (e.g. when considering giving 
1 For example, see http://www.ncbi.nlm.nih.gov/books/
bv.fcgi?rid=hstat5.chapter.72248
an opioid antagonist to start maintenance treatment). In 
this situation, an accidental positive reaction is likely to be 
significantly milder than the reaction that occurs when 
the test is used to confirm current neuroadaptation.
6.1.2 TeSTInG FOR InFeCTIOUS DISeASeS
Voluntary testing for HIV, hepatitis C and common 
infectious diseases should be offered as part of an 
individual assessment, accompanied by counselling 
before and after the test. In areas of high prevalence 
of HIV, patients should be strongly encouraged to 
undergo HIV testing. Serology testing and vaccination 
for hepatitis B is also recommended. As discussed above 
(Section 5.6), in some circumstances it may be more 
effective to vaccinate before testing for hepatitis B, and 
to use accelerated vaccination schedules.
TB and sexually transmitted diseases should also be 
considered during assessment.
Pregnancy testing should be offered to all women, 
particularly those contemplating opioid withdrawal, 
because it may influence the choice of treatment. 
6.1.3 IDenTIFYInG THe PATIenT
In some circumstances, it may be necessary to 
confirm the identity of the patient, particularly if 
treatment with controlled medicines is anticipated. 
Where patients do not have formal identification, it 
is advisable to take a photograph and include it in 
the record signed by the treating clinician, so that the 
patient can be identified in that clinic. The identity 
of the patient should be kept private and should not 
be released without patient consent. When collecting 
and recording information, the capacity of the service 
to keep that information private should be discussed 
with the patient. 
6.1.4 COMPleTInG THe ASSeSSMenT
Sometimes it is not possible to complete the initial 
assessment in one day; for example, the patient may 
be intoxicated, in withdrawal or in crisis. In such cases, 
it may be necessary to make a plan based on the initial 
assessment, which will then evolve in response to a more 
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comprehensive assessment and the person’s response 
to initial treatment.
6.1.4 DIAGnOSTIC CRITeRIA
A diagnosis of opioid dependence has important 
prognostic and treatment implications. Once opioid 
dependent, the patient has a significant risk of suffering 
serious health consequences or of dying from behaviours 
related to their dependence on opioids.
The International Classification of Diseases, 10th edition 
(ICD-10) defines opioid dependence as “a cluster of 
physiological, behavioural, and cognitive phenomena 
in which the use of opioids takes on a much higher 
priority for a given individual than other behaviours 
that once had greater value”. A central characteristic of 
the dependence syndrome is the desire (often strong, 
sometimes overpowering) to take opioids, which may 
or may not have been medically prescribed. Once a 
person is opioid dependent, returning to substance 
use after a period of abstinence leads to a more rapid 
reappearance of other features of the syndrome than 
occurs with nondependent individuals[104].
The ICD-10 diagnostic criteria for opioid dependence 
are:
a strong desire or sense of compulsion to take opioids•	
difficulties in controlling opioid-use behaviours in •	
terms of the onset, termination or levels of use
a physiological withdrawal state when opioid use •	
has ceased or been reduced, as evidenced by one 
of the following
the characteristic withdrawal syndrome 
use of opioids (or closely related substances)  
with the intention of relieving or avoiding 
withdrawal symptoms
evidence of tolerance, such that increased doses •	
of opioids are required to achieve effects originally 
produced by lower doses
progressive neglect of alternative pleasures or •	
interests because of opioid use
increased amounts of time spent on obtaining •	
opioids or recovering from their effects
persisting with opioid use despite clear evidence of •	
overtly harmful consequences, such as depressive 
mood states consequent to periods of heavy 
substance use, or drug-related impairment of 
cognitive functioning (efforts should be made to 
determine whether the user was actually, or could 
be expected to be, aware of the nature and extent 
of the harm).
Narrowing of the personal repertoire of patterns of 
opioid use has also been described as a characteristic 
feature of dependence.
Opioid dependence does not develop without a period 
of regular use, although regular use alone is not 
sufficient to induce dependence.
A definite diagnosis of dependence should usually be 
made only if three or more of the diagnostic criteria 
have been experienced or exhibited at some time during 
the previous year.
6.1.5 MAKInG THe DIAGnOSIS
Opioid dependence is essentially diagnosed on the 
basis of the history provided by the patient. Patients 
can sometimes be motivated to either overstate or 
understate their substance use; therefore, it is usually 
necessary to corroborate the patient history with the 
results of the physical examination and investigations, 
and sometime with the history reported by significant 
others, to be confident of the diagnosis. While any 
health-care worker can make a provisional diagnosis 
of opioid dependence provided that they have had 
appropriate training, the diagnosis should be confirmed 
by medical staff before opioid agonist treatment is 
provided.
Injection sites
Examination of injection sites can provide useful 
information on the timing and duration of injecting drug 
use. Recent injection marks are small and red, and are 
sometimes inflamed or surrounded by slight bruising. 
Old injection sites are generally not inflamed, but 
sometimes show pigmentation changes (either lighter 
or darker), and the skin may have atrophied, giving a 
sunken impression. A combination of recent and old 
injection sites would normally be seen in an opioid-
dependent patient with current neuroadaptation. Many 
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sites can be used for injection, although the cubital 
fossa (the area on the inside of the elbow joint) and the 
groin are the most common.
Interpretation of urine drug screens 
Urine drug screens provide evidence of recent drug use; 
this information can contribute to the assessment. The 
precise interpretation of a test result will depend on the 
specific commercial test or reagents used. Generally 
speaking, a positive test for the opioid class of drugs 
indicates the use of illicit or prescription opioids in the last 
few days. However, positive reactions can also be caused 
by large amounts of poppy seeds. Many commercial 
opioid drug screens do not recognise buprenorphine, 
but this situation is changing; therefore, it is best to 
check with the laboratory. Some tests, such as gas-
chromatography and mass spectrometry (GCMS), can 
determine the specific opioid. Heroin is broken down to 
6-monoacetylmorphine (6-MAM), then to morphine and 
then to codeine; thus, the presence of 6-MAM is usually 
specific for heroin use in the last 24 hours. Morphine, 
with or without small amounts of codeine, can indicate 
either heroin or morphine use in the last few days. Small 
amounts of morphine in the presence of large amounts 
of codeine can suggest intake of high doses of codeine, 
since codeine can also be metabolized to morphine 
although most is metabolized via a different pathway.
Degree of opioid intoxication and withdrawal
Features of opioid intoxication include drooping eyelids 
and constricted pupils, sedation, reduced respiratory 
rate, head nodding, and itching and scratching (due to 
histamine release).
Features of opioid withdrawal include yawning, 
anxiety, muscle aches, abdominal cramps, headache, 
dilated pupils, difficulty sleeping, vomiting, diarrhoea, 
piloerection (gooseflesh), agitation, myoclonic jerks, 
restlessness, delirium, seizures and elevated respiratory 
rate, blood pressure and pulse. Annex 10 provides useful 
scales for assessing the severity of opioid withdrawal.
6.2 Choice of treatment approach
Should agonist maintenance therapy (i.e. methadone or 
buprenorphine maintenance) be used in preference to 
withdrawal and oral antagonist therapy (naltrexone) or 
withdrawal alone? 
See evidence profiles in Annex 1 in:
Sections A1.1 and A1.2 for methadone versus withdrawal
Section A1.3 for buprenorphine versus withdrawal or placebo
Section A1.11 for naltrexone versus placebo.
Efficacy 
Methadone versus withdrawal
The recently updated Cochrane review[105] of methadone 
maintenance therapy versus no opioid replacement 
therapy identified three randomized controlled trials 
(RCTs) that compared methadone with opioid withdrawal 
followed by placebo[106, 107, 108]. These studies show that, 
compared to opioid withdrawal or placebo, methadone 
maintenance treatment dramatically reduces levels of 
illicit opioid use (relative risk [RR] 0.32; 95% confidence 
interval [CI] 0.23 to 0.44, high quality evidence) and 
increases retention in treatment (RR 3.05; 95%CI 1.75 
to 5.35). Observational studies demonstrate that the 
mortality rate in methadone treatment is approximately 
one third the rate out of treatment (RR 0.37; 95%CI 0.29 
to 0.48, low-quality evidence). 
Methadone appears to reduce the risk of HIV injection 
by approximately 50% (RR 0.45, 95%CI 0.35 to 0.59, 
moderate-quality evidence) and there is a similar 
reduction in seroconversion rates (RR 0.36, 95%CI 0.19 
to 0.66, low-quality evidence) compared to withdrawal 
or no treatment. No studies were found that compare 
methadone with naltrexone treatment.
Buprenorphine versus withdrawal or placebo
The Cochrane review of buprenorphine identified one 
study comparing buprenorphine with placebo[109], and 
one study comparing 1 mg per day with higher doses[110]. 
Compared to placebo (including 1 mg dose as placebo), 
buprenorphine leads to a dose-responsive reduction in 
heroin use and improved retention in treatment. A dose 
of 16 mg buprenorphine results in higher rates of 
retention in treatment (RR 1.52, 95%CI 1.23 to 1.88) 
and less morphine-positive urines (standardized mean 
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difference (SMD) –0.65, 95%CI –0.86 to –0.44) than 
placebo.
Naltrexone versus placebo
The Cochrane review of naltrexone for prevention of 
relapse in opioid dependence identified 6 studies, 
with a total of 249 patients [170]. In detoxified patients, 
naltrexone was more effective than placebo in reducing 
heroin use (RR 0.72, 95%CI 0.58 to 0.90, low-quality 
evidence), but did not affect retention in treatment 
(RR 1.08, 95%CI 0.74 to 1.57) or relapse at follow-up 
post treatment (RR 0.94, 95%CI 0.67 to 1.34).
Safety
Methadone maintenance is associated with an increase 
in mortality during the first two weeks of treatment 
compared to pretreatment levels, due to respiratory 
depression[111]. After that time, there is a reduction 
in mortality that remains until treatment stops. Most 
patients will resume opioid use at some stage, and the 
reduction in tolerance associated with the completion 
of opioid withdrawal can increase the risk of opioid 
overdose.
Pharmacology studies suggest that buprenorphine 
probably has less risk of overdose than methadone, but 
fatal overdoses of buprenorphine combined with other 
sedatives can still occur.
Treatment with naltrexone may increase the risk of 
sedative overdose in the period following the cessation 
of naltrexone. Some accelerated opioid withdrawal 
techniques that are used to start patients on naltrexone 
– in particular the use of antagonists in combination 
with heavy sedation – also appear to increase the risk of 
fatal complications.
A significant proportion of patients in opioid agonist 
therapy develop adverse effects (see Section 6.5). 
Methadone leads to a slight increase in the QT interval 
(i.e. the time between the start of the Q wave and 
the end of the T wave in the heart’s electrical cycle), 
possibly resulting in a slightly increased chance of life-
threatening cardiac arrhythmias, although it is difficult 
to make a precise estimate of any increased risk. 
Buprenorphine and naltrexone do not prolong the QT 
interval.
Contraindications to the use of opioid agonist 
maintenance treatment, and precautions for use of the 
treatment, include decompensated liver disease (such 
as with jaundice and ascites) – because in this context 
opioids may precipitate hepatic encephalopathy – 
and acute asthma and other causes of respiratory 
insufficiency. 
Precautions for both opioid agonist treatment and 
opioid detoxification include high-risk polydrug use, 
mental illness, low levels of neuroadaptation to opioids 
(e.g. in recent incarceration, because many people who 
are incarcerated do not use opioids with the frequency 
required to maintain their levels of tolerance to opioids) 
and significant concomitant medical problems.
Precautions to the use of opioid withdrawal over 
agonist maintenance therapy include pregnancy 
(because withdrawal can lead to miscarriage), and 
serious acute physical or psychiatric conditions (because 
withdrawal may worsen or complicate management of 
the underlying conditions).
Cost effectiveness
In a recent study of opioid substitution therapy in 
different countries[112], resource-use and cost data 
relating to methadone and buprenorphine maintenance 
treatment were collected in selected WHO member 
states (Indonesia, Iran, Lithuania and Poland). 
The total monthly cost of providing long-term 
methadone and buprenorphine maintenance treatment 
(including an initial induction phase) ranged from as 
little as US$26–36 in Indonesia and the Islamic Republic 
of Iran (approximately US$1/day) to US$296 in Poland 
(approximately US$10/day). This provides an indicative 
range within which to locate the expected investment 
needed to provide methadone maintenance treatment 
to a service user in a low or middle-income country. 
In high-income countries, costs for methadone and 
buprenorphine maintenance treatment are generally 
estimated to be US$5000 per year, or US$15 per 
day[113]. 
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Estimation of the cost of providing medication is not an 
adequate basis for budgetary planning, because it may 
represent only a fraction of total service costs (e.g. <20% 
in the Islamic Republic of Iran). Studies in Australia, 
Canada, the United States and United Kingdom have 
estimated the impact of treatment on total health-care 
costs, social security costs, lost productivity and crime. 
Thus, these studies estimate the economic “return on 
investment” in opioid-dependence treatment[62, 114]. 
They show that treatment of opioid dependence pays 
for itself, because savings in social costs are greater than 
the expenditure in treatment. It is difficult to extrapolate 
the results of these studies to lower income countries.
Estimates of cost effectiveness in high income countries 
countries have found that both methadone and 
buprenorphine maintenance are cost effective, being 
well below accepted thresholds for cost–benefit analysis 
of treatment[115, 116].
The cost of a “one off” episode of opioid withdrawal 
varies significantly between settings; it depends on the 
method of withdrawal, the length of treatment, the 
medication used and staff resources.
Because of differences between maintenance and 
withdrawal, it is difficult to estimate the long-term cost 
implications of choosing between:
opioid agonist maintenance treatment, which is low •	
intensity and long term, and has a low relapse rate 
opioid withdrawal, which is high intensity and short •	
term, and has a relatively high relapse rate.
Limitations of the data
No studies were found that directly compared the three 
different treatment approaches using a randomized 
design. It may be difficult to investigate this question 
using RCTs because patients may be reluctant to 
relinquish their right to choose a treatment modality. The 
clinical trials that were found compared the decision to 
attempt opioid withdrawal at one point in time versus 
methadone maintenance. In practice, an attempted 
opioid withdrawal that fails is usually followed by 
repeated attempts until the patient either succeeds, 
or stops trying to withdraw from opioids. This review 
found no RCTs comparing repeated attempts at opioid 
withdrawal with opioid agonist maintenance treatment. 
Also lacking were studies comparing methadone and 
buprenorphine maintenance treatment with opioid 
withdrawal and relapse prevention using naltrexone.
Treatment considerations
In practice, there is often a blurring between opioid 
agonist maintenance and opioid withdrawal using 
tapered doses of methadone or buprenorphine. Patients 
often start with tapering doses of agonist while trying 
to cease their heroin use, and increase their agonist 
dose temporarily whenever they relapse.
Benefits of opioid agonist maintenance 
treatment
The most significant benefit of opioid agonist maintenance 
treatment is that it has a much lower mortality rate than 
treatments based on opioid abstinence (the evidence 
for this effect is stronger for methadone than for 
buprenorphine). Opioid agonist maintenance treatment 
results in less heroin use for most patients, and better 
retention in drug treatment in general.
Undesirable effects and consequences
Many patients find the burden of supervised dosing 
every day onerous, and some patients experience 
adverse effects (including opioid withdrawal symptoms 
between doses) with methadone. Patients on methadone 
and buprenorphine can still experience opioid effects 
if they use illicit opioids; although the effects are 
diminished,  they are not blocked completely as they 
would be with naltrexone. This results in good rates 
of retention in opioid agonist maintenance treatment, 
even for those people with ongoing heroin use, but 
it may delay the progression to long-term abstinence. 
Travel can be difficult for patients on methadone and 
buprenorphine if they are required to have their doses 
supervised. Unsupervised administration results in 
increased rates of misuse of opioid agonist medication, 
and diversion to illicit drug markets; also, take-home 
doses are occasionally consumed by children and 
opioid-naive adults, with fatal consequences. Cessation 
of methadone and buprenorphine can result in a 
withdrawal syndrome that is more prolonged and 
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sometimes more severe than withdrawal from heroin. 
Also, many patients resume heroin use after cessation 
of methadone, even after long-term treatment.
Conclusion
For most patients, opioid agonist maintenance 
treatment will result in better outcomes than attempts 
at withdrawal, with or without the use of naltrexone 
after withdrawal. In particular, patients on opioid agonist 
maintenance treatment are more likely than those not 
undergoing such treatment to stay alive, not use heroin 
and be in contact with the treatment system.
Recommendation
For the pharmacological treatment of opioid dependence, 
clinicians should offer opioid withdrawal, opioid agonist 
maintenance and opioid antagonist (naltrexone) treatment, 
but most patients should be advised to use opioid agonist 
maintenance treatment.
Strength of recommendation – strong•	
Quality of evidence – low to moderate•	
Remarks – There is moderate evidence that agonist •	
maintenance treatment results in less illicit opioid use in 
the medium term than opioid withdrawal or antagonist 
therapy. Opioid-dependent patients should be encouraged 
to use opioid agonist maintenance treatment in preference 
to these other approaches. There is a spectrum of severity 
of opioid dependence. In less severe cases of opioid 
dependence (e.g. non-injectors and those who have 
recently commenced opioid use), treatment with agonist 
maintenance is still recommended for most patients, but 
a significant number are also likely to do well with opioid 
withdrawal-based treatments, and it would be reasonable 
to recommend these to some patients.
Recommendation
For opioid-dependent patients not commencing opioid 
agonist maintenance treatment, consider antagonist 
pharmacotherapy using naltrexone following the completion 
of opioid withdrawal.
Strength of recommendation – standard•	
Quality of evidence – low•	
Remarks – This recommendation acknowledges that not •	
all patients are able to access opioid agonist maintenance 
treatment, and that not all patients who can access it 
want it. In these circumstances, the use of naltrexone 
after withdrawal appears to have advantages over opioid 
withdrawal without naltrexone, in those patients who are 
prepared to take naltrexone.
6.3 Opioid agonist maintenance 
treatment
6.3.1 InDICATIOnS FOR OPIOID AGOnIST 
MAInTenAnCe TReATMenT
What are the indications for opioid agonist maintenance 
treatment?
Agonist maintenance treatment is indicated for all 
patients who are opioid dependent and are able to 
give informed consent, and for whom there are no 
specific contraindications. Given the long-term nature 
of the treatment and the potential for toxicity in the 
first two weeks, a high degree of certainty of the 
diagnosis is required before recommending opioid 
agonist maintenance treatment. If the diagnosis 
cannot be confirmed by observation of opioid 
withdrawal, injection sites or confirmation of previous 
treatment, then treatment should be started carefully 
and with close monitoring; in this situation, lack of 
intoxication from opioid agonists will provide direct 
evidence of opioid tolerance. Staff should be cautious 
when excluding patients seeking opioid agonist 
maintenance treatment, because such patients often 
have poor clinical outcomes if they do not receive 
treatment[117].
6.3.2 CHOICe OF AGOnIST MAInTenAnCe  
TReATMenT
In patients to be treated with agonist maintenance 
treatment, should preference be given to methadone 
or buprenorphine?
See evidence profile in Section A1.4 of  Annex 1
Efficacy
The Cochrane Collaboration conducted a systematic 
review and meta-analysis on this topic in 2004[118] and 
updated it in 2008 (in press). Ten studies compared 
methadone and buprenorphine, either using flexible 
dosing, or doses greater than 6 mg buprenorphine or 
50 mg methadone.
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Flexible dose buprenorphine versus flexible dose 
methadone
When using flexible doses, buprenorphine was less likely 
than methadone to be effective in retaining patients 
in treatment (6 studies, 837 participants; RR = 0.82, 
95%CI: 0.69 to 0.96), but there was no significant 
difference in heroin use based on results of morphine 
urinalysis (6 studies, 837 participants; SMD = –0.12, 
95%CI: –0.26 to 0.02), or in terms of self-reported 
heroin use (2 studies, 326 participants; SMD = –0.10, 
95%CI: –0.32 to 0.12).
Moderate dose buprenorphine (6–8 mg/day) versus 
moderate dose methadone (50–80 mg/day)
When using moderate doses, retention in treatment 
was better with methadone than with buprenorphine 
(RR = 0.79, 95%CI 0.64 to 0.99, moderate-quality 
evidence). Also, there was more heroin use with 
buprenorphine, as shown by morphine positive urines 
(3 studies, 314 participants: SMD = 0.27, 95%CI 0.05 
to 0.50). There was no difference in self-reported 
heroin use (2 studies, 74 participants; SMD = –0.02, 
95%CI –0.48 to 0.45).
Safety data
As a partial agonist, buprenorphine has a better 
pharmacological safety profile than methadone. Data 
on safety from randomized trials do not show significant 
differences between methadone and buprenorphine 
because of the small sample sizes. The strongest data 
for improved safety of buprenorphine comes from the 
widespread introduction of buprenorphine in France in 
1995, which was followed by a 79% reduction in opioid 
overdose mortality[119]. From 1994 to 1998, there were an 
estimated 1.4 times more deaths related to buprenorphine 
than to methadone, although 14 times more patients 
received buprenorphine than methadone[120].
Although deaths have been reported where 
buprenorphine has been used in combination with 
other sedatives[121, 122], the rate of buprenorphine-related 
deaths is estimated at 0.2 per 1000 patient years[123], 
which is much less than the mortality of untreated 
heroin dependence[124]. 
In RCTs, safety data is rarely well collected; however, 
buprenorphine patients have been found to report 
more headaches, and methadone patients greater 
sedation[125]. There is a trend for better psychomotor 
performance with buprenorphine[126, 127]. When 
injected, buprenorphine damages veins, and 
complications of buprenorphine injection are common 
where buprenorphine is administered to injecting 
drug users[119, 128]. Methadone appears to prolong 
the QT interval, and cardiac arrhythmia adverse 
events have been reported. In clinical trials, the extent 
to which methadone prolongs the QT interval is 
minimal; however, there appears to be a small increase 
in the risk of life-threatening cardiac arrhythmias 
with methadone that is absent with buprenorphine 
[129, 130, 131, 132].
Buprenorphine tablets have a high potential for 
abuse. Wherever buprenorphine has been prescribed 
to injecting drug users, there has been an associated 
epidemic of buprenorphine injecting, with patients 
presenting for treatment using buprenorphine as 
their first and primary drug of abuse. While some 
methadone injection occurs, this is rare – particularly 
when take-home doses are given diluted to 200 ml per 
dose – and it can be managed by supervised dosing of 
methadone. 
Supervising the dosing of buprenorphine does not 
completely remove the problem of abuse because 
it is difficult to adequately supervise the dosing of a 
sublingual medication that can take up to 15 minutes 
to dissolve. Injection of diverted buprenorphine can fuel 
ongoing dependence, transmit bloodborne viruses and 
result in fatal overdose when the drug is combined with 
other sedatives. It has also resulted in hepatitis, local 
and systemic infections, venous and arterial damage, 
and other injection-related problems.
Common buprenorphine-related adverse effects include 
headache, constipation, sleep disorders and anxiety. 
Buprenorphine does not appear to induce significant 
QT prolongation.
Overall, while buprenorphine itself is likely to be a safer 
medication, the difficulty of quantifying these benefits 
and comparing them with the risks of diversion and 
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injection of buprenorphine mean that no conclusions 
on safety differences can be drawn. 
Cost effectiveness
The cost of methadone is approximately US0.5–
1.0 cents/mg, or US60 cents to US$1.20 per effective 
dose (see next section). The cost of delivery and 
associated treatments varies from US$5000 per annum 
in well-resourced countries to approximately US$500 
per annum in less well-resourced countries.
Buprenorphine costs approximately US10 cents to US$1/
mg, or US80 cents to US$8 per minimum recommended 
dose (see next section). Other costs of treatment are 
likely to be similar to those for methadone when 
buprenorphine is supervised.
Methadone is cheaper and more effective than 
buprenorphine at the doses studied; therefore, it is 
dominant in cost-effectiveness comparisons in this 
review.
Limitations of the data
As methadone and buprenorphine are both dose-
dependent treatments, adequate comparison depends 
on doses. Also, because buprenorphine is a partial 
agonist, it is difficult to directly compare doses with 
methadone. Pharmacological evidence would suggest 
that 6–8 mg may not be the optimal buprenorphine 
dose. Higher doses of buprenorphine will be more 
effective because they act over a longer time and are 
more effective in blocking the effects of heroin use. 
Many studies have not used intention-to-treat analyses, 
and the patients who drop out of treatment are generally 
not followed up.
Treatment considerations
Methadone is available in several forms – injectable, 
oral solution and tablet. The oral solution form is 
recommended for the treatment of opioid dependence 
because its administration is more easily supervised; 
also, take-home medication is less likely to be injected 
when it is sufficiently diluted (e.g. to 200 mL) when 
administered.
Buprenorphine is a sublingual tablet most commonly 
available in sizes of 2 and 8 mg. Because it takes 
5–15 minutes to completely dissolve, its ingestion is 
difficult to supervise. On the positive side, because 
of its long duration of action, buprenorphine can 
be administered every second or third day in about 
two thirds of patients, reducing the need for daily 
supervision. A formulation of buprenorphine combined 
with naloxone in a 4:1 ratio is also now available in 
Australia, Europe and the United States (see Annex 4 
for further discussion).
When patients have a history of injecting buprenorphine 
(either illicitly obtained or prescribed), methadone 
maintenance should be used in preference to 
buprenorphine.
Other research and basic research findings
The half-life of methadone is highly variable, and a 
significant minority of patients will not tolerate 24-hourly 
methadone without withdrawal symptoms between 
doses[133]. For many of these patients, buprenorphine 
may be a better option.
Conclusion
In studies to date, methadone at standard doses has 
been more effective in retaining people in treatment 
and reducing heroin use than buprenorphine 
at standard doses; also, methadone is cheaper. 
This evidence comes from meta-analyses of well 
conducted clinical trials (moderate-quality evidence); 
however, use of higher doses of buprenorphine may 
produce different results. Although buprenorphine 
treatment might be expected to be safer than 
methadone treatment, this has not been confirmed 
by research. Currently, high-quality methadone 
provision should be considered the optimal treatment, 
with buprenorphine reserved for second-line therapy 
for patients in whom methadone is unwanted, 
inappropriate or ineffective. Patients who inject 
buprenorphine should be prescribed methadone in 
preference to buprenorphine. This conclusion places 
a high value on treatment outcomes over possible 
safety differences, because of the high mortality from 
untreated opioid dependence.
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Recommendation
For opioid agonist maintenance treatment, most patients 
should be advised to use methadone in adequate doses in 
preference to buprenorphine. 
Strength of recommendation – strong•	
Quality of evidence – high•	
Remarks – Although the general preference may be •	
for methadone over buprenorphine, some patients 
may do better with buprenorphine. Reasons for use 
of buprenorphine may include previous response to 
buprenorphine or lack of response to methadone, short 
duration of action of methadone (i.e. withdrawal symptoms 
between doses), interaction between methadone and other 
medications taken, specific adverse effects of methadone, 
treatment availability and patient preference for subjective 
effects of buprenorphine compared to methadone. 
Reasons not to use buprenorphine include a history of 
buprenorphine injection, buprenorphine-specific adverse 
effects and failure of buprenorphine treatment in the past. 
6.3.3 InITIAl DOSeS OF OPIOID AGOnIST MAInTenAnCe 
TReATMenT
What initial doses of methadone or buprenorphine 
should be used?
Initial dose of methadone 
The initial dose of methadone should be based on a 
careful assessment of the degree of neuroadaptation 
of the patient. The first two weeks of methadone 
treatment is a high-risk period for overdose, because 
it can be difficult to assess with certainty the level of 
neuroadaptation. For patients on prescribed opioids, the 
total daily dose should be converted to an equivalent 
methadone dose given once daily. For patients using 
street opioids (e.g. heroin), methadone doses of 20 mg 
a day will typically be adequate to relieve withdrawal 
symptoms and retain patients in treatment, while at the 
same time having a low risk of opioid overdose. Patients 
with low or uncertain degree of neuroadaptation 
should start on low doses of methadone and be 
closely observed. Some patients with high levels of 
neuroadaptation will experience some discomfort if 
ceasing heroin and commencing methadone at 20 mg 
daily. In this group, the use of higher doses (up to 30 mg) 
to retain patients in treatment and at greater comfort 
should be balanced against the risk of fatal overdose if 
the level of neuroadaptation is overestimated. A safer 
but more labour-intensive strategy is to provide an initial 
safe dose and review the patient several hours later to 
assess the response to that dose, adjust the next daily 
dose and, if necessary, provide a supplementary dose.
Once it has been established that the initial dose is well 
tolerated, the methadone dose should be gradually 
increased until the patient is comfortable and not using 
heroin or other illicit opioids. The rate of increase should 
be individually assessed, and should generally not be 
greater than 10 mg every few days.
Recommendation
During methadone induction, the initial daily dose should 
depend on the level of neuroadaptation; it should generally 
not be more than 20 mg, and certainly not more than 30mg. 
Strength of recommendation – strong•	
Quality of evidence – very low•	
Initial dose of buprenorphine
The risk of overdose during buprenorphine induction is 
low. In patients with high neuroadaptation to opioids, 
however, buprenorphine may precipitate withdrawal 
symptoms initially, and such patients may benefit from 
lower initial doses (2 mg). In addition, patients should 
wait until they are experiencing mild opioid withdrawal 
before taking the first dose of buprenorphine (generally 
at least 12 hours since last heroin or other short-acting 
opioids), to reduce the risk of withdrawal symptoms 
precipitated by buprenorphine. Patients with moderate 
levels of neuroadaptation will generally tolerate initial 
doses of 4–8 mg a day. 
Once it has been established that the initial dose is well 
tolerated, the buprenorphine dose can be increased 
fairly rapidly to a dose that provides stable effects for 
24 hours and is clinically effective.
6.3.4 FIxeD OR FlexIBle DOSInG In AGOnIST 
MAInTenAnCe TReATMenT
Should methadone and buprenorphine doses by fixed 
or individually tailored?
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No studies were identified comparing fixed and flexible 
doses for methadone or buprenorphine maintenance 
treatment. Flexible dosing schedules are thought 
to be preferable because of individual differences 
in absorption and metabolism, and dose-related 
differences in clinical response. In general, the dose of 
methadone and buprenorphine should be increased 
until illicit opioid use ceases. Thereafter, the dose should 
be reviewed frequently, without allowing patients to 
become obsessed with minor changes in their dose. The 
methadone dose should be reviewed more frequently 
during induction and dose increases, after missed doses 
and during dose reduction. In general, the patient should 
be reviewed at least monthly during the maintenance 
phase of treatment.
6.3.5 MAInTenAnCe DOSeS OF MeTHADOne
What maintenance doses of methadone and 
buprenorphine should be used?
See evidence profile in Section A1.5 of Annex 1
There is moderate-quality evidence that high doses 
of methadone (>60 mg) result in better retention in 
treatment and less heroin use than lower doses (<40 mg). 
Health professionals should prescribe effective doses 
of methadone and be prepared to increase the dose if 
patients are still using illicit opioids.
Fixed-dose methadone studies were divided into 
studies that compared 1–39, 40–59, 60–109 and above 
109 mg (patients in this latter category all received 
160 mg).
Efficacy
60–109 mg versus 1–39 mg
When compared to doses in the range 1–39 mg, 60–
109 mg doses resulted in better retention in treatment 
(RR 1.36, 95%CI 1.13 to 1.63, high-quality evidence) 
and had higher rates of opioid abstinence (RR 1.59, 
95%CI 1.16 to 2.18, low-quality evidence) and cocaine 
abstinence (RR 1.81, 95%CI 1.15 to 2.85, moderate-
quality evidence).
60–109 mg versus 40–59 mg
When compared to doses in the range 40–59 mg, 60–
109 mg doses resulted in better retention in treatment 
in the long term (RR 1.23, 95%CI 1.05 to 1.45, high-
quality evidence), and a non-statistically significant 
reduction in heroin use (RR 1.51, 95%CI 0.63 to 3.61, 
low-quality evidence).
40–59 mg versus 1–39 mg
There was no demonstrable difference between 
medium (40–59 mg) and low doses (1–39 mg) in terms 
of retention in treatment (RR 1.26, 95%CI 0.91, 1.75, in 
favour of medium doses, moderate-quality evidence).
Doses above 109mg
When compared to doses in the range 60–109 mg, 
160 mg per day did not result in better treatment 
retention (RR 0.96, 95%CI 0.69 to 1.34, low-quality 
evidence), although this higher dose resulted in better 
retention in treatment than doses below 60mg (RR 
1.67, 95%CI 1.05 to 2.66). 
Non-randomized studies
Numerous non-randomized studies have identified 
better outcomes for patients on high methadone 
doses[134, 135, 136, 137, 138, 139].
Safety
High methadone doses may be associated with 
increased risk of QT prolongation. The precise risk 
of QT-related adverse effects is difficult to quantity, 
but it is probably smaller than the benefits of high 
methadone doses. This is supported by the evidence 
for lower mortality risk for patients on high methadone 
doses[140].
Cost effectiveness
No studies were found that compared the cost 
effectiveness of high and low doses of methadone. In 
well-resourced countries, the cost of methadone is a 
small part of the overall cost of treatment, and using 
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high doses is likely to increase the cost-effectiveness 
of methadone. In less well resourced countries, where 
the cost of methadone may make up a substantial 
portion of the costs of treatment, the situation is less 
clear. However, if heroin use is ongoing at any given 
methadone dose, increasing the methadone dose is 
likely to be a cost-effective response.
Limitations of data
The quality of the evidence on this issue is not high. 
Specifically, there is a lack of research of the impact 
of methadone doses from RCTs. Although there is a 
strong association between high methadone doses 
and good clinical outcomes based on evidence from 
non-randomized studies, this finding may be biased 
by patients who respond to methadone staying in 
treatment longer and on higher doses rather than is the 
case with those who do not respond. 
Treatment considerations
In clinical practice, doses are individually tailored, based 
on ongoing heroin use, withdrawal symptoms between 
doses and adverse effects. Pharmacokinetic studies 
indicate large differences in methadone absorption and 
metabolism. In this context, trough methadone levels, 
measured 24 hours after dosing, are likely to be a better 
measure of the active dose. Some patients are likely to 
be adequately treated with low doses; others may need 
doses above the target dose range.
Conclusion
Doses in the range of 60–109 mg are more effective 
than lower doses. Clinicians should be encouraged to 
aim for doses in this range in general. Clinicians should 
encourage patients to use these high doses and not 
reduce their dose, particularly when they are still using 
illicit opioids.
Recommendation
On average, methadone maintenance doses should be in the 
range of 60–120 mg per day. 
Strength of recommendation – strong•	
Quality of evidence – low•	
6.3.6 MAInTenAnCe DOSeS OF BUPRenORPHIne 
Efficacy
No systematic reviews of the effectiveness of 
buprenorphine at different doses were found. In 
randomized trials that have been conducted comparing 
doses, 6 mg has resulted in less heroin use than 2 mg[141], 
8 mg/day has been shown to have better retention than 
3 mg per day[142] and 12 mg/day has resulted in less heroin 
use than 4 mg/day[143]. Two studies examining higher 
doses have shown a trend (not statistically significant in 
either study) for 16 mg to be more effective than 8 mg 
daily[110, 144].
Safety
Buprenorphine dose does not appear to have 
implications for safety. However, there is a suggestion 
from one RCT that alanine transaminase (ALT) and 
aspartate transaminase (AST) levels are more likely to be 
elevated in patients on higher doses of buprenorphine.
Cost effectiveness
No studies covering cost effectiveness of different doses 
of buprenorphine were identified in this review. The 
cost of buprenorphine is a significant component of 
buprenorphine treatment and, while higher doses are likely 
to be more effective, the cost effectiveness is not clear.
Limitations of the data
There are few data comparing low doses to those above 
6 mg.
Other evidence
High doses of buprenorphine (16– 32 mg) block the 
additional effects of heroin better than lower doses[145, 
146, 147, 148, 149, 150] and last for longer without inducing 
significant additional sedation.
Conclusion
Although the quality of evidence is low, higher doses 
are likely to result in better retention and less heroin use 
35Patient level guidelines – for clinicians
than lower doses, with minimal adverse consequences 
other than cost. On average, doses should be at least 
8 mg per day. If patients are continuing to use illicit 
opioids, consideration should be given to increasing the 
dose by 4–8 mg, to a limit of 32 mg daily.
Recommendation
Average buprenorphine maintenance doses should be at 
least 8 mg per day. 
Strength of recommendation – standard•	
Quality of evidence – very low•	
6.3.7 SUPeRVISIOn OF DOSInG In OPIOID AGOnIST 
MAInTenAnCe TReATMenT 
Should opioid agonist maintenance treatment doses be 
supervised?
There has been very little systematic research on the 
supervision of dosing in opioid agonist maintenance 
treatment. All of the clinical trials demonstrating the 
efficacy and safety of methadone and buprenorphine 
against placebo or opioid withdrawal have been 
conducted using supervised administration, as have 
trials comparing methadone and buprenorphine. Non-
supervised administration is used in some countries 
for buprenorphine treatment, most notably France, 
and some countries have limited supervision of dosing 
(such as once a week or less) for stable methadone 
patients. Diversion occurs with both methadone and 
buprenorphine if they are unsupervised, although there 
appears to be much greater diversion and injection of 
buprenorphine, even when combined with naloxone, 
than of methadone[151]. 
This is probably due to multiple factors. 
Buprenorphine is an attractive drug for injection •	
because it produces strong effects, even in low 
doses, resulting in a group of individuals using 
buprenorphine as their first and main drug of abuse.
The milder withdrawal symptoms with reduced •	
buprenorphine dosing mean that patients can take 
some of their own buprenorphine and divert the 
remainder without experiencing strong withdrawal 
symptoms.
Buprenorphine is difficult to supervise effectively •	
because it is sublingually administered, taking 
5-15 minutes to dissolve, wheras methadone is 
swallowed.
Methadone is difficult to divert when dosing is supervised 
and when given in diluted form (i.e. 200 mL) for take-
home use its injection is rare. It has a long duration 
of action, making it less attractive to inject regularly. 
People who do purchase methadone illicitly generally 
use it for self treatment purposes[152].
The data on diversion and overdose deaths consistently 
indicate that unsupervised methadone is a hazard, 
because it results in a substantial number of overdose 
deaths in people for whom it is not prescribed[153]. 
Diverted buprenorphine, on the other hand, is less likely 
to result in death (although deaths have occurred in 
combination with other sedatives); however, it is likely 
to be injected. The main problem with buprenorphine 
diversion is the creation of a group of people primarily 
dependent on illicit buprenorphine, who are at risk from 
the problems associated with buprenorphine injection, 
which can lead to hepatitis C, HIV, endocarditis and 
local infections. Whether an epidemic of diverted 
buprenorphine is a net benefit or harm is not easy to 
ascertain, because it may result in a corresponding drop 
in heroin use; however, it would not be acceptable in 
many countries, because it would threaten the viability 
of the drug treatment system.
These points form the public health argument 
for supervision of treatment. On the other hand, 
unsupervised treatment is cheaper to set up and easy 
to expand. Expansion of treatment is a high priority 
in many areas where HIV in injecting drug users is a 
problem and current rates of treatment are low. Rapid 
expansion of unsupervised buprenorphine is argued to 
be the most feasible method of meeting the unmet need 
for treatment in the short term[154]. However, it is not 
clear whether unsupervised buprenorphine treatment, 
with its associated problems of buprenorphine 
injecting, would reduce HIV spread to the extent that 
has been demonstrated for supervised methadone 
treatment.
The impact of supervision of treatment on patients 
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themselves must be considered. Opioid dependence 
implies a lack of control over opioid use; thus, there 
are strong theoretical reasons why – at the start of 
treatment at least – supervision of methadone and 
buprenorphine may be advantageous to the patient. 
Unfortunately, there is a lack of clinical trial data on this 
topic. Research has tended to focus on patients who 
have been in treatment for some time, examining the 
impact of providing unsupervised treatment to those 
who meet certain criteria of stability. In this situation, 
RCTs demonstrate that making unsupervised treatment 
contingent upon cessation of illicit drug use results in a 
reduction in illicit opioid use.
On balance, initiating treatment with supervised dosing, 
assessing response to treatment, and subsequently 
allowing unsupervised doses to patients who 
demonstrate stability appears to substantially reduce 
diversion, probably does not diminish efficacy and is 
supported by patient groups.
The key elements of “stability” appear to include 
housing, employment, not being dependent on 
multiple drugs and ceasing to inject after entering 
treatment.
It has been argued that because the risk of overdose on 
buprenorphine is lower then that of methadone, and 
because unsupervised doses are cheaper to provide and 
readily accepted by patients, that in places where opioid 
agonist treatment is not currently available, the greatest 
public health benefit would occur from the introduction 
of buprenorphine with unsupervised dosing. It is 
not possible based on the current data to draw firm 
conclusions on this proposition. The potential benefits 
of making treatment more accessible, affordable and 
possibly more attractive to patients need to be balanced 
against risk of less effective treatment, creation of an 
illicit buprenorphine market and potential community 
antagonism.
Practical considerations
Supervised methadone dosing involves first dispensing 
methadone liquid into a clean cup, the liquid is then 
consumed under the direct observation of a nurse, 
pharmacist or doctor. Talking to patients after they 
have consumed their methadone is generally adequate 
to ensure that the dose has been taken.
Buprenorphine supervision is more difficult, because 
the tablet can easily be sequestered in a corner of the 
mouth as it takes up to 15 minutes to dissolve. The 
tablet should be dispensed into a clean container and 
tipped into the mouth of the patient, under the tongue. 
Periodic examination should reveal the tablet in various 
stages of dissolution.
If no longer needed, for whatever reason, unconsumed 
unsupervised doses should be returned to the place 
where they were dispensed.
Conclusions
On balance, initiating treatment with supervised 
dosing, assessing the response to treatment and 
subsequently allowing unsupervised doses to patients 
who demonstrate stability appears to substantially 
reduce diversion, probably does not diminish treatment 
efficacy and is supported by patient groups. Routine 
supervision of dosing with methadone or buprenorphine 
is recommended for all patients unless they have 
demonstrated that they meet commonly accepted 
criteria for take-home doses, developed at a regional 
or national level.
Recommendation
Methadone and buprenorphine doses should be directly 
supervised in the early phase of treatment.
Strength of recommendation – strong•	
Quality of evidence – very low•	
Recommendation
Take-away doses may be provided for patients when 
the benefits of reduced frequency of attendance are 
considered to outweigh the risk of diversion, subject to 
regular review.
Strength of recommendation – standard•	
Quality of evidence – very low•	
6.3.8 OPTIMAl DURATIOn OF OPIOID AGOnIST 
TReATMenT
What is the optimal duration of opioid agonist treatment?
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There is little research on the optimal duration of opioid 
agonist treatment. Studies comparing short-term opioid 
agonist treatment (i.e. weeks to months) to longer 
term treatment (6–12 months) find better results for 
longer term treatment. This is consistent with opioid 
dependence being a longer-term disease. No RCTs 
comparing longer treatment durations were found. 
Observational studies indicate that those who remain in 
long-term opioid agonist therapy are more likely to stay 
alive than those who do not, and that cessation of opioid 
agonist maintenance treatment is associated with a risk 
of relapse to opioid use. Given these findings, these 
guidelines recommend that opioid agonist treatment 
should be seen as open ended, and should be continued 
as long as clinically indicated. Patients and clinical staff 
should not take lightly the decision to terminate opioid 
agonist maintenance treatment (e.g. for administrative 
reasons). Factors predicting successful termination of 
opioid agonist maintenance treatment are not well 
described, but are likely to include employment or other 
meaningful activity, abstinence from opioid and other 
drug use while taking opioid agonists, and changes 
in the psychosocial environment after starting opioid 
agonist treatment.
Practical considerations
The decision to stop opioid substitution therapy can be a 
difficult one for patients, and they often seek guidance 
from treatment staff. On the other hand, some patients 
simply make up their minds that they want to cease 
opioid agonist treatment. In both situations, patients 
should be informed of the risks of cessation of the 
therapy and encouraged to make healthy choices. In 
patients doing well on opioid substitution therapy, this 
can also be an occasion to consider the option of more 
take-home doses as an alternative to cessation of opioid 
substitution therapy.
6.3.9 USe OF PSYCHOSOCIAl InTeRVenTIOnS In 
MAInTenAnCe TReATMenT
Should psychosocial treatments be used in addition to 
pharmacological maintenance treatments?
See evidence profile in Section A1.12 of Annex 1
Efficacy
A recent Cochrane Collaboration review identified 
eight RCTs that addressed the issue of whether 
psychosocial interventions should be used in addition 
to pharmacological maintenance treatments. 
Comparing methadone plus psychosocial treatment 
to methadone alone, the pooled analysis found no 
difference in treatment retention (RR 0.94, 95%CI 0.85 
to 1.02, high-grade evidence); however, heroin use was 
significantly reduced with the addition of psychosocial 
treatment (RR 0.69, 95%CI 0.53 to 0.91, high-grade 
evidence).
Cost effectiveness
Cost effectiveness studies in the United States found 
that methadone with moderate intensity psychosocial 
services (1–2 hours per week) are more cost effective 
than methadone either without psychosocial services 
or with high intensity services (i.e. several hours a day)
[155,156,157].
Limitations of data
Studies have used different techniques, including 
hypnotherapy, psychotherapy, acceptance and 
commitment therapy, interpersonal psychotherapy, 
supportive–expressive psychotherapy, counselling, 
cognitive behavioural therapy (CBT), contingency 
management, dialectic behaviour therapy and 
comprehensive validation therapy. It is difficult 
to compare these interventions in meta-analyses. 
Contingency management studies have the most 
consistently positive findings, regardless of whether 
vouchers, take-home methadone privileges or prize 
draw incentives are used. It is not clear whether these 
interventions can be generalised to settings outside the 
one in which they were carried out (mainly the United 
States).
Conclusion
Psychosocial assistance in methadone maintenance can 
reduce heroin use in methadone maintenance. In the 
United States, such services are most cost effective if 
they are of moderate intensity (1–2 hours a week).
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Recommendation
Psychosocial support should be offered routinely in association 
with pharmacological treatment for opioid dependence. 
Strength of recommendation – strong•	
Quality of evidence – high•	
Remarks – While patients should be offered psychosocial •	
support, they should not be denied agonist maintenance 
treatment should they refuse such support.
6.4 Management of opioid withdrawal
Although distressing, the opioid withdrawal syndrome 
is rarely life threatening; however, pharmacologically 
assisted management of opioid withdrawal can make 
withdrawal from opioids more comfortable and more 
likely to succeed. Given the high rate of relapse, assisted 
opioid withdrawal is not considered an effective 
treatment of opioid dependence on its own (see section 
6.3).
6.4.1 SIGnS, SeVeRITY AnD TReATMenT PRInCIPleS
The severity of opioid withdrawal depends on the dose 
and pharmacological properties of the opioids used, 
and on the extent of neuroadaptive changes that have 
taken place in the patient. Drugs with short half-lives 
will give rise to withdrawal symptoms at an earlier phase 
than those with long half-lives; the symptoms will also 
peak and resolve earlier. Untreated heroin or morphine 
withdrawal typically reaches its peak 36–72 hours 
after the last dose, and symptoms will have subsided 
substantially after 5 days. Untreated withdrawal from 
methadone or other long-acting opiates typically reaches 
its peak at 4–6 days, and symptoms do not substantially 
subside for 10–12 days. Untreated buprenorphine 
withdrawal following the abrupt cessation of long-term 
buprenorphine treatment emerges within 3–5 days of 
the last dose, and mild withdrawal features can continue 
for several weeks.
Opioid antagonists (e.g. naltrexone), which induce rapid 
changes in receptor activity, can precipitate withdrawal 
symptoms of greater severity than those normally seen 
in heroin withdrawal, if administered in close connection 
with opioid use. Treatment with naltrexone can be 
started within one week of cessation of short-acting 
opioids and buprenorphine. By contrast, naltrexone is 
usually not started until 10–14 days after the cessation 
of methadone.
The severity of withdrawal is related to the degree and 
rate of reversal of neuroadaptive changes related to 
opioid use. The most severe withdrawal occurs with the 
sudden reversal of significant levels of neuroadaptation; 
for example, when naltrexone is taken by patients who 
are taking high doses of methadone.
6.4.2 ASSeSSMenT OF OPIOID WITHDRAWAl
When assessing the severity of current opioid withdrawal 
features, both subjective and objective withdrawal 
features are relevant. Subjective withdrawal features 
are a more sensitive measure of opioid withdrawal, but 
objective signs, when present, are more reliable. For 
the purpose of dose titration, it is best to place greater 
emphasis on observable signs rather than subjective 
symptoms.
Symptoms and signs of opioid withdrawal and 
assessment of withdrawal severity are listed below – 
the asterisks indicate withdrawal symptoms that can be 
quantified by the Subjective Opiate Withdrawal Scale 
(SOWS):
sweating*•	
lacrimation (excessive tear  •	
formation)*
yawning*•	
feeling hot and cold*•	
anorexia and abdominal cramps*•	
nausea•	
vomiting and diarrhoea*•	
tremor•	
insomnia and restlessness*•	
generalized aches and pains*•	
tachycardia•	
hypertension*•	
piloerection (gooseflesh)•	
dilated pupils •	
increased bowel sounds. •	
Severity of withdrawal symptoms can also be quantified 
with the Objective Opioid Withdrawal Scale (OOWS), or 
with a combined single objective and subjective scale 
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such as the Clinical Opiate Withdrawal Scale (COWS) 
(Annex 11).
When assessing the patient for planned opioid 
withdrawal, including admission to a residential 
detoxification facility or provision of medication to 
manage withdrawal symptoms, it is important to 
complete a thorough assessment of the patient (see 
section 6.1).  and, as appropriate, inform the patient of 
the estimated risks of opioid withdrawal (including the 
effects of subsequent relapse), as compared to opioid 
agonist maintenance treatment. Since withdrawal from 
opioids is associated with higher mortality than opioid 
agonist maintenance treatment, some indication of the 
patient's informed consent for opioid detoxification 
is advised. Precautions for opioid dependence include 
pregnancy (specifically the first and third trimesters) and 
current acute comorbid conditions.
6.4.3 CHOICe OF TReATMenTS FOR ASSISTInG 
WITHDRAWAl FROM OPIOIDS
Opioid withdrawal can be managed by controlling the 
rate of cessation of opioids and by providing medication 
that relieves symptoms, or by a combination of the 
two.
This analysis focuses on the three approaches to 
assisting withdrawal from opioids that have been most 
widely evaluated: tapered oral methadone, tapered 
sublingual buprenorphine and tapered oral adrenergic 
alpha-2 agonists.
There are many other alternative treatments; for 
example:
shorter acting oral opioids – these are not •	
examined here due to an absence of research on 
their use and difficulties in enabling supervised 
administration, should it be required
recently developed transdermal formulations of •	
opioids and adrenergic alpha-2 agonists – these 
may have a role to play, although research is also 
limited at this stage
 medications to manage specific withdrawal •	
symptoms used in combination with opioids 
or alpha-2 agonists (e.g. benzodiazepines for 
anxiety and insomnia, anti-emetics for nausea and 
vomiting, and paracetamol and non-steroidal anti-
inflammatory drugs [NSAIDs] for muscle aches)
Detailed guidance on the use of these medications is 
beyond the scope of these guidelines.
What treatments should be used to assist withdrawal 
from opioids?
See evidence profile in Section A1.6 of Annex 1
Efficacy
Methadone versus alpha-2 agonists
In the pooled analysis (7 studies, 577 participants), there 
was no significant difference between methadone and 
alpha-2 agonists in treatment completion (RR 1.09, 
95%CI 0.90 to 1.32, moderate-quality evidence). 
There was no difference in rates of relapse at follow-
up (intention-to-treat analysis) (RR 1.06: 95%CI 0.55 to 
2.02, low-quality evidence).
Methadone versus buprenorphine
In the pooled analysis (2 studies, 63 participants), there 
was no significant difference in completion of treatment 
between methadone and buprenorphine (RR 0.88: 
95%CI 0.67 to 1.15, low-quality evidence).
Buprenorphine versus alpha-2 agonists
In the pooled analysis (8 studies, 653 participants) 
comparing buprenorphine to alpha-2 agonists, there 
were higher completion rates with buprenorphine 
(RR 1.53, 95%CI 1.18 to 1.99, moderate-quality 
evidence), lower peak objective withdrawal scores 
(SMD –0.61, 95%CI –0.86 to –0.36, moderate-quality 
evidence), and lower overall self reported levels of 
opioid withdrawal (SMD –0.59, 95%CI –0.79 to –0.39, 
high-quality evidence).
Safety
Methadone has the greatest risk of over sedation, 
although this is reduced with the use of lower doses 
(<20 mg). Buprenorphine, while safer than high doses 
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of methadone, is nonetheless potent even at low doses, 
and can cause significant respiratory depression when 
used in combination with other sedatives, including 
benzodiazepines, alcohol, tricyclic antidepressants, 
sedating antihistamines and major tranquilizers. A 
number of deaths have been reported involving the 
combination of buprenorphine with benzodiazepines 
and other sedatives. As a partial agonist, buprenorphine 
can induce precipitated withdrawal if used while 
heroin is still bound to receptors. This may occur on 
up to 10% of occasions in which buprenorphine is 
used for opioid withdrawal. The main adverse effect of 
buprenorphine is headache. Alpha-2 agonists can cause 
postural hypotension, which can lead to dizziness and 
fainting. In overdose, alpha-2 agonists induce profound 
bradycardia which may require intensive care treatment 
but is not usually fatal. Lofexidine induces less postural 
hypotension than clonidine; Cochrane Collaboration 
reviews of clinical trials detected no difference in safety.
Cost effectiveness
There are limited data to differentiate the cost 
effectiveness of these medications when used for opioid 
withdrawal. Buprenorphine and lofexidine are more 
expensive than methadone. Despite this, an analysis in 
Australia found outpatient buprenorphine to be more 
cost effective than outpatient clonidine [158].
Limitations of data
It is difficult to make an assessment of the relative 
effectiveness of withdrawal treatment from 
detoxification trials because of variations in practice and 
because participants often leave withdrawal units on 
the day of the last dose, before withdrawal symptoms 
are completed. Data on severity of withdrawal are 
useful to compare treatments, but are not uniformly 
collected and are difficult to include in meta-analysis. 
Furthermore, withdrawal methods vary and few studies 
use the same techniques.
Treatment considerations, duration of the 
treatment
All treatments can be used in inpatient and outpatient 
withdrawal settings. Methadone and buprenorphine 
can be administered as once-daily supervised doses, to 
reduce diversion and increase safety (guanfacine can 
also be administered once daily, although the need for 
supervised dosing is less with alpha adrenergic agonists). 
Gradual reduction of methadone and buprenorphine 
can reduce the severity and increase the length of opioid 
withdrawal. Such gradual reductions improve treatment 
retention but reduce the rate of successful completion 
of withdrawal[159].
Conclusion
Buprenorphine is suitable for once-daily •	
administration; it leads to less severe withdrawal 
and higher rates of completion than alpha-2 
agonists.
Methadone is cheaper than buprenorphine and •	
carries no risk of precipitated withdrawal; it is 
suitable for use in pregnancy.
Alpha-2 agonists can lead to shorter duration •	
of withdrawal symptoms and shorter time to 
commencement of naltrexone.
All three medications listed above can be used for 
opioid withdrawal. Clinical trials clearly show that 
buprenorphine is more effective than alpha-2 agonists, 
and clinical experience would suggest that methadone 
lies somewhere between the two, even though equivalent 
to both in the Cochrane Collaboration reviews. Choice 
should depend on the individual situation, capacity to 
tolerate withdrawal symptoms, timeframe and patient 
preferences.
Recommendation
For the management of opioid withdrawal, tapered doses of 
opioid agonists should generally be used, although alpha-2 
adrenergic agonists may also be used. 
Strength of recommendation – standard•	
Quality of evidence – moderate•	
Remarks – Buprenorphine and methadone are both •	
recommended in the management of opioid withdrawal. 
As a partial agonist with slow receptor dissociation, 
buprenorphine has the best pharmacological profile 
for use in withdrawal, reducing the risk of rebound 
withdrawal when opioids are ceased. While buprenorphine 
is probably slightly more effective, it is more expensive. 
continued on next page
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6.4.4 ACCeleRATeD WITHDRAWAl MAnAGeMenT 
TeCHnIQUeS
Accelerated withdrawal techniques use opioid 
antagonists to induce withdrawal and thus complete 
the process more quickly. Here, the techniques are 
divided depending on whether they co-administer 
minimal or heavy sedation. Minimal sedation refers 
to levels that might commonly be prescribed in the 
management of opioid withdrawal in outpatient or 
residential settings, because they have a low risk of 
inducing respiratory depression. Heavy sedation refers 
to the administration of either oral or parenteral 
sedatives or anaesthesia that have a significant risk 
of inducing respiratory depression. The use of heavy 
sedation requires intensive monitoring and the capacity 
to assist respiration, such as would be provided in an 
intensive care setting.
Should antagonists with minimal sedation be used for 
opioid withdrawal?
See evidence profile in Section A1.8 of Annex 1
Efficacy
Four studies (394 participants) were found that 
examined the issue of whether antagonists with 
minimal sedation should be used for opioid 
withdrawal. In the pooled analysis, there were 
no significant differences in rates of completion 
between different opioid antagonist techniques, 
(RR 1.26, 95%CI 0.80 to 2.00, moderate-quality 
evidence). No difference in relapse rates was 
detected (RR 0.83, 95%CI 0.52 to 1.35, low-quality 
evidence[160].
Safety
Data from observational studies suggest higher rates of 
adverse effects with the use of opioid antagonists (RR 3.7, 
95%CI 0.65 to 21.32, very low-quality evidence).
Cost effectiveness
Although the use of opioid antagonists adds to the 
cost of medications for opioid withdrawal, the overall 
cost effectiveness may be greater than conventional 
withdrawal treatment if the duration of withdrawal 
treatment is reduced[158].
Treatment considerations
Naltrexone hydrochloride is available primarily as a solid 
oral formulation in 25 mg and 50 mg tablets. Naloxone 
is available as ampoules for injection, at a concentration 
of 0.4 mg in 1 mL, or as a prefilled syringe.
Treatment regimens
Dosing regimens used in clinical trials range from a 
single dose of 50 mg naltrexone daily to a graduated 
increase of 12.5 mg naltrexone daily.  Techniques 
vary from a single daily dose of naloxone to the use 
of naloxone infusions. Other than the observation that 
regimens that use higher initial doses of naltrexone are 
associated with higher rates of delirium, it is not clear 
which of these approaches is more effective. Careful 
and continuous monitoring is necessary during the 
hours immediately following administration of opioid 
antagonists, because of the possibility of delirium, 
vomiting and diarrhoea. To prevent and treat excessive 
diarrhoea and vomiting, expensive medications, such 
as ondansetron and octreatide, are often required, 
combined with intravenous fluid replacement. Opioid 
antagonist withdrawal techniques should not be 
undertaken in patients with a history of cardiac disease, 
psychosis, chronic renal impairment or decompensated 
liver disease, or current dependence on alcohol, 
benzodiazepines or stimulants.
Benefits
Use of antagonists may reduce the duration of 
The duration of the dose taper should be at least 3 days, 
with a taper over 5 days for buprenorphine and 10 days 
for methadone resulting in acceptable withdrawal 
symptoms during treatment and minimal rebound 
withdrawal symptoms on cessation of the opioid agonist. 
Lofexidine should be used in preference to clonidine, 
particularly in outpatient settings, because it has less 
adverse effects.
recommendation continued
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withdrawal; thus reducing the overall severity of 
withdrawal and increasing the chances of successful 
completion. In inpatient settings where the cost of the 
facility is high compared to the cost of medication, this 
may result in significant cost savings. This technique 
facilitates commencement of naltrexone treatment.
Undesirable effects and consequences
Adverse effects of opioid withdrawal treatment may 
include a higher peak severity of withdrawal symptoms, 
possibly resulting in dehydration (and resulting 
complications such as renal failure) and delirium. 
Complications from excessive sedation used in managing 
the increase in peak withdrawal severity could include 
aspiration pneumonia and respiratory depression.
Conclusion
The small number of clinical trials conducted on 
treatments for opioid withdrawal have used a variety 
of approaches, making generalization difficult. Results 
from these trials suggest that antagonist-induced 
withdrawal techniques increase the severity of opioid 
withdrawal initially, and may increase the adverse 
effects of withdrawal. Given the potential for harm, 
there is not enough evidence of benefit to recommend 
the routine use of these techniques.
Recommendation
Clinicians should not routinely use the combination of opioid 
antagonists and minimal sedation in the management of 
opioid withdrawal.
Strength of recommendation – standard•	
Quality of evidence – very low•	
Remarks – This recommendation places a higher value •	
on the prevention of adverse outcomes due to delirium 
and dehydration than on any potential for reduced 
duration or overall severity of withdrawal symptoms. If 
opioid antagonists are to be used, careful and continuous 
monitoring is necessary for at least 8 hours following the 
administration of opioid antagonists, due to the possibility 
of delirium, vomiting and diarrhoea, and systems should be 
available for identifying and managing people who become 
dehydrated or delirious. Opioid antagonist withdrawal 
should not be undertaken in pregnant women because of 
the risk of inducing abortion or premature labour.
Should antagonists with heavy sedation or anaesthesia 
be used for opioid withdrawal?
Opioid withdrawal with opioid antagonists and heavy 
sedation or anaesthesia is defined as withdrawal that 
requires monitoring of vital functions such as respiratory 
rate and oxygen saturation. Such withdrawal usually 
takes place in intensive care settings.
See evidence profile in Section A1.9 of Annex 1
Efficacy
A recent Cochrane Collaboration review[161] identified 
RCTs in which ultra-rapid opioid detoxification (UROD) 
was compared to:
inpatient opioid withdrawal with clonidine (two •	
studies[162, 163])
inpatient withdrawal with buprenorphine (one study•	 [163]) 
opioid antagonist and minimal sedation techniques •	
(two studies[164, 165]). 
Completion of treatment and commencement of 
naltrexone
In the pooled analysis, there was no difference in 
the rates of completion of treatment of naltrexone 
compared to either clonidine (RR 1.15, 95%CI 0.79 to 
1.68, moderate-quality evidence), or buprenorphine 
(RR 0.82, 95%CI 0.34 to 1.97, low-quality evidence). 
The use of antagonists and heavy sedation resulted 
in higher rates of naltrexone commencement than 
inpatient clonidine withdrawal (RR 3.40: 95%CI 2.32 
to 4.98, moderate-quality evidence), but not inpatient 
buprenorphine withdrawal (RR 0.97: 95%CI 0.88 to 
1.07, low-quality evidence).
Relapsed at follow-up
Heavy sedation or anaesthesia made no difference in 
rates of heroin use at the 6 month follow-up (RR 0.97, 
95%CI 0.88 to 1.08, moderate-quality evidence).
Retention in treatment at 12 months 
Heavy sedation or anaesthesia made no difference to 
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rates of retention in treatment at 12 months (RR 0.95, 
95%CI 0.69 to 1.30, moderate-quality evidence).
Safety
Higher rates of adverse effects were seen with 
techniques involving heavy sedation or anaesthesia 
(RR 3.21, 95%CI 1.13 to 9.12, moderate-quality 
evidence).Potential adverse effects include severe opioid 
withdrawal resulting in dehydration (and resulting 
complications such as renal failure) and delirium. 
Potential complications from excessive sedation include 
aspiration pneumonia and respiratory depression[166].
Three life-threatening adverse events occurred out of 
35 participants in the heavy sedation groups, and none 
out of 71 participants in the non-heavy sedation groups 
(RR 14, 95%CI 0.74 to 264, low-quality evidence).
Cost effectiveness
Techniques using heavy sedation and anaesthesia are 
expensive. In an Australian analysis, these techniques did 
not offer any cost-effective advantages over techniques 
using antagonists and minimal sedation[158].
Limitations of data
Studies do not have enough numbers to accurately 
determine safety data. Variations in technique may 
result in different patterns of safety and efficacy.
Treatment considerations
At a minimum, techniques involving heavy sedation 
should be conducted in a setting that is suitable for 
managing respiratory depression, such as an intensive 
care or high-dependency unit. A number of patients 
have died when this technique has been used outside 
intensive care unit settings[166, 167].
Summary
Compared with use of methadone and alpha-2 
adrenergic agonist treatment for opioid detoxification, 
use of opioid antagonists and heavy sedation may mean 
that it is possible to start naltrexone earlier. However, 
use of opioid antagonists and heavy sedation is of little 
benefit over buprenorphine-assisted withdrawal or use 
of opioid antagonists with minimal sedation. In addition, 
the use of opioid antagonists and heavy sedation leads 
to significantly higher complication rates. Given this 
balance, techniques combining opioid antagonists and 
heavy sedation are not recommended.
Recommendation 
Clinicians should not use the combination of opioid 
antagonists with heavy sedation in the management of 
opioid withdrawal.
Strength of recommendation – strong•	
Quality of evidence – low•	
6.4.5 TReATMenT SeTTInG FOR OPIOID WITHDRAWAl
Should withdrawal from opioids be conducted in 
inpatient or outpatient settings?
See evidence profile in Section A1.10 of Annex 1
Efficacy
A recent Cochrane Collaboration review[168] identified 
one RCT that directly addressed the issue of whether 
withdrawal from opioids should be conducted in 
inpatient or outpatient settings. The review found 
better rates of completion of treatment for the inpatient 
group (RR 1.91, 95%CI 1.03 to 3.55, very low-quality 
evidence). There were no differences in relapse rates 
between inpatient and outpatient groups (RR 1.07, 
95%CI 0.97 to 1.18).
Safety
There were no data to compare the safety of inpatient 
and outpatient withdrawal. It might be expected 
that inpatient withdrawal would be safer than 
outpatient withdrawal, but no data are available on this 
topic.
Cost effectiveness
Inpatient opioid detoxification is significantly more 
expensive than outpatient opioid detoxification. 
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Australian data suggest that outpatient withdrawal with 
buprenorphine is significantly more cost effective[158].
Limitations of data
The RCT upon which the efficacy data is based has 
significant flaws; as a result, the grade of evidence 
is low. It seems that many patients allocated to the 
inpatient group either refused inpatient treatment or 
dropped out before opioid withdrawal was arranged.
Treatment considerations
Inpatient treatment is expensive to administer because 
it generally requires a secure environment, 24-hour 
nursing care and daily medical care. Patients in opioid 
withdrawal are generally restless and irritable, and it 
can be a challenging environment in which to work. 
Ensuring the health and safety of the staff in residential 
withdrawal units requires adequate staffing and training 
levels.
Benefits
Opioid withdrawal in residential facilities has higher rates 
of success and is probably safer.
Undesirable effects and consequences
Opioid withdrawal in residential facilities is expensive 
and is inconvenient for many patients.
Conclusion
Inpatient detoxification appears to have higher 
rates of completion of withdrawal than outpatient 
detoxification, but there is no demonstrable difference 
in relapse rates. Data to estimate the relative safety of 
inpatient and outpatient detoxification are lacking. It is 
more cost effective to provide most opioid detoxification 
on an outpatient basis, reserving inpatient opioid 
detoxification for patients who:
have previously failed to complete outpatient •	
detoxification 
have had complications during opioid withdrawal•	
have insufficient social support or comorbid medical or •	
psychiatric conditions.
6.4.8 PSYCHOSOCIAl ASSISTAnCe In ADDITIOn 
TO PHARMACOlOGICAl ASSISTAnCe FOR OPIOID 
WITHDRAWAl
Is psychosocial assistance plus pharmacological 
assistance for opioid withdrawal more useful than 
pharmacological assistance alone?
See evidence profile in Section A1.13 of Annex 1
Efficacy 
The pooled results of five RCTs (184 participants) indicate 
that combined psychosocial and pharmacological 
assistance results in greater rates of completion of 
treatment (RR 1.68, 95%CI 1.11 to 2.55, moderate-
quality evidence), lower rates of relapse at follow-up (RR 
0.41, 95%CI 0.27 to 0.62, moderate-quality evidence), 
despite a trend towards higher rates of opioid use during 
detoxification (RR 1.3, 95%CI 0.99 to 1.70, moderate-
quality evidence). There were no differences in rates of 
other substance use during detoxification[169].
Treatment considerations
The types of psychological assistance provided in the 
studies were contingency management, community 
reinforcement, psychotherapeutic counselling and family 
therapy. The data show no clear advantage of one technique 
over the others, although the evidence (from four studies) 
is strongest for contingency management approaches 
combined with methadone or buprenorphine.
Benefits
Psychosocial assistance can:
help patients to clarify their goals around their drug •	
use
 increase patients’ motivation to stop or reduce their •	
drug use
increase accountability for the outcomes of the •	
attempted opioid detoxification. 
In addition, psychosocial support can help to educate 
patients about the sort of withdrawal symptoms they 
will experience, provide them with useful strategies for 
45Patient level guidelines – for clinicians
minimizing withdrawal and help them to interpret the 
current withdrawal phenomena. It can also facilitate 
transfer to post-withdrawal treatment options, and 
assist with reintegration into society.
 
Undesirable effects and consequences
There is a theoretical risk that psychosocial interventions 
to assist people undertaking opioid withdrawal may 
inadvertently encourage people to continue with opioid 
detoxification instead of moving to more effective longer 
term interventions, such as opioid agonist maintenance 
treatment.
Conclusion
For those who wish to withdraw from opioids, 
combined psychosocial and pharmacological assistance 
increases the chance of successfully completing opioid 
withdrawal. The evidence is strongest for contingency 
management approaches.
Recommendation
Psychosocial services should be routinely offered in combination 
with pharmacological treatment of opioid withdrawal.
Strength of recommendation – standard•	
Quality of evidence – moderate•	
6.5 Opioid antagonist (naltrexone) 
treatment
Should opioid antagonist therapy be used for opioid 
dependence and, if so, what are the indications for use?
Naltrexone is a highly specific opioid antagonist with 
a high affinity for opioid receptor sites. It effectively 
reverses and blocks the opioid effects of lower affinity 
reversible agonists, such as methadone and heroin. 
Naltrexone hydrochloride is available by prescription in 
many countries as 25 and 50 mg tablets; it is also used 
in the treatment of alcohol dependence.
6.5.1 InDICATIOnS FOR OPIOID AnTAGOnIST THeRAPY
See evidence profile in Section A1.11 of Annex 1
Efficacy
Naltrexone was compared to placebo for post-opioid 
withdrawal (with or without psychosocial treatment). 
There was no effect of naltrexone on retention in 
treatment (RR 1.08, 95%CI 0.74 to 1.57, moderate-
quality evidence). There was a reduction in heroin use 
with naltrexone (RR 0.72, 95%CI 0.58 to 0.90, low-
quality evidence). There was no difference in relapse at 
follow-up (RR 0.94, 95%CI 0.67 to 1.34, very low-quality 
evidence). There was also a large reduction in criminal 
behaviour with naltrexone (RR 0.50, 95%CI 0.27 to 
0.91, very low-quality evidence).
Safety
There was no difference in reported rates of adverse 
effects (RR 1.21, 95%CI 0.81 to 1.81). However, 
some observational studies have found high rates of 
opioid overdose in the period after ceasing naltrexone 
treatment.
Limitations of data
Only a small number of studies have examined naltrexone 
for prevention of relapse in opioid dependence.
Benefits
Naltrexone treatment results in a reduction in heroin 
use and criminal behaviour. Family members of opioid 
addicts often like naltrexone treatment because it is 
clear that if the patient is taking the naltrexone they 
are not using heroin. Also, when family members 
directly observe naltrexone consumption, it gives 
them an opportunity to become involved in the 
treatment of the individual. Naltrexone blocks the 
effects of heroin for approximately 24 hours after 
each 50mg dose.
Undesirable effects and consequences
Patients often cease taking naltrexone with the 
intention of using heroin again, and when they do so it 
is difficult for them to assess the dose of heroin to use, 
because the effects of naltrexone are wearing off. In 
the space of 12 hours, the same dose of heroin can be 
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blocked or can be fatal. This may result in higher rates 
of unintentional opioid overdose in people ceasing 
naltrexone therapy.
There is a concern that naltrexone may be used as a 
coercive treatment. Such coercive pharmacological 
treatment would be unethical. Furthermore, naltrexone 
used in this way would not necessarily have the same 
efficacy as with voluntary participants.
Treatment considerations
Naltrexone is formulated in 15 and 50 mg tablets. 
The cost of the medication currently varies from 
approximately US50 cents to US$5 per tablet. Each 
tablet blocks the effects of heroin for 24–48 hours. 
Because it completely blocks the effects of heroin, 
naltrexone should be prescribed to those who are 
aiming at complete abstinence from opioids; this limits 
its use to a subpopulation of more motivated patients.
Other research and basic research findings
Naltrexone may be more effective when family members 
are involved in the treatment or directly observe the 
patient taking naltrexone. Clinical experiences with 
naltrexone vary considerably between countries, with 
some countries finding levels of retention similar to 
opioid agonists and others finding very poor rates of 
retention. It is possible that cultural and social differences 
could result in a variable efficacy and acceptability of 
naltrexone treatment. Clinical experience suggests that 
naltrexone may be more effective in patients who are 
motivated to abstain from opioid use – for example, 
professionals at risk of losing their employment, or 
patients who have come before the courts and risk 
incarceration.
Conclusion
The limited evidence available suggests that, in 
dependent opioid users who have withdrawn from 
opioids, those who take naltrexone are less likely to use 
heroin or engage in criminal activity than those who do 
not take naltrexone. Opioid dependence has a spectrum 
of severity and early stages of dependence may respond 
better to naltrexone than more severe dependence. 
Retention in treatment is generally likely to be lower 
than opioid agonist maintenance therapy; nevertheless, 
in those patients who have withdrawn from opioids and 
are motivated to cease opioid use completely, relapse 
prevention efforts with naltrexone are likely to be 
superior to those without naltrexone.
Recommendation
For opioid-dependent patients not commencing opioid 
agonist maintenance treatment, antagonist pharmacotherapy 
using naltrexone should be considered following the 
completion of opioid withdrawal. 
Strength of recommendation – standard•	
Quality of evidence – low•	
Remarks – This recommendation is based on evidence from •	
clinical trials that there is less heroin use with naltrexone, 
and on clinical experience from some countries of adequate 
rates of retention in treatment of patients on naltrexone. 
There is a concern that naltrexone may be used as a 
coercive treatment. Such treatment would be unethical.
6.5.2 InDICATIOnS FOR nAlTRexOne THeRAPY
Patient selection
Given the potential for overdose after relapse, opioid 
antagonist therapy is likely to be most useful for those 
with a reasonable chance of remaining abstinent (this 
statement is based on expert opinion). Such groups 
include employed patients, those who have been using 
drugs for only a short time (e.g. younger patients) and 
those under threat of legal sanctions.
Naltrexone appears to be most useful when there is 
a “significant other” to administer and supervise the 
medication; for example, a family member, close friend 
or, in some cases, an employer.
Patients with severe opioid dependence should be 
cautious taking naltrexone; also, naltrexone is not 
recommended for people with cirrhosis who have a 
Child’s severity rating of C or above.
Use in pregnancy
There is limited experience of naltrexone in pregnancy, 
but the likelihood of congenital abnormalities is 
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thought to be low. If a woman taking naltrexone 
treatment becomes pregnant, the benefits of 
continuing naltrexone should be weighed against 
possible unforeseen risks.
The role of psychosocial therapy in naltrexone 
treatment
As with other pharmacological treatments, psychosocial 
treatment should routinely also be offered. There are 
insufficient data to make recommendations about 
specific psychosocial approaches for use in combination 
with naltrexone therapy; however, contingency 
management with vouchers has been found to be 
useful in maintaining abstinence and retention in 
treatment for patients on naltrexone[171]. In a second 
study, a structured group-counselling approach gave no 
better outcomes than optional unstructured individual 
counselling control group[172]. One study comparing 
individual counselling plus naltrexone to family 
counselling plus naltrexone found family counselling to 
be superior both during treatment and at 12 months 
follow-up[173].
6.6 Psychosocial interventions 
The term “psychosocial support” is used here to 
refer to a broad range of interventions at a social 
and psychological level. Interventions at a social level 
include assistance with basic needs such as food, 
clothing, accommodation and employment, as well 
as basic health-care, friendship, community and the 
pursuit of happiness. Interventions at a psychological 
level range from unstructured supportive psychotherapy 
and motivational interviewing techniques, to highly 
structured psychological techniques. Clinicians and 
health providers should choose which psychosocial 
intervention to offer to opioid-dependent patients, 
based on research evidence, how appropriate a method 
is to the patient’s individual situation, how acceptable it 
is to the patient, whether trained staff are available, and 
cultural appropriateness.
6.6.1 PSYCHOlOGICAl InTeRVenTIOnS
A complete discussion of the range of psychological 
interventions is beyond the extent of this document; 
however, two subtypes of therapy dominate the 
literature – CBT and contingency management.
CBT has become the leading approach in a variety of 
mental and behavioural disorders including phobias, 
anxiety and obsessive-compulsive disorders; it can also 
be effective in depression and eating disorders. CBT in 
substance dependence is based on the principle that 
addictions are learned behaviours that can be modified. 
Cognitive approaches primarily aim to change addictive 
behaviours by changing faulty cognitions that serve to 
maintain behaviour, or by promoting positive cognitions 
or motivation to change behaviour. Commonly used 
variants are cognitive therapy and motivational-
enhancement therapy.
Behavioural approaches aim primarily to modify 
behaviours underpinned by conditioned learning; 
that is, by classical and operant conditioning. They 
include interventions that aim to extinguish classically 
conditioned responding (e.g. cue exposure and 
response prevention), or that are based on instrumental 
conditioning (e.g. community reinforcement or 
contingency management) – an approach in which 
positive non-drug taking behaviours are rewarded. 
Behavioural approaches involving aversive conditioning 
are historically important, mainly in the alcohol 
treatment field, but their use has ceased, mainly for 
ethical reasons. CBT requires training of staff in, for 
example, clinical psychology.
Contingency management rewards or punishes specific 
types of behaviours using a structured, transparent 
approach that increases learning of desired behaviours. 
Most programmes focus on positive behaviours, with 
reinforcement for the desired behaviour. The elements 
of a contingency management programme are:
clear definitions of the desirable behaviour (e.g. •	
opioid abstinence);
regular monitoring for the presence or absence  •	
of the desired behaviour (e.g. regular urine  
tests);
specified rewards for the desired behaviour (e.g. •	
money, vouchers, take-home methadone doses or 
lottery tickets);
positive personal feedback from staff for the •	
desired behaviour.
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Contingency management can be administered by staff 
with relatively little training. 
Counsellors should be aware of links to available social 
services or other social resources in the community.
6.6.2 SOCIAl InTeRVenTIOnS
Vocational training
Vocational training includes a range of programmes 
designed to help patients find and retain employment. 
Vocational training can include skills training, sheltered 
work environments and monitoring of drug use during 
employment[174, 175, 176].
Housing
Housing services can vary from group accommodation 
for the homeless to more stable, affordable, long-term 
accommodation. The importance of housing is such 
that assistance with housing may be necessary before 
cessation of drug use can be attempted. While there 
may be risks in accommodating drug users together in 
institutional settings, stable accommodation in a drug-
free environment is desirable. The strategies adopted 
will depend on local resources and norms.
Activities
The ability of patients to participate in and enjoy leisure 
activities of their choice is an important aspect of 
psychosocial support. Programmes can provide access 
to a range of healthy leisure activities.
Self-help groups
In the context of opioid dependence, self-help groups are 
voluntary, small-group structures formed by peers to assist 
each other in their struggle with opioid dependence. Usually 
abstinence oriented, they often provide both material 
assistance and emotional support, and promulgate an 
ideology or values through which members may attain a 
greater sense of personal identity[177].
Patients receiving pharmacological treatment should be 
encouraged to participate in self-help groups. Although 
there has been little research on this form of treatment, 
observational studies on 12-step groups (e.g. Narcotics 
Anonymous) are positive, with strong “in-treatment” 
effects. This form of therapy is inexpensive and provides 
important psychosocial support.
Social skills training
Social skills training refers to methods that use the 
principles of learning theory to promote the acquisition, 
generalization and durability of skills needed in social 
and interpersonal situations. Training should take place 
in the context of real everyday life experiences, not in 
closed, unrealistic settings.
Traditional healers
Traditional and spiritual healers may have a role in the 
provision of psychosocial support, if they are culturally 
acceptable to the patient. Although the assessment of 
these methods is beyond the scope of this document, 
clinical staff might wish to explore what options there 
are for such support with their patients.
6.6.3 PROVISIOn OF PSYCHOSOCIAl SUPPORT
Staff and volunteers can provide psychosocial support 
commensurate with their level of expertise. As a 
minimum, anyone providing psychosocial support to 
people with opioid dependence should participate 
in a brief training programme so that they do not 
put themselves at risk or inadvertently cause harm. 
Professional staff without specific psychotherapeutic 
training might be expected to be able to provide 
supportive psychotherapy or structured therapy based 
on an appropriate manual after a brief training period 
(e.g. 1–2 weeks).
6.7 Treatment of overdose
Opioid overdose is identifiable by a combination of 
signs and symptoms, including pinpoint pupils and 
respiratory depression. Dilated pupils suggest an 
alternative diagnosis. Patients with suspected opioid 
overdose should be treated if the respiratory rate is 
less than 10 per minute or if they are hypoxic on pulse-
oxymetry (oxygen saturation <92%).
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Initial treatment of hypoxic patients should include 
supplemental oxygen and assisted ventilation, as 
necessary. This would typically include clearing the 
airway and applying bag and mask ventilation with 
oxygen.
Naloxone is a non-selective, short-acting opioid receptor 
antagonist that has a long clinical history of successful 
use for the treatment of overdose. It is an effective 
antidote for overdoses of short-acting opiates such 
as heroin. In managing opioid overdoses, the primary 
concern should always be respiration and oxygenation. 
Any respiratory arrest should be managed with assisted 
ventilation and oxygen while waiting for naloxone to 
be administered or to take effect. Typically, adequate 
respiration will resume within 30 seconds of naloxone 
administration. The ideal dose of naloxone is one that 
improves ventilation without inducing withdrawal. If in 
doubt, it is better to err on the side of too high rather 
than too low a dose. A standard dose for the treatment 
of suspected heroin overdose is 400 mcg intramuscularly 
or 800 mcg subcutaneously, repeated 2 minutes later, 
if necessary. If there is IV access and adequate patient 
ventilation, small aliquots of 100 mcg can be given in 
repeated doses until the patient is breathing with a rate 
of greater than 10 breaths a minute, without inducing 
opioid withdrawal.
Initial use of doses of naloxone that are too high (>2 mg) 
can induce severe withdrawal, with the risk of vomiting 
and aspiration; very high doses (>10 mg) may even be 
life threatening[178].
Overdoses of long-acting opioids are more difficult 
to manage. In this situation, the duration of sedation 
will outlast the effects of naloxone. The safest method 
of treating long-acting opioid overdose is likely to be 
ventilation, if available. Although patients can also 
be managed with repeated boluses of naloxone or 
naloxone infusions, death can occur if there is unnoticed 
interruption to the naloxone infusion, or if the patient 
wakes up and discharges themselves from medical 
care.
Ideally, patients should be observed for 2 hours after 
naloxone administration before they are discharged. In 
practice, this can be difficult to achieve, but it is most 
important in patients where overdose is suspected to 
involve long-acting opioids.
In some countries, prefilled naloxone syringes are 
distributed to patients and family members, in 
combination with training in resuscitation[78, 79]. Although 
the use of naloxone by non-medical personnel is not 
without risks[80, 178], and may even be illegal in some 
countries, such use may prevent overdoses. Evaluation 
of such distribution systems has been positive[78,79], and 
naloxone distribution is likely to be an affordable approach 
to the prevention of opioid overdose, particularly where 
inexpensive prefilled syringes are available.
6.8 Special considerations for specific 
groups and settings
6.8.1 PATIenTS WITH HIV/AIDS, HePATITIS AnD TB
As described in section 5.6.8, opioid agonist treatment 
enhances adherence to treatment with anti-infective 
agents in patients with opioid dependence (see section 
5.6.8 for a more detailed discussion). 
When presented with an active drug user with TB and 
opioid dependence, the first priority of the treatment 
service should be to treat the active TB without 
spreading it further. If opioid dependence treatment 
can be commenced in a way that does not put other 
patients at risk, then this is ideal. Otherwise, it may be 
better to delay treatment until the patient is no longer 
infectious. 
When presented with an active drug user with HIV and 
opioid dependence, it is simpler to delay antiretroviral 
treatment until the patient is stabilized on opioid 
substitution treatment than to attempt to start 
antiretroviral drugs before opioid substitution treatment. 
There is no need to delay antibiotic treatments such as 
co-trimoxazole or isoniazid, if it is indicated.
6.8.2 ADOleSCenTS
Adolescents 12–18 years old present to treatment 
services with the full range of opioid-dependence 
severity. Some adolescents may be brought to the clinic 
by their families, who are concerned about recent drug 
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use that may not have reached the level of dependent 
use. On the other hand, many adolescents presenting 
to treatment services come from socially disadvantaged 
backgrounds, are living on the street and may have 
more severe dependence than many adult patients. In 
between these two groups is a third with dysfunctional 
families. Studies suggest that the earlier that substance 
use commences, the higher the risk of dependence and 
adverse health consequences[179].
Working with adolescents requires a sensitivity to the 
issues pertinent to adolescent health in general, because 
drug use is often a result of events occurring elsewhere 
in an adolescent’s life. Assessment should be broad and 
should include medical, psychological, education, family 
and other aspects of the adolescent’s life. Treatment 
should cover as many aspects of the adolescent’s 
life as possible. Given their special treatment needs, 
adolescents with opioid dependence often benefit from 
special health services aimed directly at them.
Treatment approaches should accommodate 
adolescents, who often have higher levels of risk 
taking, novelty seeking and responses to peer pressure 
than older individuals (probably due to incomplete 
development of brain areas of inhibitory control). Thus, 
training in self-control, resilience and decision-making 
should be included in psychosocial interventions. To 
ensure that treatment is as effective as possible, the 
treatment programme needs to be individualised and 
comprehensive, and needs to take into consideration 
an adolescent’s strengths, psychosocial supports, 
education, legal and medical status and history, and 
pattern of illicit drug use.
Recent research has provided important information 
about the clinical profile of opioid-dependent adolescents, 
and has underscored the high prevalence of comorbid 
psychiatric disorders among this population. Psychiatric 
disorders that often accompany opioid dependence 
include depression, post-traumatic stress disorder, 
conduct disorder and attention deficit hyperactivity 
disorder. Some of these disorders (e.g. depressive 
disorders) are more evident among opioid-dependent 
female adolescents than among their male counterparts. 
It is unclear to what extent existing psychiatric disorders 
lead to “self-medication” with opioids and other drugs 
among this adolescent population; however, addressing 
psychiatric comorbidity along with substance use is 
likely to lead to more effective, comprehensive care.
Adolescents may live with one or more parents, and 
are likely to still be in the legal custody of one or more 
parents. Parents may play a central role in the lives of 
adolescents entering substance abuse treatment, in 
comparison to adults entering treatment. Adolescents 
may thus be in need of family counselling, to improve 
relationships with parents or to help parents learn how 
to be as supportive as possible of their adolescent while 
that person is in treatment for their substance use 
disorder. High levels of parental involvement and low 
levels of parental detachment protect against opioid 
use among adolescents.
Experimentation with substance use often starts in 
adolescence; thus, Addiction. or substance dependence, 
has frequently been referred to as a developmental 
disorder. Providing effective interventions early in an 
adolescent’s drug involvement is critical if this progression 
is to be altered. Early intervention is particularly 
important in light of emerging research, suggesting 
that adolescents may progress from substance use to 
dependence more rapidly than adults. Additionally, 
substance use among adolescents may interfere with 
cognitive, social and emotional development[15, 180].
Effective early intervention for opioid-dependent 
adolescents – combining pharmacotherapy and 
psychosocial treatment – can help to prevent adolescents 
from following a substance-using life trajectory, and 
from transitioning from intranasal or oral to injecting 
opioid use. Moreover, early psychosocial intervention 
with young people who have used heroin but who are 
not yet opioid dependent can help to prevent young 
people from becoming dependent on opioids.
Should pharmacological treatment for adolescents with 
opioid dependence differ from that for adults?
No systematic reviews addressing this question were 
found. Some clinical trials were found that supported 
the use of agonist pharmacotherapy, both for opioid 
withdrawal and maintenance. One RCT demonstrated 
that, compared to clonidine patches, 28-day reducing 
51Patient level guidelines – for clinicians
buprenorphine retained more people in treatment 
(72% versus 39%), and led to higher rates of induction 
to naltrexone (61% versus 5%)[181].
The use of agonist pharmacotherapy is still the 
recommended therapy for adolescent opioid 
dependence. However, adolescents with a short period 
of dependence and those living in families may respond 
to opioid withdrawal with or without naltrexone, and 
these would be reasonable alternatives. Opioid agonist 
pharmacotherapy in this population can also be started 
on an interim or trial basis, and short-term therapy may 
be all that is required if the response is positive.
A comprehensive treatment programme that addresses 
this entire clinical profile is more likely to produce better 
outcomes than a programme that focuses on one 
clinical problem in isolation.
6.8.3 WOMen
Women have been found to differ from men in their 
drug-use patterns, with women using less quantity but 
advancing more quickly to dependence, and using more 
prescription sedatives. Women who become opioid 
dependent are more likely to have less education, fewer 
financial resources and higher rates of sexual and physical 
abuse[183]. Often, the needs of women in substance 
dependence treatment settings are also different. They 
are more likely to have child-care responsibilities that 
may limit access to treatment, and they may be reluctant 
to participate in group psychosocial activities with men. 
They also report significant rates of sexual harassment 
by male treatment staff[183].
Data are lacking on the relative efficacy of gender-specific 
services for women. To retain women, services may need to 
provide either individual or female-only group counselling, 
cater for people with small children (e.g. provide child-
care facilities), and have measures to guard against sexual 
harassment of female patients by male staff.
6.8.4 PReGnAnCY AnD BReASTFeeDInG
For women who are pregnant or breastfeeding, opioid 
agonist maintenance with methadone is seen as the 
most appropriate treatment, taking into consideration 
effects on the fetus, neonatal abstinence syndrome, 
and impacts on antenatal care and parenting of 
young children. Opioid-dependent women not in 
treatment should be encouraged to start opioid 
agonist maintenance treatment with methadone or 
buprenorphine. Pregnant women who are taking opioid 
agonist maintenance treatment should be encouraged 
not to cease it while they are pregnant. Although many 
women want to cease using opioids when they find 
out they are pregnant, opioid withdrawal is a high-risk 
option because a relapse to heroin use will affect the 
capacity to care for the child. In addition, severe opioid 
withdrawal symptoms may induce a spontaneous 
abortion in the first trimester of pregnancy, or premature 
labour in the third trimester. Relapse to heroin use 
during pregnancy can also result in poorer obstetric 
outcomes. Opioid agonist maintenance is thought to 
have minimal long-term developmental impacts on 
children when compared to the risk of maternal heroin 
use and resulting harms.
Methadone is preferred over buprenorphine because of 
the longer experience of the safety of methadone in 
pregnancy compared to buprenorphine, despite the fact 
that early research with buprenorphine suggests that 
its use may result in less neonatal abstinence syndrome 
than occurs with the use of methadone. If women are 
being successfully treated with buprenorphine, then 
the benefit of staying with a treatment that is working 
should also be taken into consideration.
In the second and third trimester, methadone doses 
may need to be increased, due to increased metabolism 
and circulating blood volume. Splitting the dose into 
two 12-hour doses may produce more adequate opioid 
replacement in this period. After birth, the dose of 
methadone may also need to be adjusted as some of 
these changes reverse.
Although methadone and buprenorphine are detectable 
in breast milk, the levels are low and are not thought 
to significantly affect the infant. Breastfeeding, on the 
other hand, has many benefits, including mother–infant 
bonding, nutrition and prevention of childhood illness. 
Opioid-dependent mothers should be encouraged 
to breastfeed, with the possible exception of HIV-
positive mothers or those using alcohol or cocaine and 
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amphetamine type drugs; in such cases, specific advice 
should be sought.
Untreated neonatal abstinence syndrome can cause 
considerable distress to infants and, in rare cases, can 
cause seizures. Cochrane Collaboration reviews indicate 
that opioids and barbiturates are more effective than 
placebo or benzodiazepines, with opioids probably 
more effective than barbiturates.
Recommendation
Opioid agonist maintenance treatment should be used for 
the treatment of opioid dependence in pregnancy. 
Strength of recommendation – strong•	
Quality of evidence – very low •	
Recommendation
Methadone maintenance should be used in pregnancy in 
preference to buprenorphine maintenance for the treatment 
of opioid dependence; although there is less evidence about 
the safety of buprenorphine, it might also be offered. 
Strength of recommendation – standard•	
Quality of evidence – very low•	
6.8.5 OPIUM USeRS
People dependent on opium who are suffering 
harm as a result can be treated with opioid agonist 
maintenance treatment, consistent with the approach 
for dependence on other opioids. Two trials have 
demonstrated the effectiveness of buprenorphine in 
this population[184, 185].
It is important to ensure that opium smokers meet 
criteria for opium dependence beyond simple tolerance 
and withdrawal. If unclear, it may be wise for opium 
smokers to attempt withdrawal first before commencing 
opioid agonist maintenance treatment. 
6.8.6 DRIVInG AnD OPeRATInG MACHIneRY
Opioid intoxication can occur during induction onto 
methadone or buprenorphine. Patients should be 
advised not to drive while sedated. As patients will 
not know what effect their first few methadone and 
buprenorphine doses will have on them, they should be 
advised not to plan to drive at this time.
6.8.7 PSYCHIATRIC COMORBIDITY WITH OPIOID 
DePenDenCe
Psychiatric comorbidity with opioid dependence 
is common; in particular, depression, anxiety, 
personality and post-traumatic stress disorders 
should be specifically looked for early in treatment 
and on a regular basis thereafter. As with medical 
comorbidity, there is likely to be a greater uptake of 
treatment if the treatment can be provided by the 
same medical practitioner or at the same facility in 
an integrated service. Failing that, strong links with 
other services should be established to facilitate 
referral and to establish the framework for joint 
involvement; such a framework should include 
clarification about prescribing of psychoactive 
medication and about giving the patient a consistent 
therapeutic message.
6.8.8 POlYSUBSTAnCe DePenDenCe
Annex 12 lists the acute and chronic interactions of 
opioids, alcohol, benzodiazepines, stimulants and 
cannabis.
In the treatment of polysubstance dependence, opioid 
agonist maintenance treatment can be started for 
the opioid dependence component, in an inpatient 
facility if necessary, while the person is simultaneously 
withdrawn from alcohol, benzodiazepines and 
stimulants.
For withdrawal from high doses of benzodiazepines, 
gradual withdrawal may be necessary. If 
benzodiazepines are to be given to outpatients on 
opioid agonist maintenance treatment, this should 
be done carefully, because there is little evidence 
to support the long-term use of these drugs and 
they increase the risk of sedative overdose. If 
gradually reducing doses of benzodiazepines are 
prescribed to facilitate the safe withdrawal from 
benzodiazepines, the prescription should be from a 
single practitioner, and the dispensing should occur 
with administration of the dose of methadone, 
if possible. Patients should be discouraged from 
withdrawing from opioid agonist maintenance before 
ceasing benzodiazepines.
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6.9 Management of pain in patients 
with opioid dependence
6.9.1 ACUTe PAIn
Pain in patients with opioid dependence is often 
exacerbated by the lowering of the pain threshold that 
tolerance to opioids can induce. Opioid-dependent 
patients are more resistant to pain management 
with opioids, due either to their tolerance to opioids 
or to blocking effects of medications used to treat 
opioid dependence, including buprenorphine and 
naltrexone. Patients with opioid dependence have a 
right to adequate pain relief; however, some patients 
will try to manipulate the health system to obtain 
opioids. Measures that can be taken to minimize this 
include:
managing pain through a single health service •	
(hospital or primary care practice – depending on 
the severity)
adequately defining the nature of the painful •	
condition
resolving acute pain rapidly, and then moving •	
quickly to longer acting opioids that have less 
potential for abuse and produce stable opioid 
effects (as opposed to cyclical patterns of 
intoxication and withdrawal).
Clinical assessment should be used to distinguish 
between opioid withdrawal and opioid intoxication. 
Opioids should be titrated to pain response, with close 
assessment of the clinical features of withdrawal and 
intoxication, to determine appropriate dose levels.
Patients not on agonist maintenance treatment
For patients using illicit opioids without opioid agonist 
maintenance treatment, starting opioid agonist 
maintenance treatment with methadone allows for 
combined management of opioid dependence and 
pain. Inadequate analgesia often contributes to patients 
self-administering illicit opioids.
Patients on antagonist medication (naltrexone)
Patients on naltrexone will not respond to opioid 
analgesics in a regular manner. For mild Pain. non-
opioid analgesics (e.g. paracetamol and NSAIDs) 
should be used. Patients taking naltrexone will not 
benefit from opioid-containing medicines such as 
cough, cold and antidiarrhoeal preparations. In an 
emergency, pain management may consist of regional 
analgesia; conscious sedation with non-opioids such as 
benzodiazepines or ketamine; and use of non-opioid 
techniques of general anaesthesia. For elective surgery 
pain management in hospital, naltrexone should be 
discontinued at least 72 hours before elective surgery 
(including dental surgery), if it is anticipated that opioid 
analgesia may be required. The treating surgeon or 
doctor should be informed that the patient has been 
taking naltrexone. The patient should then be abstinent 
from opioids for three to seven days – depending on 
the duration of the opioid use and the half-life of the 
opioid – before resuming naltrexone treatment. If in 
doubt, a naloxone challenge test can be administered 
to determine whether naltrexone can be recommenced 
without inducing opioid withdrawal.
Patients on partial agonists (buprenorphine)
Because of the high affinity of buprenorphine for the 
opioid receptor, patients treated with buprenorphine 
may need higher effective opioid activity to manage 
acute pain. The high affinity opioid agonist fentanyl may 
be more effective than other opioids in this situation. 
For mild Pain. increasing the dose of buprenorphine 
or addition of weak opioids (e.g. tramadol) may be 
effective, although such approaches have not been 
systematically investigated. 
For treatment of acute pain not responding to these 
measures, the options are to:
cease buprenorphine and use full opioid agonists, •	
such as methadone or morphine, then switch back 
to buprenorphine when pain resolves
continue buprenorphine with the use of high •	
doses of opioids but, as the blocking effect of 
buprenorphine reduces over time, take care to 
avoid overdose if buprenorphine is ceased while 
high doses of opioids are continued
continue buprenorphine and use non-opioid •	
analgesia such a ketamine infusion; or employ 
the judicious adjunctive use of clonidine or 
benzodiazepines.
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Patients on full agonist (methadone)
For mild or acute Pain. consider non-opioid analgesics 
(e.g. paracetamol). Where parenteral analgesics are 
required, the NSAID ketorolac should be considered. 
For elective surgery, pain management in hospital 
is recommended. Patients on methadone who are 
experiencing acute pain in hospital often receive 
inadequate doses of opioids for their pain. For patients 
in methadone maintenance treatment, the same 
analgesic techniques should be used in the same way 
as for other patients; such techniques include the use of 
injectable and patient-controlled analgesia. Because of 
their tolerance of opioids, patients taking methadone 
will require larger doses of opioid analgesia for adequate 
pain relief.
Partial agonists, such as buprenorphine, should be 
avoided because they may precipitate withdrawal 
symptoms. There is evidence of cross-tolerance between 
methadone and anaesthetic agents; thus, patients on 
methadone may require higher doses of anaesthetic 
agents in the event of dental or surgical procedures. 
Patients needing methadone for ongoing management 
of chronic pain benefit from a comprehensive 
management plan. Specialist advice should be sought 
regarding such patients.
6.9.2 CHROnIC PAIn
The recent escalation in the use of opioids for chronic 
pain in some parts of the world[186] suggests a significant 
overlap between treatment of chronic pain and 
dependence on prescription opioids. This document 
does not attempt to address the use of opioids in the 
management of chronic pain; however, patients with 
chronic pain and patterns of use of their prescribed 
opioids that fit the criteria for dependence (i.e. more 
than just tolerance and withdrawal), are often referred 
(or refer themselves) to opioid-dependence treatment 
facilities. Typically, they present with problems such 
as injecting their prescribed opioids, taking rapidly 
escalating doses of opioids and taking opioids in greater 
quantities than prescribed (resulting in intoxication or 
overdose); they may also present with other features 
that raise suspicions of misuse, which they may deny.
In the management of such patients, the first 
step could be to determine that there has been a 
comprehensive assessment of the cause of the Pain. 
both physical and psychological, with any physical 
cause found being treated. For patients not on opioid 
agonist maintenance treatment, the next step would 
be to provide supervised methadone or buprenorphine 
in place of unsupervised opioids, to provide stable 
opioid effects and eliminate cycles of withdrawal and 
intoxication. For pain persisting despite adequate 
opioid agonist maintenance treatment, opioid rotation 
should be considered.
In some cases, it could be that the opioid treatment is 
no longer useful, either because it is being abused or 
because it is suspected that pain is being exacerbated 
by opioid-induced hyperalgaesia[187]. Opioid withdrawal 
may be considered as an approach to reverse opioid-
induced hyperalgaesia, although it may risk relapse to 
illicitly obtained opioids.
Measures that can be taken to prevent the abuse of 
prescription opioids include systems that encourage 
all opioid analgesia to be provided by one doctor, 
a graded approach to supervision of dosing, 
prescription of formulations less liable to abuse (e.g. 
liquid methadone formulations) and careful patient 
selection.
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The following evidence profiles have been produced by applying the GRADE 
working group approach to determining the quality of evidence to the 
questions addressed. More information on this approach is contained in 
Section 2.
Annex 1 Evidence profiles
A1.1 Is methadone effective for the treatment of opioid dependence?
GRADE evidence profile
Author(s):  Amato L
Date:  23 August 2006
Question:  Should methadone maintenance treatment versus opioid withdrawal or no treatment be used for opioid dependence?
Patient or population:  opioid addicts
Settings:  outpatient
Systematic review:  Mattick RP et al. (in press) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence 
(CLIB 3, 2003)[105]; Bargagli AM et al. (2007) A systematic review of observational studies on treatment of opioid 
dependence.[197]
(Throughout this annex, –1 is used to indicate that the score has been reduced by one because of a weakness in this area).
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Methadone 
maintenance 
treatment
No treatment Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Use of opiates[66,188,189] (subjective follow-up: 1 month–2 years) 
3a Randomized 
trialsb
Some 
limitationsb 
(–1)
no important 
inconsistency
no 
uncertainty
none 28/104 
(26.9%)
110/126 
(87.3%)
RR 0.323 
(0.23 to 0.44)
AR 630/1000 less 
(830 less to 430 less)
⊕⊕⊕ 
Moderate
7
Criminal behaviour[66,188,189] (objective follow-up: 1 month–2 years) 
3a Randomized 
trialsb
Some 
limitationsb 
(–1)
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (–1)
5/178 
(2.8%)
18/185 
(9.7%)
RR 0.393 
(0.12 to 1.25)
AR 250/1000 less 
(700 less to 19 more)
⊕⊕ 
low
6
Mortality from randomized controlled trials[188,106,189] (RCTs) (objective follow-up: 2–3 years) 
3d Randomized 
trialse
no 
limitations
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (–2)
3/216 
(1.4%)
7/219 
(3.2%)
RR 0.493 
(0.06 to 4.23)
AR 16/1000 less 
(100 less to 30 more)
⊕⊕ 
low 
9
Mortality (any cause) from observational studies[190,191,192,193,194] (objective follow-up: 2.5 years–21 years) 
5f Observational 
studiesg
no 
limitations
no important 
inconsistency
no 
uncertainty
none 257/19421 
(1.3%)
1063/23614 
(4.5%)
RR 0.37 
(0.29 to 0.48)
AR 20/1000 less 
(30 less to 10 less)
⊕⊕ 
low
9
Mortality (overdose) from observational studies [190,191,195,193,196] (objective follow-up: 2.5 years–12 years) 
5h Observational 
studiesi
no 
limitations
Inconsistent results 
between studies  
(–1)10
no 
uncertainty
extremely strong 
effect (+2)
70/37516 
(0.2%)
416/32454 
(1.3%)
RR 0.17 
(0.05 to 0.63)
AR 10/1000 less 
(20 less to 0.00)
⊕⊕⊕ 
Moderate
9
Retention in treatment[106,108,107] (objective follow-up: 1 month–2 years) 
3k Randomized 
trialsl
no 
limitations
no important 
inconsistency
no 
uncertainty
none 173/254 
(68.1%)
63/251 
(25.1%)
RR 3.053 
(1.75 to 5.35)
AR 460/1000 more 
(270 more to 650 
more)
⊕⊕⊕⊕ 
High
7
a  Three studies in an outpatient setting; two were conducted in the United States and one in Sweden.
b  Three randomized controlled trails (RCTs): one with adequate allocation concealment, one unclear and one inadequate.
c  Random effect model.
d  Three RCTs, one conducted in the United States, one in Sweden and one in China.
e  One adequate and two unclear allocation concealment.
f  Five studies in an outpatient setting; conducted in Italy, Australia, Sweden, the United States and Spain (one in each).
g  Quality of studies using Newcastle–Ottawa Scale: selection, two studies rated 3 and three studies rated 2; comparability, one study rated 3, three studies rated 1 and one study rated 0; 
outcome, two studies rated 2 and three studies rated 1.
h Five studies in an outpatient setting: two conducted in the Netherlands and one each in Italy, the United States and Spain.
i  Quality of studies using Newcastle–Ottawa Scale: selection, four studies rated 3 and one study rated 2; comparability, two studies rated 2 and three studies rated 1; outcome, one study rated 2 and 
four studies rated 1.
j  High statistical heterogeneity P < 0.00001, but all consistent results.
k  Three studies in an outpatient setting, conducted in Hong Kong, Thailand and the United States (one each).
l  Three RCTs, all with unclear allocation concealment.
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A1.2 Does opioid agonist maintenance treatment reduce the spread of HIV?
GRADE evidence profile 
Author(s):  Amato L, Minozzi S
Date:  22 May 2006
Question:  Should agonist maintenance treatment be used for the prevention of HIV infection or reduction of high-risk behaviours?
Patient or population:  injecting opioid dependent
Settings:  Outpatient
Systematic review:  Gowing L et al. (2004) Substitution treatment of injecting opioid users for prevention of HIV infection (CLIB 4, 2004)[203].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Agonist 
maintenance 
treatment
No treatment Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Injecting behaviour: prevalence of injecting, cohort study[198] (subjective follow-up: 18 months)
1a Observational 
studiesb
no limitations no important 
inconsistency
no 
uncertainty
none 125/152 
(82.2%)
97/103 
(94.2%)
RR 0.873 
(0.80 to 0.95)
AR 120/1000 less 
(200 less to 40 less)
⊕⊕ 
low
6
Injecting behaviour: prevalence of injecting[199] (subjective follow-up: 4 months) 
1d Randomized 
trialse
no limitations no important 
inconsistency
Some 
uncertainty 
(–1)f
none 44/129 
(34.1%)
93/124 
(75.0%)
RR 0.453 
(0.35 to 0.59)
AR 410/1000 less 
(520 less to 300 less)
⊕⊕⊕ 
Moderate
6
Injecting behaviour: proportion of patients sharing injecting equipment, observational studies[198, 200, 201] (subjective follow-up: 0–18 months) 
3g Observational 
studiesh
no limitations no important 
inconsistency
no 
uncertainty
none 83/301 
(27.6%)
424/1020 
(41.6%)
RR 0.54c 
(0.37 to 0.79)
AR 230/1000 less 
(400 less to 60 less)
⊕⊕ 
low
7
Sexual behaviour: commercial sex [198] (follow-up: 18 months) 
1a Observational 
studiesi
no limitations no important 
inconsistency
no 
uncertainty
none 43/152 
(28.3%)
47/103 
(45.6%)
RR 0.62c 
(0.45 to 0.86)
AR 170/1000 less 
(290 less to 50 less)
⊕⊕ 
low
7
Sexual behaviour: unprotected sex[198, 200] (follow-up: 3–6 months) 
2j Observational 
studiesk
no limitations no important 
inconsistency
no 
uncertainty
none 174/213 
(81.7%)
554/654 
(84.7%)
RR 0.94d 
(0.87 to 1.02)
AR 60/1000 less 
(130 less to 10 more)
⊕⊕ 
low
6
Seroconversion to HIV [198, 200] (variable follow-up: up to 5 years)
2l Observational 
studies
no limitations no important 
inconsistency
no 
uncertainty
none 16/579  
(2.8%)
24/297 
(8.1%)
RR 0.36c 
(0.19 to 0.66)
AR 50/1000 less ⊕⊕ 
low
8
a One study in an outpatient setting, conducted in the United States (Metzger, 1993)[198].
b  One descriptive study in which the author rated the quality of the study on the basis of six items (description of the population, description of eligibility criteria, adjustment for 
confounding, less than 20% loss to follow-up, presence of co-intervention, inconsistency in data collection between groups) rated from 0 to 1 where 0 = no bias. On the basis of this 
rating system the study was rated 1.
c  Random effect model.
d  One study conducted in Australia, in an inpatient setting (in prison).
e  The study was rated 1 (see footnote 2).
f  Opioid-dependent prisoners.
g  All three studies were conducted in an outpatient setting, two in the United States and one in Germany.
h  Three cohort studies, two rated 1 and one 2 (see footnote 2).
i  One cohort study rated 1 (see footnote 2).
j  Both outpatient, one conducted in the United States and one in Germany.
k  Both rated 1 (see footnote 2).
l  Two cohort studies: Metzger (1993)[198] a non-treatment control group selected by methadone group, and Moss (1994)[202] a control group selected from contemporaneous entry to opioid 
withdrawal programme.
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A1.3 Is buprenorphine effective for the treatment of opioid dependence?
GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  23 May 2006
Question:  Should buprenorphine maintenance versus placebo be used for opioid addiction?
Patient or population:  Opioid dependent
Settings:  Outpatient and inpatient
Systematic review:  Mattick RP et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (2008, in 
press)[118].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Buprenorphine Placebo5 Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Retention in treatment: 2–4 mg buprenorphine versus placebo or 1 mg buprenorphine[184, 204, 109, 110] (objective follow-up: 2–16 weeksd)
2 Randomized 
trialsb
no limitations no important 
inconsistency
One inpatient 
study (–1)
none 141/242 
(58%)
114/245 
(47%)
RR 1.24c 
(1.06 to 1.45)
AR 100/1000 more 
(30 more to 210 
more)
⊕⊕⊕ 
Moderate
7
Morphine positive urines: 2–4 mg buprenorphine versus placebo or 1 mg buprenorphine
2 Randomized 
trialsb
no limitations Inconsistent 
results between 
studies (–1)
One inpatient 
study (–1)
none 242 245 – SMD 0.10c 
(–0.8 to 1.01)
⊕⊕ 
low
7
Retention in treatment: 8 mg buprenorphine versus placebo or 1 mg buprenorphine[184, 204, 109, 110] (objective follow-up: 2–16 weeks d)
2 Randomized 
trialsb
no limitations no important 
inconsistency
One inpatient 
study (–1)
none 119/218 
(54%)
114/245 
(47%)
RR 1.21c 
(1.02 to 1.44)
80/1000 more 
(9 more to 191 more)
⊕⊕⊕ 
Moderate
7
Morphine positive urines: 8 mg buprenorphine versus placebo or 1 mg buprenorphine
2 Randomized 
trialsb
no limitations Inconsistent 
results between 
studies (–1)
One inpatient 
study (–1)
none 218 245 – SMD –0.28c 
(–0.47 to -0.10)
⊕⊕ 
low
7
Retention in treatment: 16 mg buprenorphine versus 1 mg buprenorphine[184, 204, 109, 110] (objective follow-up: 2–16 weeks d)
1 Randomized 
trialsb
no limitations no important 
inconsistency
no 
uncertainty
none 110/181 
(61%)
74/185 
(40%)
RR 1.52c 
(1.23 to 1.88)
210/1000 more 
(90 more to 350 
more)
⊕⊕⊕⊕	
High
7
Morphine positive urines: 16 mg buprenorphine versus placebo or 1 mg buprenorphine
1 Randomized 
trialsb
no limitations no important 
inconsistency
no 
uncertainty
none 181 185 –- SMD –0.65c 
(–0.44 to –0.86)
⊕⊕⊕⊕	
High
7
a  Two RCTs: one inpatient, one outpatient, both conducted in the United States.
b  Both with unclear allocation concealment.
c  Random effect model.
d  Length of treatment.
e  Placebo or 1 mg buprenorphine daily.
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A1.4 Methadone versus buprenorphine
GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  22 March 2006
Question:  Should buprenorphine maintenance flexible doses versus methadone maintenance flexible doses be used for opioid 
maintenance treatment?
Patient or population:  Opiate dependents
Settings:  Outpatient
Systematic review:  Mattick RP et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (2008, in 
press).[105]
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Buprenorphine 
maintenance 
flexible doses 
Methadone 
maintenance 
flexible 
doses
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Retention in treatment flexible doses buprenorphine versus flexible doses methadone[205, 206, 68, 207, 125, 208, 209] (objective follow-up: 6–48 weeksd)
7a Randomized 
trials
no limitationsb no important 
inconsistency
no 
uncertainty
none 255/484 
(52.7%)
310/492 
(63.0%)
RR 0.82c 
(0.72 to 0.94)
130/1 000 
(220 less to 40 less)
⊕⊕⊕⊕	
High
7
Use of opiate during the treatmentg [210, 205, 207, 125, 208, 209] (better indicated by: lower scores) 
6e Randomized 
trials
no limitationsf no important 
inconsistency
no 
uncertainty
none 411 426 -– SMD –0.12 
(-0.26 to +0.02)
⊕⊕⊕⊕	
High
7
Use of cocaine during the treatmentg [210, 205, 207, 208, 209] (better indicated by: lower scores) 
5h Randomized 
trials
no limitationsi no important 
inconsistency
no 
uncertainty
none 384 395 -– SMD 0.11 
(–0.03 to +0.25)
⊕⊕⊕⊕	
High
5
Use of benzodiazepine during the treatmentg [210, 207, 208, 209] (better indicated by: lower scores) 
4j Randomized 
trials
no limitationsk no important 
inconsistency
no 
uncertainty
none 329 340 -– SMD 0.11 
(–0.04 to +0.26)
⊕⊕⊕⊕	
High
4
Criminal behaviour [207] (better indicated by: lower scores) 
1l Randomized 
trials
no limitationsm no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data 
(–1)n
95 117 -– SMD –0.14 
(-0.41 to +0.14)
⊕⊕⊕ 
Moderate
6
a  All outpatient, country of origin: three United States, one Austria, one Switzerland, one Australia, one United Kingdom.
b  Two studies with adequate allocation concealment, for the others five not described; 5/7 double blind.
c  Random effect model.
d  Length of treatment.
e  All outpatient, country of origin: three United States, one Austria, one Australia, one Switzerland.
g  5/6 double blind; one adequate allocation concealment, five not stated.
h  Data based on urinalysis.
i  All outpatient, country of origin: three United States, one Austria, one Australia.
j  4/5 double blind; one adequate allocation concealment, five not stated.
j  All outpatient, country of origin: two United States, one Austria, one Australia.
k  3/4 double blind; one adequate allocation concealment, five not stated.
k  Outpatient, conducted in Australia.
m  Double blind, adequate allocation concealment.
n  Only one study with the results not statistically significant.
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GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  23 March 2006
Question:  Should buprenorphine maintenance moderate doses (6–12 mg/day) versus methadone maintenance moderate doses 
(50–80 mg/day) be used for opioid dependence?
Patient or population:  Opiate dependents
Settings:  Outpatient
Systematic review:  Mattick RP et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (2008, in 
press)[105].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Buprenorphine 
maintenance high 
doses (6–12 mg/
day)
Methadone 
maintenance high 
doses (50–80 mg/
day)
Relative risk 
(RR) 
(95% CI)
Absolute risk 
(AR) 
(95% CI)
Retention in treatment [205, 206, 68, 207, 125, 208, 209] (follow-up: 17–52 weekse)
7a Randomized 
trials
no 
limitationsb
Important 
inconsistency 
(–1)c
no 
uncertainty
none 158/356 
(44.4%)
199/352 
(56.5%)
RR 0.79d 
(0.64 to 0.99)
120/1000 
(230 less to 10 
less)
⊕⊕⊕ 
Moderate
7
Use of opiates7 [210, 205, 207, 125, 208, 209] (better indicated by: lower scores) 
3f Randomized 
trials
no 
limitationsh
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (–1)
157 157 -– SMD 0.27 
(0.05 to 0.50)
⊕⊕⊕ 
Moderate
7
Use of cocaine7 [210, 205, 207, 208, 209] (better indicated by: lower scores) 
1i Randomized 
trials
no 
limitationsa
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (–2)l
29 28 -– SMD 0.22 
(–0.30 to 0.74)
⊕⊕ 
low
5
a  All outpatient, six conducted in the United States, one in Italy.
b  All double blind, one adequate allocation concealment, the others not described.
c  High heterogeneity P = 0.04
d  Random effect model.
e  Length of treatment.
f  All outpatient and all conducted in the United States.
g  Based on urinalysis.
h  Three double blind, one with adequate allocation concealment, the others not stated.
i  Outpatient, conducted in the United States.
j  Double blind, allocation concealment not stated.
k  Only one study, few patients, result not statistically significant.
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A1.5 What maintenance doses of methadone should be used?
GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  24 March 2006
Question:  Should methadone maintenance (40–59 mg/day) versus methadone maintenance (1–39 mg/day) be used for opioid 
dependence?
Patient or population:  Opioid dependents
Settings:  Outpatient
Systematic review:  Faggiano F et al. Methadone maintenance at different dosages for heroin dependence (CLIB 3, 2003)[140].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Methadone 
maintenance 
medium doses 
(40–59 mg/day)
Methadone 
maintenance 
low doses (1–39 
mg/day)
Relative risk 
(RR) 
(95% CI)
Absolute risk 
(AR) 
(95% CI)
Retention in treatment [108] (objective follow-up: 20 weeks)
1a Randomized 
trial
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (–1)c
44/84 
(52.4%)
34/82 
(41.5%)
RR 1.26d 
(0.91 to 1.75)
110/1000 more 
(40 less to 260 
more)
⊕⊕⊕ 
Moderate
7
Mortality [196] (objective follow-up: 6 years) 
1e Observational 
studiesh
no 
limitationsf
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (–1)g
1/362 
(0.3%)
4/822 
(0.5%)
RR 0.57d 
(0.06 to 5.06)
2/1000 less(20 
less to 5 more)
⊕ 
Very low
9
a  Outpatient, conducted in the United States.
b  Double blind, allocation concealment unclear.
c  Only one study.
d  Fixed effect model.
e  One CPS, outpatient, conducted in Dutch; for CPS medium doses = 55–70 mg/day, low doses = 5–55 mg/day.
f  One CPS of moderate quality.
g  Large confidence interval.
h  CPS.
GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  24 March 2006
Question:  Should methadone maintenance (60–120 mg/day) versus methadone maintenance (1–39 mg/day) be used for opioid 
dependence?
Patient or population:  Opioid dependents
Settings:  Outpatient
Systematic review:  Faggiano F et al. Methadone maintenance at different dosages for heroin dependence (CLIB 3, 2003)[140].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Methadone 
maintenance 
(60–120 mg/day)
Methadone 
maintenance 
(1–39 mg/day)
Relative risk 
(RR) 
(95% CI)
Absolute risk 
(AR) 
(95% CI)
Retention in treatment at 7–26 weeks (objective follow-up: 7–26 weeks)
5 Randomized 
trials
no limitations no important 
inconsistency
no 
uncertainty
none 138/247 
(55.9%)
102/249 
(41.0%)
RR 1.36, 
(1.13 to 1.63)
150/1000 more 
(50 to 260)
⊕⊕⊕⊕	
High
7
Opioid abstinence (proportion of negative urine samples over 12 weeks) 
1 Randomized 
trials
no limitations no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (–2)
55 55 -– WMD –2.0 
(–4.8 to –0.8)
⊕⊕ 
low
7
Opioid abstinence at 3–4 weeks (urinalysis) 
3 Randomized 
trials
no limitations Inconsistent 
findings (–1)a
no 
uncertainty
Imprecise or sparse 
data (–1)
55/118 34/119 -– RR 1.59 
(1.16 to 2.18)
⊕⊕ 
low
7
Cocaine abstinence at 3–4 weeks (urinalysis) 
2 Randomized 
trials
no limitations no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (–1)
35/83 20/85 -– RR 1.81 
(1.15 to 2.85)
⊕⊕⊕ 
Moderate
6
a Significant heterogeneity.
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GRADE evidence profile
Author(s):  Amato L, Minozzi S
Date:  24 March 2006
Question:  Should methadone maintenance (60–120 mg/day) versus methadone maintenance (40–59 mg/day) be used for opioid dependence?
Patient or population:  Opioid dependents
Settings:  Outpatient
Systematic review:  Faggiano F et al. Methadone maintenance at different dosages for heroin dependence (CLIB 3, 2003)[140].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Methadone 
maintenance 
(60–120 mg/day)
Methadone 
maintenance 
(40–59 mg/day)
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Retention in treatment at 7-13 weeks [211, 212] (Objective follow-up: 7–13 weeks)
2a Randomized 
trials
no 
limitations2b
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-1)
138/173 
(79,8%)
137/174 
(78,7%)
RR 1.01c 
(0.91 to 1.12)
10 more/1 000 
(80 less to 90 more)
⊕⊕⊕ 
Moderate
7
Retention in treatment at 27- 40 weeks[213, 211, 214] (Objective follow-up: 27–40 weeks) 
3d Randomized 
trials
no 
limitationse
no important 
inconsistency
no 
uncertainty
none 157/277 
(56,7%)
130/283 
(45,9%)
RR 1.23c 
(1.05 to 1.45)
100/1 000 more 
(30 more to 190 more)
⊕⊕⊕⊕	
High
7
Opioid abstinence[212] (Objective7, follow-up: 3–4 weeksj) 
1f Randomized 
trials
no 
limitationsh
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)i
10/31 
(32,3%)
6/28 
(21,4%)
RR 1.51c 
(0.63 to 3.61)
110/1 000 more 
(120 less to 330 more)
⊕⊕ 
low
7
Criminal activity[212] (Objective and subjectivel, Range: to . Better indicated by: lower scores) 
1k Randomized 
trials
no 
limitationsh
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)i
31 28 - WMD 0.05 
(-0.03 to 0.13)
⊕⊕ 
low
6
Mortality[196] (Objective follow-up: 6 years) 
1m Observational 
studiesn
no 
limitationsn
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)o
0/316 
(0%)
1/362 
(0,3%)
RR 0.38c 
(0.02 to 9.34)
0/1 000 
(10 less to 10 more)
⊕ 
Very low
9
a Both outpatient and both conducted in USA
b Both double blind, allocation concealment unclear
c Fixed effect model
d All outpatient and all conducted in USA
e adequate allocation concealment, 2 unclear; 2 double blind, 1 single blind
f Outpatient, conducted in USA
g Based on urinalysis
h Double blind, allocation concealment unclear
i  only 1 study, few participants
j  During the treatment
k Outpatient, conducted in USA
l Medium number/week of criminal activities
m 1 CPS, outpatient, conducted in Dutch. For CPS high doses = >75 mg/day, medium dose = 55–70 mg/day
n 1 CPS of moderate quality
o Few events
GRADE evidence profile
Author(s):  Amato, Minozzi
Date:  24/03/2006
Question:  Should Methadone maintenance very high doses (>120 mg/day) versus Methadone maintenance high doses (60–120 mg/day) 
be used for Opioid dependence?
Patient or population:  Opioid-dependent patients Settings: Outpatient
Systematic review:  Faggiano F et al. Methadone maintenance at different dosages for heroin dependence (CLIB 3, 2003)[140].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Methadone 
maintenance very high 
doses (>109 mg/day)
Methadone 
maintenance high 
doses (60-109 mg/day)
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Retention in treatment[213] (Objective follow-up: 27 weeks)
1a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-2)c
25/40 
(62,5%)
26/40 
(65%)
RR 0.96d 
(0.69 to 1.34)
30/1 000 less 
(240 less to 190 more)
⊕⊕ 
low
1
a Outpatient, conducted in USA
b Single blind, adequate allocation concealment
c 1 study, few participants
d Fixed effect model
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A1.6 Tapered methadone versus alpha2 adrenergic agonists for withdrawal from opioids
GRADE evidence profile
Author(s):  Amato
Date:  02/02/2006
Question:  Should tapered methadone versus alpha2 adrenergic agonists be used in opioid users?
Patient or population:  any opioid-dependent patients wishing to withdraw from opioids
Settings:  Inpatient or outpatient
Systematic review:  Gowing L; Alpha-2 adrenergic agonists for the management of opioid withdrawal (CLIB 4, 2004)[222]; Amato et al.; 
Methadone at tapered doses for the management of opioid withdrawal (CLIB 3, 2005) [222].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Tapered 
methadone
Alpha2 adrenergic 
agonists
Relative risk (RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
completion of treatment[215, 216, 217, 218, 219, 220, 221] (Objective follow-up: max 30 dayse)
7a Randomized 
trials
no 
limitationsb
Important 
inconsistency (-1)c
no 
uncertainty
none 168/251 
(66,9%)
192/326 
(58,9%)
RR 1.09d 
(0.90 to 1.32)
60/1 000 more 
(60 less to 180 more)
⊕⊕⊕ 
Moderate
7
relapsed at 6 months follow-up (intention to treat (ITT) analysis)[217] (objective follow-up: 6 months) 
1g Randomized 
trials
no 
limitationsh
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-2)i
11/25 
(44%)
10/24 
(41,7%)
RR 1.06j 
(0.55 to 2.02)
20/1 000 more 
(250 less to 300 more)
⊕⊕ 
low
5
a 5/7 studies were conducted in inpatient setting, 2 in outpatient; Country of origin: USA (3), United Kingdom (2), Spain (2). There are two more studies that considered this outcome but 
they are observational studies, this is the reason why they have been excluded from the meta-analysis
b 2/7 studies with adequate allocation concealment, 5/7 method unclear; all double blind
c Significant heterogeneity: p = 0.0045 and no statistical significant results
d Random effect model
e Length of treatment
f The quality of reporting was very poor for this outcome. The way to report the results was very heterogeneous and prevented to pool the results in the meta-analysis. Four out of seven 
studies showed that alpha2 adrenergic agonists have an hypotensive effect more than methadone
g The study was conducted in USA in outpatient setting
h Double blind, unclear allocation concealment
i Only 1 study with few participants (49)
j Fixed effect model
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A1.7 Medications for opioid withdrawal
GRADE evidence profile
Author(s):  Amato L
Date:  02/02/2006 16.01.56
Question:  Should tapered methadone versus tapered buprenorphine be used in all opioid-dependent patients?
Patient or population:  opioid users
Settings:  outpatient or inpatient
Systematic review:  Gowing et al.; Buprenorphine for the management of opioid withdrawal (CLIB 2, 2006)[159]; Amato et al.; Methadone at 
tapered doses for the management of opioid withdrawal (CLIB 3, 2005)[224].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Tapered 
methadone
Tapered 
buprenorphine
Relative risk (RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Completion of treatment[223, 220] (Objective follow-up: 14 to 30 daysh)
2a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-2)d
21/30 
(70%)
26/33 
(78,8%)
RR 0.88c 
(0.67 to 1.15)
100/1 000 less 
(290 less to 100 more)
⊕⊕ 
low
7
Side effects[223] (variations in systolic blood pressure Range: to . Better indicated by: lower scores) 
1e Randomized 
trials
no 
limitationsf
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-2)g
18 19 - WMD -5.1 
(-14 to 5.3)
⊕⊕ 
low
5
a Both studies were conducted in inpatient setting; Country of origin: Germany (1), USA (1)
b 2/2 allocation concealment unclear, both double blind
c Random effect model
d Few patients (63)
e The study was conducted in USA with an inpatient setting
f Double blinded, allocation concealment unclear
g Only 1 study with few participants (39)
h Length of treatment
GRADE evidence profile
Author(s):  Amato
Date:  13/09/2007
Question:  Should tapered buprenorphine versus alpha-2 adrenergic agonists be used for opioid withdrawal?
Patient or population:  Opiate addicts
Settings:  Outpatient and Inpatient
Systematic review:  Gowing L et al.; Buprenorphine for the management of opioid withdrawal (CLIB 2, 2006)[159].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Buprenorphine Alpha-2 adrenergic 
agonists
Relative risk (RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Completion of treatment[163, 226, 227, 228, 229, 230, 231] (Objective follow-up) 
8a Randomized 
trialsb
no 
limitations
Important 
inconsistency (-1)f
no 
uncertainty
none 271/349 
(77,7%)
151/304 
(49,7%)
RR 1.53e 
(1.18 to 1.99)
300/1 000 more 
(140 to 410)
⊕⊕⊕ 
Moderate
7
Adverse effects (Objective follow-up) 
3c Randomized 
trialsd
no 
limitations
no important 
inconsistency
no 
uncertainty
none 60/292 
(20,5%)
51/166 
(30,7%)
RR 0.95e 
(0.77 to 1.17)
100/1 000 less 
(60 less to 50 more)
⊕⊕⊕⊕ 
High
3
Withdrawal scores (peak objective withdrawal score)
3c Randomized 
trials
no 
limitations
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-1)
133 133 - SMD -0.61h (-0.86 
to -0.36)
⊕⊕⊕ 
Moderate
6
Withdrawal scores (overall participant completed score)
2g Randomized 
trials
no 
limitations
no important 
inconsistency
no 
uncertainty
none 287 165 - SMD -0.598(-0.79 
to -0.39)
⊕⊕⊕⊕ 
High
5
a 10 studies, all outpatient, 7 conducted in USA, 1 in Australia, 1 in India and 1 in Italy
b For the allocation concealment, 3 rated as a, 6 b, and 1 c
c 3 studies, 1 conducted in Australia and 2 in USA
d 2 RCTs 1 rated a and 1 b
e random effect model
f significant heterogeneity
g 2 studies, one conducted in the US, one in Australia
h fixed effect model
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A1.8 Should antagonists with minimal sedation be used for opioid withdrawal?
GRADE evidence profile 
Author(s):  Davoli M, Amato L
Date:  02/02/2006
Question:  Should opioid antagonists with minimal sedation be used for opioid withdrawal?
Patient or population:  opioid dependents undergoing managed withdrawal
Settings:  Inpatient
Systematic review:  Gowing L et al.; Opioid antagonists with minimal sedation for opioid withdrawal (CLIB 1, 2006)[160].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Opioid 
antagonists with 
minimal sedation 
Control Relative risk 
(RR) 
(95% CI)
Absolute risk 
(AR) 
(95% CI)
Completion of treatment[232, 233, 234, 231] (Objective follow-up: 3-6 dayse) 
4a Randomized 
trials
no limitationsb Important 
inconsistency 
(-1)c
no uncertainty none 198/231 
(85,7%)
118/163 
(72,4%)
RR 1.26d 
(0.80 to 2.00)
70/1 000 
(40 less to 180 
more)
⊕⊕⊕ 
Moderate
7
Severity and duration of withdrawal symptoms[235, 236, 237, 231] (Subjective and objective follow-up)
4a Randomized 
trials
Serious 
limitations 
(-1)b, f
no important 
inconsistencyg
no uncertainty High probability of 
reporting bias (- 1)g
- - Unable to 
compare 
scales
- ⊕⊕ 
low
5
Side effects[235, 237] (Subjective follow-up: 3-6 dayse) 
2h Observational 
studiesn
no limitationsi no important 
inconsistency
no uncertainty Imprecise or sparse 
data (-1)f 
High probability of 
reporting bias (- 1)f, j
6/94 
(6,4%)
1/80 
(1,2%)
RR 3.71d 
(0.65 to 
21.32)
50/1 000 more 
(10 less to 110 
more)
⊕ 
Very low
8
Patients who have relapsed at follow-up[234] (Subjective follow-up: 6 months ) 
1k Randomized 
trials
no limitationsl no important 
inconsistency
Some uncertainty 
(-1)m
Imprecise or sparse 
data (-1)m
15/32 
(46,9%)
18/32 
(56,2%)
RR 0.83 
(0.52 to 1.35)
100/1 000 less 
(2700 less to 100 
more)
⊕⊕ 
low
5
a Country of origin of the studies: Italy (2), United Kingdom (1) and USA (1); 3 studies were conducted in an outpatient setting, 1 inpatient
b 3/4 the allocation concealment was unclear, and in 1/4 inadequate; 2 double blind, 2 no information on blindness
c Statistically significant heterogeneity
d Random effect model
e Length of treatment
f In addition, there are major differences in treatment schedules and the type of additional therapy
g Measured on the basis of subjective symptoms using different scales preventing the possibility of pooling data
h 2 controlled prospective trial, both conducted in USA and in outpatient setting
i Allocation concealment unclear in 1 study and inadequate in the other
j The RR is greater than 3
k The study was conducted in Italy in outpatient setting
l Unclear allocation concealment, no information on blindness
m only 1 study, few participants (98) and conducted in outpatient setting
n Observational studies
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A1.9 Should opioid antagonists with heavy sedation or anaesthesia be used for opioid withdrawal?
GRADE evidence profile 
Author(s):  Davoli M, Amato L
Date:  02/02/2006
Question:  Should opioid antagonist under heavy sedation be used for opioid withdrawal?
Patient or population:  opioid-dependent patients undergoing managed withdrawal
Settings:  inpatient
Systematic review:  Gowing L et al.; Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal (CLIB 2, 2006)[161].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Opioid antagonist 
under heavy 
sedation
Standard 
opioid 
withdrawal
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Completion of treatment5 (clonidine comparison)[163, 162] (Objective follow-up: 1-3 daysd)
2a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-1)
74/86 
(86%)
95/121 
(78,5%)
RR 1.15c 
(0.79 to 1.68)
150/1 000 more 
(140 less to 350 more)
⊕⊕⊕ 
Moderate
7
Completion of treatmente (buprenorphine comparison)[163] (Objective follow-up: 1-3 daysd)
1 Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-2)
7/35 
(20%)
9/37 
(24,3%)
RR 0.82c 
(0.34 to 1.97)
50 less/1 000 
(230less to 150 more)
⊕⊕ 
low
7
Commencement of naltrexone (clonidine comparison)
2 Randomized 
trials
no 
limitations
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-1)
73/86 
(85%)
21/84 
(25%)
RR 3.4c 
(2.32 to 4.98)
⊕⊕⊕ 
Moderate
5
Commencement of naltrexone (buprenorphine comparison)
1 Randomized 
trials
no 
limitations
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-2)
33/35 
(94%)
36/37 
(97%)
RR 0.97c 
(0.88 to 1.07)
⊕⊕ 
low
5
Severity and duration of withdrawal[163] (subjective rating scales follow-up: ) 
1f Randomized 
trials
no 
limitationsg
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-1)h 
High probability of 
reporting bias (-1)i
/ / unable to 
compare 
scales
- ⊕⊕ 
low
7
Adverse events (Objective follow-up: 1-4 daysd)
2 Randomized 
trials
no 
limitations
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-1)
14/287 
(5%)
4/285 
(1.4%)
RR 3.41 
(1.13 to 9.12)
⊕⊕⊕ 
Moderate
6
Life threatening adverse events[163] (Objective follow-up: 1-4 daysd)
1f Randomized 
trials
no 
limitationsg
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-2)j
3/35 
(8,6%)
0/71 
(0%)
RR 14c 
(0.74 to 
263.78)
90/1 000 
(10 less to 180 more)
⊕⊕ 
low
9
Relapsed at follow-up (ITT analysis)[163, 162] (Objective (urine analysis) follow-up: 12 months) 
2a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertaintym
Imprecise or sparse 
data (-1)
74/86 
(86%)
109/121 
(90,1%)
RR 0.973 
(0.88 to 1.08)
30/1 000 less 
(110 less to 70 more)
⊕⊕⊕ 
Moderate
5
Retention at 12 months[163, 162] (Objective follow-up: 12 months) 
2a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-1)
35/86 
(40,7%)
43/121 
(35,5%)
RR 0.95c 
(0.69 to 1.30)
20/1 000 less 
(110 less to 110 more)
⊕⊕⊕ 
Moderate
5
a The countries in which the 2 studies were conducted are: USA (1), Australia (1), both trials were conducted with inpatients.
b In both studies method of allocation concealment was not stated, 1 study was single blind (patients blind) and the other one no blindness
c Fixed effect model
d Length of treatment
e The outcome is not relevant in this context
f The study was conducted in the USA in inpatient setting
g Method of allocation concealment not stated, no blindness
h Only one study and data based on self-reporting
i Based on self-reporting and no dose response effect shown by other 2 RCTs for withdrawal symptoms and duration
j Only one study and few participants (106)
k This is a relevant outcome
l Dose response effect shown by other 2 RCTs comparing different doses
m Data based on study with very high proportion of patients lost to follow-up
n Only two studies, few participants (78)
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A1.10 Should withdrawal from opioids be conducted in inpatient or outpatient settings?
GRADE evidence profile
Author(s):  Amato L
Date:  02/02/2006
Question:  Should inpatient detoxification treatment versus outpatient detoxification treatment be used for opioid detoxification?
Patient or population:  opioid users
Settings:  inpatient versus outpatient
Systematic review:  Day E. et al.; Inpatient versus other settings for detoxification for opioid dependence (CLIB 2, 2005)[168].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Inpatient 
detoxification 
treatment
Outpatient 
detoxification 
treatment
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Completion of treatment[238] (objective follow-up: 10 daysd)
1a Randomized 
trials
Serious 
limitations (-1)b
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-2)e
7/10 
(70%)
11/30 
(36,7%)
RR 1.91c 
(1.03 to 3.55)
330/1 000 more 
(0 to 670 more)
⊕ 
Very low
7
Relapsed at follow-up[238] (Objective follow-up: 10 days)
1a Randomized 
trials
Serious 
limitations (-1)b
no important 
inconsistency
no 
uncertainty
Imprecise or sparse 
data (-2)e
10/10 
(100%)
28/30 
(93,3%)
RR 1.07c 
(0.97 to 1.18)
70/1 000 more 
(90 less to 220 more)
⊕ 
Very low
7
a The study was conducted in USA
b There are serious methodological problems regarding the randomization method
c Fixed effect model
d Length of treatment
e Very few participants (40)
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A1.11  Should antagonist pharmacotherapy, naltrexone, be used for the treatment of opioid dependence?
GRADE evidence profile 
Author(s):  Minozzi, Amato
Date:  23/03/2006
Question:  Should oral naltrexone be used for opioid dependence?
Patient or population:  Opioid-dependent patients
Settings:  Outpatient
Systematic review:  Minozzi et al.; Oral naltrexone treatment for opioid dependence (CLIB 1, 2006)[170].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Oral naltrexone Placebo Relative risk 
(RR) (95% CI)
Absolute risk (AR) 
(95% CI)
Retention in treatment[239, 240, 241, 242,243] (Objective follow-up: 2-9 monthsd)
5a Randomized 
trials
no limitationsb no important 
inconsistency
no uncertainty Imprecise or 
sparse data (-1)
35/105 
(33,3%)
31/98 
(31,6%)
RR 1.08c 
(0.74 to 1.57)
20/1 000 more 
(90 less to 140 more)
⊕⊕⊕ 
Moderate
6
Use of opioids [239, 244, 240, 241, 242, 243] (Objective6 follow-up: 2-9 monthsd)
6e Randomized 
trials
Serious 
limitations (-1)g
no important 
inconsistency
no uncertainty Imprecise or 
sparse data (-1)
68/139 
(48,9%)
69/110 
(62,7%)
RR 0.72c 
(0.58 to 0.90)
180 less / 1 000 
(290 less to 60 less)
⊕⊕ 
low
7
Relapsed at follow-up[241, 242] ( follow-up: 6 months-1 year)
2h Randomized 
trials
no limitationsi no important 
inconsistency
no uncertainty Imprecise or 
sparse data (-2)j
26/43 
(60,5%)
24/38 
(63,2%)
RR 0.94c 
(0.67 to 1.34)
40 less / 1 000  
(250 less to 180 more)
⊕⊕ 
low
7
Criminal behaviour[245, 246] (objectivep follow-up: 6-10 monthsd)
2n Randomized 
trials
no limitationsp no important 
inconsistency
Specific 
population (prison 
release) (-1)
Imprecise or 
sparse data (-2)
13/54 
(24,1%)
15/32 
(46,9%)
RR 0.50c 
(0.27 to 0.91)
240 less / 1 000 
(440 less to 30 less)
⊕ 
Very low
6
a Outpatient. Country of origin: Israel 2,USA 1, Russia 1, Spain 1
b 2 adequate allocation concealment, the other unclear; all double blind
c Fixed effect model
d Length of treatment
e All outpatient. Country of origin: Israel 2, USA 1, China 1, Russia 1, Spain 1
f Based on urinalysis
g 2 adequate allocation concealment, the other unclear; all double blind. ITT analyses not used.
h Both outpatient, one conducted in Israel, the other in Spain
i 1 with adequate allocation concealment, 1 unclear, both double blind
j Few patients, result not statistically significant
k All outpatient, conducted in USA, China and Russia 1 each
l 1 adequate allocation concealment, 2 unclear, all double blind
m Number of subjects with at least one side effect
n Both outpatient and both conducted in USA
o Number re-incarcerated
p Both unclear allocation concealment and open design
q 2 studies, few patients
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A1.12 Should psychosocial treatments be used in addition to pharmacological maintenance treatments?
GRADE evidence profile 
Author(s):  Amato, Minozzi
Date:  23/03/2006
Question:  Should psychosocial plus pharmacological maintenance treatments versus pharmacological maintenance treatments alone 
be used for opioid dependence?
Patient or population:  Opiate dependent patients
Settings:  Outpatient
Systematic review:  Amato et al.; Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone 
for treatment of opioid dependence (CLIB 4, 2004)[257].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Psychosocial plus 
pharmacological 
maintenance 
treatments
Pharmacological 
maintenance 
treatments alone
Relative 
risk (RR) 
(95% CI)
Absolute risk 
(AR) 
(95% CI)
Retention in treatment[247, 248, 249, 212, 250, 251, 252, 253] (Objective follow-up: 6-24 weeksd)
8a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
none 228/296 
(77%)
170/214 
(79,4%)
RR 0.94c,e 
(0.85 to 
1.02)
50 less / 1 000 
(120 less to 20 
more)
⊕⊕⊕⊕ 
High
7
Use of opiates[254, 156, 251, 252, 253] (Objectiveg follow-up: 6-32 weeksd)
5f Randomized 
trials
no 
limitationsh
no important 
inconsistency
no 
uncertainty
none 70/187 
(37,4%)
105/201 
(52,2%)
RR 0.69i 
(0.53 to 
0.91)
190 less / 1 000 
(320 less to 50 
less)
⊕⊕⊕⊕ 
High
7
Retention in treatment at the end of follow-up[255, 248, 256] (Objective follow-up: 4-48 weeks) 
3j Randomized 
trials
no 
limitationsk
no important 
inconsistency
no 
uncertainty
none 105/163 
(64,4%)
62/87 
(71,3%)
RR 0.90c 
(0.76 to 
1.07)
70 less / 1 000 
(190 less to 50 
more)
⊕⊕⊕⊕ 
High
7
Abstinent at the end of follow-up[248, 256] ( follow-up: 1-12 months) 
2l Randomized 
trials
no 
limitationsm
Important 
inconsistency 
(-1)n
no 
uncertainty
Imprecise or 
sparse data (-1)n
44/70 
(62,9%)
27/38 
(71,1%)
RR 0.88c 
(0.67 to 
1.15)
90 less / 1 000 
(260 less to 90 
more)
⊕⊕ 
low
6
a All outpatient and all conducted in USA
b All but 1 unclear allocation concealment, 1 inadequate; 2 double blind
c Fixed effect model
d Length of treatment
e Excluding the study with inadequate allocation concealment the result do not change
f All outpatient and all conducted in USA
g Based on urinalysis
h All with unclear allocation concealment, 1 double blind
i Random effect model
j All outpatient and all conducted in USA
k All with unclear allocation concealment, 1 double blind
l Both outpatient and both conducted in USA
m 1 double blind, 2 unclear allocation concealment
n Two studies with conflicting results
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A1.13 Is psychosocial assistance plus pharmacological assistance for opioid withdrawal more useful than pharmacological 
assistance alone?
GRADE evidence profile 
Author(s):  Hill S, Davoli M, Amato L
Date:  02/02/2006
Question:  Should any pharmacological withdrawal treatment plus psychosocial treatment versus any pharmacological withdrawal 
treatment alone be used in opioid-dependent patients requiring withdrawal?
Patient or population:  Opioid users
Settings:  Outpatients
Systematic review:  Amato et al.; Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification 
(CLIB 2, 2004)[169].
Quality assessment Summary of findings
No of patients Effect Quality
Im
portance
No. 
studies
Design Limitations Consistency Directness Other 
considerations
Pharmacological 
withdrawal plus 
psychosocial 
treatment 
Pharmacological 
withdrawal 
alone
Relative risk 
(RR) 
(95% CI)
Absolute risk (AR) 
(95% CI)
Completion of treatment[258, 259, 260, 261, 262] (Objective follow-up: average 18 weeks, range 2-52e)
5a Randomized 
trials
no 
limitationsb
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-1)
37/89 
(41,6%)
24/95 
(25,3%)
RR 1.68c, e 
(1.11 to 2.55)
170 more / 1 000 
(40 more to 300 more)
⊕⊕⊕ 
Moderate
7
Use of primary substance during treatment[258, 260, 261] (urine samples) (follow-up: average 18 weeks, range 2-52d)
3a Randomized 
trials
no 
limitationsf
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-1)g
40/55 
(72.7%)
30/54 
(55.6%)
RR 1.30c 
(0.99 to 1.70)
170 more / 1 000 
(10 less to 330 more)
⊕⊕⊕ 
Moderate
7
Relapsed at follow-up[258, 261, 263] (Objective :urine test. follow-up: 1 year)
3a Randomized 
trials
no 
limitationsf
no important 
inconsistency
no 
uncertainty
Imprecise or 
sparse data (-1)
25/123 
(20.3%)
38/85 
(44.7%)
RR 0.41c,m 
(0.27 to 0.62)
280 less / 1 000 
(400 less to 150 less)
⊕⊕⊕ 
Moderate
7
Subjects using other substances: barbiturates[258] (Objective: urine samples) follow-up: 16 weekse)
1h Randomized 
trials
no 
limitationsi
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)j
9/19 
(47,4%)
6/20 
(30%)
RR 1.58c 
(0.70 to 3.59)
170 more / 1 000 
(130 less to 470 more)
⊕ 
Very low
4
Subjects using other substances: benzodiazepines[258] (Objective (urine samples) follow-up: 16 weekse)
1h Randomized 
trials
no 
limitationsi
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)l
15/19 
(75%)
17/20 
(89.5%)
RR 0.84c 
(0.62 to 1.13)
140 less / 1 000 
(380 less to 90 more)
⊕ 
Very low
4
Subjects using other substances: cocaine[258] (urine test follow-up: 16 weekse)
1h Randomized 
trials
no 
limitationsi
no important 
inconsistency
no 
uncertainty
Very imprecise or 
sparse data (-2)l
11/19 
(55%)
12/20 
(63.2%)
RR 0.87c 
(0.52 to 1.47)
80 less / 1 000 
(390 less to 230 more)
⊕ 
Very low
5
a All studies were conducted in the USA and all in outpatient setting
b Four studies with unclear allocation concealment and one with inadequate; 2 studies were single blind (participants blind only for pharmacological interventions) and 3 did not report 
data on blindness
c Fixed effect model
d Performing a sensitivity analysis excluding the study with inadequate allocation concealment (class C) from meta-analysis (Robles 2002, 48 participants)[262]. The result did not change, 
remaining significantly in favour of the associated treatments (RR 0.46 (95% CI 0.27 to 0.79)
e Length of treatment
f All studies with unclear allocation concealment, 2 single blind an 1 not blind
g Few patients (109)
h The study was conducted in USA, in outpatient setting (Bickel 1997)[258]
i Unclear allocation concealment, single blind
j Only one study, few participants and wide confidence interval
k Low generalizability of treatments offered
l Only one study, few participants
m Performing a sensitivity analysis excluding the study with inadequate allocation concealment (class C) from meta-analysis (Yandoli 2002, 119 participants)[263]. The result became not 
statistically significant RR 0.84 (95% CI 0.68 to 1.04)
n Inadequate allocation concealment, open label
o Few patients and wide confidence interval
p The study was conducted in USA, in an outpatient setting (Yandoli, 2002)[263]
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A2.1 Dispensing
Dispensing of methadone and buprenorphine may take place in a variety of 
clinical and community settings.
In specialist clinical settings, an onsite pharmacy or dispensary can enable 
observation of patients at the time of each dosing. This observation means that 
clinic staff can more thoroughly assess patients whom they would normally 
observe less frequently. In community settings, dispensing may occur at 
community pharmacies or, in some countries, buprenorphine may be dispensed 
in a physician’s office.
Dispensing staff can make a valuable contribution to multidisciplinary care 
planning, which is more easily accommodated in the clinic setting. In the 
community setting, where agonist treatment is dispensed in community 
pharmacies, medical staff should be encouraged to discuss patients regularly with 
the dispensing pharmacist, to determine, if applicable, the number of missed 
doses or the level of intoxication on presentation for dosing. If the pharmacy 
that is dispensing the methadone or buprenorphine is external to the agency 
prescribing the methadone or buprenorphine, then patients should be informed, 
before they commence methadone or buprenorphine, that communication with 
the external pharmacy is a condition of treatment. 
Methadone and buprenorphine should be kept in a secure safe, according to 
local requirements. The amounts should be checked and witnessed by a second 
party daily, to ensure the amount used is reconciled with amount dispensed.
Generally, dispensing staff are pharmacists, although in most jurisdictions, 
medical and nursing staff can also dispense medication. Pharmacists and 
other dispensing staff should be trained in the issues involved in dispensing 
methadone and buprenorphine.
Before dispensing methadone and buprenorphine, dispensing staff should:
establish the identity of the patient and confirm this with the name on the •	
prescription
confirm that the patient is not intoxicated•	
check that the prescription is valid and that the current day is a •	
dosing day (for alternate days or three-times-a-week buprenorphine 
prescriptions)
confirm the dose of the prescription.•	
To further reduce dosing errors and assist with record keeping, computerized 
systems are available that confirm the identity of the patient using retinal or iris 
scanners, and automatically dispense the dose on the prescription (after it has 
been entered by the pharmacist).
It is vital that methadone or buprenorphine are not dispensed to people who 
are sedated or intoxicated because this may lead to over sedation. Dispensing 
staff should be skilled in the assessment of the degree of sedation and 
confident in refusing doses to intoxicated patients. It can be helpful to test 
breath alcohol levels if patients have been drinking. Patients who present 
intoxicated or sedated should be asked to return when the intoxication or 
sedation has abated.
The dose dispensed should be recorded in accordance with jurisdictional 
requirements.
A2.2 Administration of buprenorphine
Buprenorphine tablets should be dispensed in a dry dosing cup after the 
number and strength of the tablets have been checked. Before administration, 
a patient should be advised to place the tablets under the tongue and to refrain 
from swallowing (tablets or saliva) until the tablets have dissolved (5 minutes 
on average , but can take up to 15 minutes). The pharmacist should check 
a patient’s mouth cavity for food or receptacles that might be used to divert 
buprenorphine. After administration, the pharmacist should check the patient’s 
mouth cavity again, to determine that the buprenorphine has dissolved. The 
patient should then be offered a drink to rinse the mouth cavity.
To avoid disputes over doses, patients should indicate that they have received 
a dose in some way, such as by signing a dosing card. If a patient attempts 
to spit out a dose or to leave the dispensary before the dose has dissolved, 
the prescribing doctor should be informed. Crushing buprenorphine tablets 
into course granules has been tried in some places to limit diversion of 
buprenorphine, but the efficacy of this approach has not been evaluated.
A2.3 Prescriptions
Legal requirements for prescriptions vary by jurisdiction; however, in general 
a prescription for opioid agonist maintenance therapy should specify the 
following:
name, address and telephone number of the prescribing doctor•	
name of the pharmacy to dispense methadone or buprenorphinename •	
and address of the patient
date of the prescription•	
preparation to be dispensed (i.e. methadone liquid or buprenorphine •	
sublingual tablets)
dose to be dispensed in milligrams (words and numbers)•	
frequency of dispensing (daily, twice daily, alternate daily, three times a •	
week)
start and end dates of dosing covered by the prescription•	
whether doses are to be supervised or if some are to be taken away •	
(specify the maximum number that can be taken home per week)..
Because of the potential seriousness of dosing error, some jurisdictions ensure 
that the prescribing medical practitioner endorses a photograph of the patient, 
which is supplied to the pharmacy or dispensing point. It is a requirement in 
some jurisdictions for doses of opioids to be written in both words and figures. 
To reduce prescription fraud, it can be useful to send a copy of the prescription 
to the pharmacy by facsimile or secure email.
Annex 2 Dispensing, dosing and prescriptions
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This annex describes the codes from the International Classification of Diseases, 
10th edition (ICD-10) that are relevant to these guidelines[14].
F11.0 Intoxication (opioids)
A condition that follows the administration of a psychoactive substance 
resulting in disturbances in level of consciousness, cognition, perception, 
affect or behaviour, or other psycho-physiological functions and responses. 
The disturbances are directly related to the acute pharmacological effects of 
the substance and resolve with time, with complete recovery, except where 
tissue damage or other complications have arisen. Complications may include 
trauma, inhalation of vomitus, delirium, coma, convulsions, and other 
medical complications. The nature of these complications depends on the 
pharmacological class of substance and mode of administration. 
Excludes: intoxication meaning poisoning (T36–T50).
F11.2 Dependence syndrome (opioids)
A cluster of behavioural, cognitive, and physiological phenomena that 
develop after repeated substance use and that typically include a strong 
desire to take the drug, difficulties in controlling its use, persisting in its 
use despite harmful consequences, a higher priority given to drug use than 
to other activities and obligations, increased tolerance, and sometimes a 
physical withdrawal state.
The dependence syndrome may be present for a specific psychoactive substance 
(e.g. tobacco, alcohol, or diazepam), for a class of substances (e.g. opioid drugs), 
or for a wider range of pharmacologically different psychoactive substances.
The ICD-10 diagnostic criteria for opioid dependence are:
a strong desire or sense of compulsion to take opioids•	
difficulties in controlling opioid-use behaviours in terms of the onset, •	
termination or levels of use
a physiological withdrawal state when opioid use has ceased or been •	
reduced, as evidenced by one of the following: 
the characteristic withdrawal syndrome 
use of opioids (or closely related substances) with the intention of  
relieving or avoiding withdrawal symptoms
evidence of tolerance, such that increased doses of opioids are required •	
to achieve effects originally produced by lower doses
progressive neglect of alternative pleasures or interests because of opioid •	
use; increased amounts of time spent to obtain opioids or to recover from 
their effects
persisting with opioid use despite clear evidence of overtly harmful •	
consequences, such as depressive mood states consequent to periods of 
heavy substance use, or drug-related impairment of cognitive functioning 
(efforts should be made to determine that the user was actually, or could 
be expected to be, aware of the nature and extent of the harm).
Narrowing of the personal repertoire of patterns of opioid use has also been 
described as a characteristic feature of dependence.
Opioid dependence does not develop without a period of regular use, although 
regular use alone is not sufficient to induce dependence.
A definite diagnosis of dependence should usually be made only if three or 
more of the diagnostic criteria have been experienced or exhibited concurrently 
at some time during the previous 12 months.
F11.3 Withdrawal state (opioids)
A group of symptoms of variable clustering and severity occurring on absolute 
or relative withdrawal of a psychoactive substance after persistent use of that 
substance. The onset and course of the withdrawal state are time-limited 
and are related to the type of psychoactive substance and dose being used 
immediately before cessation or reduction of use. The withdrawal state may be 
complicated by convulsions. 
Annex 3 ICD-10 codes for conditions covered in these 
guidelines
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A4.1 Methadone
Methadone is a potent synthetic opioid agonist. It has two oral formulations, a 
tablet and a solution. The solution is recommended for the treatment of opioid 
dependence because it is easier to supervise the consumption of a liquid than 
a tablet and because take-home doses can be diluted to reduce the risk of 
injection. Both oral formulations have a bitter taste.
In opioid-naive people, the effects of methadone are qualitatively similar to 
morphine and other opiates; however, in opioid-dependent people, methadone 
prevents withdrawal symptoms without producing significant sedation or 
intoxication.
Methadone has a high (85%) oral bioavailability (i.e. the proportion of a 
therapeutically active drug that reaches the systemic circulation and is available 
at the site of action after being consumed orally). Peak plasma concentrations 
are generally 2–4 hours after dosing. Methadone is distributed widely in tissues 
and protein binding is reported to be 60 to 90%. Methadone is demethylated 
via hepatic cytochrome P450 3A4 (CYP3A4) and 2D6 (CYP2D6) enzymes to its 
major metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). This 
inactive metabolite is excreted in the faeces and urine, together with unchanged 
methadone. Concomitant use of drugs that affect these enzymes may result in 
clinically significant interactions. Methadone doses should be adjusted accordingly.
Declining plasma concentrations have been reported during methadone 
maintenance, suggesting that tolerance occurs, possibly as a result of 
autoinduction of hepatic microsomal enzymes.
Marked inter-individual variations in absorption, distribution, circulation, 
metabolism or elimination (kinetics) have been observed with methadone. 
Elimination half-lives vary considerably – a range of 15 to 60 hours has been 
reported – and careful adjustment of dosage is necessary with repeated 
administration, after which there is a gradual accumulation in the tissues.
Methadone is included in Schedule I of the Single Convention in Narcotic Drugs, 
1961 (see Annex 7).
A4.2 Buprenorphine
Buprenorphine is a potent synthetic partial opioid agonist with high receptor 
affinity and slow receptor dissociation. This means that its clinical effects 
vary both on the level of neuroadaptation of the person consuming the 
buprenorphine (tolerance) and the level of receptor occupancy at the time of its 
use (the timing of most recent opioid use). The partial activity of buprenorphine 
means that it does not induce tolerance to opioids to the same extent as 
methadone. Its high receptor affinity means that buprenorphine can block the 
effects of additional opioid use without inducing the same degree of tolerance 
as methadone. Its slow receptor dissociation and partial activity combined mean 
that it has a withdrawal syndrome that is milder that methadone.
Under low levels of opioid neuroadaptation, all doses of buprenorphine 
produce agonist effects, with high doses producing qualitatively similar effects 
to low doses, but for a longer period of time. However, under high levels 
of neuroadaptation with recent opioid use, high doses of buprenorphine can 
displace heroin and other opioids from receptors, leading to a rapid drop in 
opioid effect, which is experienced as opioid withdrawal.
Low doses of buprenorphine have been used extensively in many countries for 
the management of acute pain.
The potential advantage of buprenorphine is that it has a very good margin of 
safety. Its partial agonist activity at the μ opioid receptor prevents buprenorphine 
from causing the potentially fatal respiratory depression that is associated with 
excessive ingestion of full agonist opioids. This margin of safety also allows higher 
doses to be used for the purposes of prolonging action, without significantly 
increasing the opioid effect.  In this way a double dose of buprenorphine can be 
given every second day, with no dose in between.
Buprenorphine is included in Schedule III of the Convention on Psychotropic 
Substances, 1971.
A4.3 Buprenorphine–naloxone 4:1 combination product
A combination product of buprenorphine and naloxone in a 4:1 ratio is available 
in two-dose strengths (2 mg buprenorphine:0.5 mg naloxone and 8 mg 
buprenorphine:2 mg naloxone). The efficacy of this medication is not reviewed 
in these guidelines due to the lack of clinical trials; however, as this drug is 
registered and used in several countries, the pharmacology is reviewed here.
While buprenorphine is absorbed sublingually, naloxone has only a 5–10% 
sublingual absorption[267]. It is thought that this results in too low a dose to 
have an effect clinically. As buprenorphine and naloxone have similar affinity 
for opioid receptors, the buprenorphine effect dominates because it is present 
in much higher concentrations in the blood. However, if the buprenorphine/
naloxone combination product is injected, the dose of naloxone can induce 
opioid withdrawal, depending on the circumstances.
In the dependent user of heroin or other opioid agonists, the injection 
of the buprenorphine–naloxone combination product results in opioid 
withdrawal[268, 269]. Higher doses of buprenorphine–naloxone induce more 
significant withdrawal[270]. In the non-dependent opioid user, injection of the 
buprenorphine–naloxone product does not induce opioid withdrawal, but 
the opioid effect of buprenorphine is attenuated by the naloxone, resulting 
in a delayed and reduced opioid effect[271]. For patients in treatment using 
buprenorphine, or for those using buprenorphine illicitly, injection of the 
buprenorphine–naloxone product does not appear to induce withdrawal[272], 
either because higher doses of naloxone are needed to displace buprenorphine 
or because the half-life of naloxone is too short in comparison with the slow 
dissociation of buprenorphine from opioid receptors.
A4.4 Opioid antagonist medications 
Naltrexone
 
Naltrexone is an orally active opioid antagonist, with an effective duration of 
action of 24–48 hours, making it suitable for use once a day. It has a very high 
affinity for opioid receptors and will displace heroin and methadone in minutes, 
and buprenorphine in 1–4 hours. It is used clinically after opioid withdrawal to 
prevent relapse to opioid dependence.
Naloxone
 
Naloxone is a short-acting injectable opioid antagonist used in the management 
of opioid overdose to reverse the effects of opioids. It is poorly absorbed orally 
and so is used either intramuscularly or intravenously. It has a half-life of 
approximately one hour but continues to have 50% receptor occupancy at 2 
hours after injection due to its receptor binding [273]. 
A4.5 Medication for the management of opioid withdrawal
Alpha adrenergic agonists
 
The alpha-2 agonists clonidine, lofexidine and guanfacine act on the central 
and peripheral autonomic nervous system, reducing the endogenous release 
Annex 4 Pharmacology of medicines available for the 
treatment of opioid dependence
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of adrenaline and noradrenalin, which are in comparative excess in opioid 
withdrawal. This slows the heart rate, lowers blood pressure, reduces muscle 
tone and induces sedation. Lofexidine is more specific to peripheral actions 
and does not induce hypotension to the same extent. Both lofexidine and 
clonidine are short acting and are taken four times a day. Guanfacine, on the 
other hand, is taken once a day.
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Drug interactions occur because medications have synergistic or antagonistic 
effects (so-called pharmacodynamic interactions), or because the presence of 
one medication affects the absorption, distribution, circulation, metabolism or 
elimination of another medication (so-called pharmacokinetic interactions).
A5.1 Pharmacodynamic interactions
Sedation
Any drugs that cause sedation may cause additive sedation with methadone 
and buprenorphine, increasing the risk of sedative overdose. Such drugs 
include benzodiazepines, alcohol, other sedative psychotropic medications 
(e.g. phenothiazines and other antipsychotics), tricyclic and other sedating 
antidepressants, alpha adrenergic agonists (e.g. clonidine and lofexidine) and 
sedative antihistamines. Most overdose deaths associated with methadone and 
buprenorphine are in combination with one or more of these sedatives.
Opioid withdrawal
Opiate antagonists, such as naltrexone, result in opioid withdrawal for 
patients on methadone and buprenorphine. Naltrexone cannot be used for 
the management of alcohol dependence in this population. A combination of 
agonists and partial agonists can also result in opioid withdrawal. Methadone 
should generally not be combined with the partial agonists buprenorphine, 
pentazocine, nalbuphine or butorphanol. Patients on buprenorphine who are 
also taking opioid agonists for pain may experience incomplete pain relief.
QT prolongation
A group of medications affect the time it takes cardiac ventricular 
muscle to depolarize and subsequently repolarize – the QT interval in an 
electrocardiogram. A prolongation of the QT interval predisposes people to 
serious cardiac arrhythmias, such as torsades de pointes and other ventricular 
tachyarrhythmias, which may be fatal if untreated. Methadone is one such 
medication. Combinations of methadone with other medications that prolong 
the QT interval should be used with caution, as they may further increase the 
risk of QT prolongation-associated cardiac arrhythmias. These medications are 
mainly class I or III antiarrhythmic agents, calcium channel blocking agents, 
some antipsychotic agents and some antidepressants (see Table A5.1 for a 
more complete list). Drugs that result in electrolyte disorders (e.g. hypokalaemia 
and hypomagnesaemia) also result in an increased risk of QT prolongation-
related arrhythmias (i.e. diuretics, laxatives, corticosteroid hormones with 
mineralocorticoid activity). Buprenorphine does not appear to produce clinically 
significant prolongation of the QT interval.
A5.2 Pharmacokinetic interactions
Methadone and buprenorphine are metabolized principally by the cytochrome 
P450 enzyme pathways. A range of drugs and medication either induce or 
inhibit cytochrome P450 enzymes. The process of induction is relatively slow 
as it depends on the synthesis of new enzyme proteins, and occurs over days, 
whereas inhibition can occur rapidly, depending on the concentration of the 
inhibiting substance.
Methadone is largely metabolized from active to largely inactive metabolites 
through CYP3A4 and to a lesser extent CYP1A2, CYP2D6, CYP2B6, CYP2C8 
and also possibly CYP2C9 and CYP2C19[275, 276, 277, 278, 279, 280, 281, 282, 283]. CYP 
enzyme inducers can result in lower plasma methadone levels and inhibitors can 
result in higher levels. Because of the potential for sedative overdose, patients 
on methadone should be observed particularly closely when commencing 
cytochrome P450 inhibitors, and consideration should be given to simultaneous 
methadone reduction. After introducing a potentially interacting new medicine, 
it is important to make careful clinical observations and adjust the dose of 
methadone if necessary.
Buprenorphine is metabolized in the liver, principally by the CYP3A4 
isoenzyme[282]. The active metabolite, nor-buprenorphine is metabolized via a 
separate pathway. Drugs that inhibit CYP3A4 (e.g. ketoconazole, erythromycin, 
some protease inhibitors) may result in increases in buprenorphine concentration 
and the need to reduce the buprenorphine dose. Drugs that induce CYP3A4 
(e.g. rifampicin, phenytoin, phenobarbital, carbamazepine) may result in 
reduced buprenorphine concentrations. Research on drug interactions involving 
buprenorphine is limited. 
A more comprehensive list of drugs that interact on the cytochrome P450 
system are listed in Table A5.2[282].
CYP450 inducers
Alcohol
Chronic consumption of alcohol has been reported to increase the 
metabolism of methadone, whereas acute consumption has been reported 
to increase the area under the curve (AUC)1  of methadone, resulting in 
increased potential for adverse effects.
Anticonvulsants
Phenytoin, carbamazepine and phenobarbital are all significant inducers 
of CYP3A4 and have all resulted in withdrawal symptoms in patients on 
methadone.
Antidepressants
Sertraline, fluoxetine and fluvoxamine are inducers of CYP3A4. Methadone 
may potentiate the effects of tricyclic antidepressants.
Antimycobacterials
Rifampicin (rifampin) has resulted in clinically significant reductions in 
methadone levels.
1 Area under the curve is a measure of the bioavailability of a drug or medicine. It is the 
area under the plasma concentration-time curve for that drug in a particular patient. 
Increase in this indicates more of the drug has reached the systemic circulation and this 
is nearly always accompanied by a rise in plasma concentration.
Annex 5 Drug interactions involving methadone and 
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Table A5.1 Drugs that increase the risk of torsades de pointes or QT interval prolongation
Amiodarone Arsenic trioxide Bepridil Chloroquine
Chlorpromazine Cisapride Clarithromycin Disopyramide 
Dofetilide Domperidone Droperidol erythromycin 
Halofantrine Haloperidol Ibutilide Mesoridazine
Methadone Pentamidine Pimozide Procainamide 
Quinidine Sotalol Sparfloxacin Thioridazine
Source: Arizona Center for Education and Research on Therapeutics 2008[274]
75Annexes
Antiretrovirals
Many antiretroviral medications interact with methadone and buprenorphine, 
see Table A5.2 and Table A5.3.
Other agents
St John’s wort (Hypericum) is also a CYP3A4 inducer.
CYP450 inhibitors
Antifungals
Azole agents including ketoconazole, fluconazole and itraconazole, are potent 
inhibitors of CYP3A4 and have increased the effects of both methadone and 
buprenorphine. Prophylactic dose reductions should be considered.
Antiretrovirals
Many antiretroviral medications interact with  methadone and buprenorphine, 
see Table A6.2 and Table A6.3.
Macrolide antibiotics
Most macrolides (erythromycin, clarithromycin, dirithromycin, roxithromycin) 
inhibit CYP3A4. Only azithromycin does not inhibit CYP3A4.
Other agents
Grapefruit juice is also a significant inhibitor of cytochrome P450 enzymes.
Table A5.2 Interactions between antiretroviral agents and methadone
Antiretroviral agent Effect on methadone Methadone effect on antiretroviral agent Comment
Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs)
Abacavir (ABC) Methadone clearance increased 
by 22%
Concentrations slightly decreased (but not 
clinically significant)
Patients should be monitored for methadone withdrawal symptoms; dose increase 
unlikely, but may be required in a small number of patients
Didanosine (ddI) none Buffered ddI concentration decreased by 57% eC 
ddI unchanged
Buffered ddI dose increase may be considered or use eC ddI in preference
emtricitabine (FTC) none none no known interactions
lamivudine (3TC) none none no known interactions
Stavudine (d4T) none Methadone co-administration reduced stavudine 
AUC and Cmax by 23% and 44%, respectively
The clinical significance of a change in drug exposure of this magnitude is not 
certain
Tenofovir (TDF) none none –
Zidovudine (AZT) none Concentration increased by 29–43% Monitor for AZT adverse effects, in particular bone marrow suppression (especially 
anaemia).
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
efavirenz (eFV) Decreased methadone Cmax (45%) 
and AUC (52%), withdrawal reported
none Symptoms of withdrawal may develop after 3–7 days, requiring significant 
increases in the methadone dose
etravirine (TMC-125) no clinically significant effect no clinically significant effect Observe, but no dose adjustments are likely to be needed.
nevirapine (nVP) Decreased, withdrawal reported none Withdrawal symptoms frequent; generally occurring between 4 and 8 days after 
starting nevirapine; in case series of chronic methadone recipients initiating 
nevirapine, 50–100% increases in the daily methadone doses were required to 
treat opiate withdrawal
Protease inhibitors (PIs)
Atazanavir (ATV) none none --- (if RTV-boosted: see RTV#).
Darunavir (DRV) none none --- (if RTV-boosted: see RTV#).
Fos-amprenavir (FPV) Mildly decreases methadone levels Decreased amprenavir levels Monitor and titrate to methadone response as necessary. Possibility of reduced 
effectiveness of fos-amprenavir, or consider using an alternative agent. 
Indinavir (IDV) none non-clinically significant interaction --- (if RTV-boosted: see RTV#).
lopinavir/ritonavir (lPV/r) Decreased significantly none Methadone withdrawal possible; monitor and titrate to methadone response as 
necessary
nelfinavir (nFV) Decreases methadone levels Mildly decreased, but not clinically significant Clinical withdrawal rarely reported; methadone dose modification unlikely
Ritonavir (RTV) Decreases methadone concentrations 
even at boosting dosage
none May require higher methadone dose, even if only booster doses of ritonavir used; 
observe closely for signs of methadone withdrawal
Saquinavir (SQV) none none --- (if RTV-boosted: see RTV#).
Tipranavir (TPV) none none --- (if RTV-boosted: see RTV#).
Integrase Inhibitors 
Maraviroc (MRV) no data - potentially safe no data - potentially safe
Raltegravir (RAl) none expected none expected
– = no comment; --- = unknown; AUC =area under the curve, EC = enteric coated; RTV = ritinovir; RTV-boosted = ritinovir used in combination with other medication
Table adapted from the Integrated Management of Adolescent and Adult Illness manual on HIV care in injecting drug users,[284] the Liverpool HIV Pharmacology Group web site 2, the 2006 
World Health Organization antiretroviral therapy guidelines,[285] and the Department of Health and Human Services Guidelines for the use of Antiretrovirals Agents in HIV-1-Infected Adults 
and Adolescents.[286]
2 http://www.hiv-druginteractions.org/
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Table A5.3 Interactions between antiretroviral agents and buprenorphine
Antiretroviral agent Effect on buprenorphine Buprenorphine effect on antiretroviral agent Comment
Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs)
Abacavir (ABC) --- --- Potential interaction that may require close monitoring, 
alteration of drug dosage or timing of administration
Didanosine (ddI) none none –
emtricitabine (FTC) none none –
lamivudine (3TC) none none –
Stavudine (d4T) none none –
Tenofovir (TDF) none none –
Zidovudine (AZT) none none –
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
efavirenz (eFV) Decreased buprenorphine concentration none Observe; may need buprenorphine dose increase
etravirine (TMC-125) no data no data Observe
nevirapine (nVP) no data no data Observe
Protease Inhibitors (PIs)
Atazanavir (ATV) Increased buprenorphine effects none Observe; buprenorphine dose reduction may be necessary
Darunavir (DRV) no data no data Observe
Fos-Amprenavir (FPV/APV) no data no data Observe
Indinavir (IDV) Potential for increased buprenorphine 
effects
no data Observe; buprenorphine dose reduction may be necessary
lopinavir/ritonavir (lPV/r) no data no data Observe
nelfinavir (nFV) no data no data Observe
Ritonavir (RTV) Potential for increased buprenorphine 
effects
no data Observe; buprenorphine dose reduction may be necessary
Saquinavir (SQV) Potential for increased buprenorphine 
effects
no data Observe; buprenorphine dose reduction may be necessary
Tipranavir (TPV) Potential for increased buprenorphine 
effects
no data Observe; buprenorphine dose reduction may be necessary
Integrase Inhibitors 
Maraviroc (MRV) no data – potentially safe no data – potentially safe
Raltegravir (RAl) none expected none expected
– = no comment; --- = unknown; EC = enteric coated
Table adapted from the Integrated Management of Adolescent and Adult Illness manual on HIV care in injecting drug users,[284] the Liverpool HIV Pharmacology Group web site3, the 2006 
World Health Organization antiretroviral therapy guidelines,[285] and the Department of Health and Human Services Guidelines for the use of Antiretrovirals Agents in HIV-1-Infected Adults 
and Adolescents.[286]
3  http://www.hiv-druginteractions.org/
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A6.1 Heroin maintenance
The limited evidence is inadequate to support any recommendations on heroin 
maintenance.
A Cochrane review of heroin prescription identified five RCTs comparing heroin 
with methadone[287]. It was not possible to draw definitive conclusions about 
the overall effectiveness of heroin prescription because the experimental studies 
available were not compatible. Heroin use in clinical practice is still a matter of 
research in most countries. Results favouring heroin treatment over methadone 
come from studies conducted in patients who have failed previous methadone 
treatments.
A6.2 Slow or sustained-release oral morphine
The limited evidence is inadequate to support any recommendations on slow or 
sustained-release oral morphine.
Recent formulations of morphine can be used in once-daily doses for the 
treatment of chronic pain[288, 289, 290] and there have been a number of studies 
of these formulations in opioid dependence[210, 291, 292, 293]. The results of these 
trials are promising, demonstrating a long duration of action of morphine 
and comparable levels of self-reported heroin use to methadone treatment. 
The use of morphine in the treatment of addiction is complicated by 
difficulties in assessing heroin use and supervising doses.
A6.3 Levo-alpha-acetylmethadol
Although still registered in the United States, levo-alpha-acetylmethadol (LAAM) 
has been withdrawn from the market by the manufacturer, due to the risk of life-
threatening cardiac arrhythmias.
Levo-alpha-acetylmethadol (LAAM) is a long-acting opioid agonist approved for 
use as a maintenance treatment for opioid dependence. For persons in whom 
methadone and buprenorphine are not effective, LAAM offers an alternative 
effective medication. In a Cochrane review and recent RCT, LAAM was found 
to be better at suppressing heroin use than methadone[294, 295] but its use is, at 
present, limited by its effect of QT prolongation[296]. The active metabolite – nor-
acetylmethadol – does not have the same effect on QT prolongation[131, 297], and 
may be a promising treatment alternative.
A6.4 Buprenorphine-naloxone combination
The limited evidence is inadequate to support any recommendations on a 
buprenorphine–naloxone combination. However, the combination is likely to have 
similar efficacy to buprenorphine alone.
As with methadone, intravenous abuse of buprenorphine has been reported in 
many countries[119, 128, 298, 299, 300, 301, 302, 303]. Buprenorphine–naloxone comprises 
the partial agonist buprenorphine in combination with the opioid antagonist 
naloxone in a 4:1 ratio. It is hoped that by the addition of naloxone, the resulting 
product will be less subject to abuse by injection than buprenorphine alone. 
When the combination is taken sublingually, absorption of naloxone is minimal 
and the opioid agonist effects of buprenorphine should predominate. However, 
when buprenorphine–naloxone tablets are injected, naloxone will induce 
withdrawal in people dependent on opioids other than buprenorphine[269, 271, 
304].
Efficacy of buprenorphine/naloxone in maintenance therapy for opioid 
dependence is described in three RCTs in comparing the combination with 
placebo[305] and clonidine[226], and comparing stepped combination-based 
treatment with methadone treatment alone[306]. Three trials investigating the 
efficacy of the combination with different counselling or medication-dispensing 
regimens have been published[307, 308, 309].
A6.5 Slow-release naltrexone implants and injections
The limited evidence is inadequate to support any recommendations on slow-release 
naltrexone implants and injections.
Injectable, slow-release naltrexone formulations provide clinically significant 
opioid blockade for 3-6 weeks (depending on the dose) in early clinical 
research[310, 311, 312, 313, 314].
A number of naltrexone implants have been developed that can be inserted 
subcutaneously using local anaesthesia, either post withdrawal or as part 
of an antagonist withdrawal treatment. Subsequent implants are inserted 
at 1–3 months intervals. There are no RCTs to assess the effectiveness of 
naltrexone implants, although there are some promising reports[315, 316, 317, 318]. 
Local implant site allergies and infections have been described with implantable 
formulations.
Annex 6 Alternatives for the treatment of opioid dependence 
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The Single Convention on Narcotic Drugs, 1961 (as amended by the 1972 
Protocol) and the Convention on Psychotropic Substances, 1971 contain specific 
control provisions for some psychoactive substances[321, 322]. Pursuant to these 
conventions, the Commission on Narcotic Drugs (CND) has the authority to 
decide, upon a recommendation from the World Health Organization, whether a 
substance should be scheduled as a narcotic drug or a psychotropic substance.
Methadone is currently scheduled as a “narcotic drug”, falling under the 
Single Convention on Narcotic Drugs and buprenorphine as a “psychotropic 
substance”, falling under the Convention on Psychotropic Substances.
The International Narcotics Control Board (INCB) is charged with monitoring the 
compliance by Governments with the above international treaties, ensuring on 
the one hand that controlled substances are available for medical and scientific 
use and on the other hand that diversion from licit sources to illicit traffic does 
not occur[321].
A7.1 Single Convention on Narcotic Drugs 1961
The Single Convention on Narcotic Drugs is the principal international treaty 
regulating the control of opioids. It seeks to limit exclusively to medical and 
scientific purposes the production, manufacture, export, import, distribution 
of, trade in, use and possession of narcotic drugs. Heroin, opium, morphine, 
oxycodone, methadone, and most other potent pharmaceutical opioids (with 
the exception of buprenorphine) are listed as narcotic drugs under the 1961 
Single Convention.
To comply with the convention with regard to methadone, countries must:
estimate the annual medical and scientific requirements for methadone •	
and submit their estimates to the INCB for confirmation
limit the total quantities of methadone manufactured and imported to •	
the relevant estimates, taking into account the quantity exported
ensure that methadone remains in the hands of licenced parties from the •	
point of manufacture or importation to dispensing
provide that methadone is dispensed against a medical prescription•	
report to INCB on the amount of methadone imported, exported, •	
manufactured and consumed and of stocks held
maintain a system of inspection of manufacturers, exporters, importers, •	
and wholesale and retail distributors of narcotic drugs and of medical 
and scientific institutions that use such substances; premises, stocks and 
records should be inspected
in addition, a country has a responsibility to ensure that diversion and •	
abuse of methadone is prevented.
National estimates of medical need for opioids
Every year, national drug regulatory authorities must prepare estimates of the 
requirements for methadone of their country during the following year. The 
estimates must be submitted to the INCB six months in advance of the period for 
which they apply, but supplementary estimates may be submitted at any time. INCB 
publishes changes in the estimates received from governments on a monthly basis, 
as a guide for exporting countries. The responsibility for determining the amounts 
of opioids necessary to meet the medical and scientific requirements in a country 
rests entirely with the national governments, but the INCB must be informed of 
the method used. The INCB establishes estimates of annual requirements for 
narcotic drugs for countries which fail to do so. In case an estimate is established 
by INCB, the competent authorities of the country concerned are informed by the 
Board and requested to review the established estimates.
Obtaining a supply of methadone 
After a country has received confirmation of its estimate from the INCB, it may 
commence manufacture or import procedures. In both cases, it is vital that the 
supply is reliable as interruptions to the supply of methadone are distressing for 
patients and place them at high risk of relapse to illicit opioid use. 
Domestic manufacture
Some, or all of the methadone needed may be manufactured by enterprises 
in the country itself, under the regulation of the government. Regulation of 
manufacture of opioids includes licensing, requirements for record keeping and 
reporting, secure storage, and quality control.
The import/export system
A specific sequence of steps is stipulated in the convention for the import and 
export of narcotic drugs, although additional requirements may vary from 
country to country. Importation and exportation of methadone can only take 
place with the approval of the national drug regulatory authorities, and within 
the limits of the total of the estimates for the importing country. A copy of the 
export authorization must accompany each shipment. 
The import and export authorization shall state:
the name of the drug•	
the international non-proprietary name (INN) of the drug, if any•	
the quantity of the drug to be imported or exported•	
the name and address of the importer and exporter•	
the period of validity of the authorization.•	
The export authorization shall also state the number and date of the import 
authorization and the authority by whom it has been issued.
The steps involved in the import/export process
The import/export process is outlined below in Figure A7.1. Many countries 
also have an authorization/certification procedure to prevent marketing of 
pharmaceutical products that are falsely labelled, counterfeit or substandard. 
The entity wishing to import a substance controlled under the Single 1. 
Convention applies to its regulatory authority for an import authorization. 
The regulatory authority considers whether the company is properly 2. 
licensed and whether the drug and amount are within the national 
estimate; if approved, an original import authorization and the 
appropriate number of copies are issued. One copy should be sent to 
the competent authorities of the exporting country. The original and 
one copy should be sent to the importer who will send the original to 
the exporter and will keep one copy for the Customs declaration. One 
copy should be sent to the Customs authorities of the importing country 
and an additional copy should be kept in the records of the importing 
country’s competent authority.
The importer sends the original of the import authorization to the 3. 
company responsible for the export of the substance. 
The exporter applies to its drug regulatory authority for an export 4. 
authorization. 
The regulatory authority in the exporting country checks that an import 5. 
authorization has been issued and that the exporter is properly licensed, 
and that the estimate of the importing country is sufficient; if the 
application is approved, an export authorization is issued. 
The regulatory authority in the exporting country sends a copy of the 6. 
export authorization to the regulatory authority in the importing country. 
Two copies should be provided to the exporter, one of which must 
accompany the consignment. One copy should be sent to the Customs 
authorities of the exporting country and an additional copy should be 
kept in the records of the exporting country’s competent authority.
The exporter ships the drugs to the importer, along with the copy of the 7. 
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export authorization. 
The shipment must pass a customs inspection. 8. 
The importer sends the export authorization to its regulatory authority. The 9. 
regulatory authority of the importing country shall return the accompanying 
export authorization to the regulatory authority of the exporting country 
with an endorsement certifying the amount actually imported.
Figure A7.1 Steps in opioid importation
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Adapted from WHO 1996[323]
The reporting system
National drug regulatory authorities must report to the INCB all imports and 
exports of methadone every quarter. They are also required to make an annual 
inventory and report the total amount of opioids manufactured, consumed and 
held in stock. The annual inventory does not include drugs stored in pharmacies, 
which for official purposes are considered to have been consumed. 
Regulation of health-care workers
The convention recognizes that individual governments must decide the 
level of regulation of the individuals directly involved in dispensing opioids – 
pharmacists, physicians and nurses. However, it expresses several principles that 
should be observed:
individuals must be authorized to dispense opioids by their professional •	
licence to practice, or be specially licensed to do so
movement of opioids may occur only between duly authorized parties•	
a medical prescription is required before opioids may be dispensed to a •	
patient.
Drug abuse versus patient need
The convention recognizes that governments have the right to impose further 
restrictions if they consider it necessary, to prevent diversion and misuse 
of opioids. However, this right must be continually balanced against the 
responsibility to ensure opioid availability for medical purposes.
In deciding the appropriate level of regulation, governments should bear in mind 
the dual aims of the convention. The INCB has observed that, in some countries, 
fear of drug abuse has resulted in laws and regulations, or interpretations of 
laws and regulations, which make it unnecessarily difficult to obtain opioids 
for medical use.
"…prevention of availability of many opiates for licit use does not necessarily 
guarantee the prevention of the abuse of illicitly procured opiates. Thus, an 
overly restrictive approach to the licit availability of opiates may, in the end, 
merely result in depriving a majority of the population of access to opiate 
medications for licit purposes"[324].
A7.2 Convention on Psychotropic Substances, 1971
This convention establishes an international control system for psychotropic 
substances that balances their abuse potential and therapeutic value. 
Buprenorphine is listed as a psychotropic substance and is currently included in 
Schedule III of the convention.
To comply with the convention with regard to buprenorphine, countries must:
ensure that buprenorphine remains in the hands of licensed parties from •	
the point of manufacture or importation to dispensing;
provide that buprenorphine is dispensed only with a medical prescription;•	
prohibit the advertisement of buprenorphine to the general public;•	
request that all operators manufacturing, trading or distributing •	
buprenorphine keep records on each acquisition and disposal for at least 
two years;
report to INCB on the amount of buprenorphine imported, exported and •	
manufactured on an annual basis;
maintain a system to inspect manufacturers, exporters, importers, and •	
wholesale and retail distributors of psychotropic substances and of 
medical and scientific institutions that use such substances; premises, 
stocks and records should be inspected;
ensure diversion and abuse of buprenorphine is prevented.•	
Domestic manufacture
Some or all of the buprenorphine needed by a country may be manufactured 
by domestic enterprises, under the regulation of the government. Regulation 
of manufacture of psychotropic substances includes licensing, requirements 
for record keeping and reporting. Provisions relating to manufacture of 
pharmaceutical products in general, such as secure storage, and quality control, 
also apply.
Regulation of health-care workers
The convention recognizes that individual governments must decide the level 
of regulation of the individuals directly involved in dispensing psychotropic 
substances (i.e. pharmacists, physicians and nurses). However, it expresses 
several principles that should be observed:
individuals must be adequately qualified, and authorized to dispense •	
psychotropic substances by their professional licence to practice, or be 
specially licensed to do so
movement may occur only between duly authorized parties•	
a medical prescription is required before psychotropic substances may be •	
dispensed to a patient, except when individuals may lawfully obtain, use, 
dispense or administer such substances in the duly authorized exercise of 
therapeutic or scientific functions
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prescriptions need to be issued in accordance with sound medical practice •	
and subject to regulation to protect public health and welfare, particularly 
the number of times such prescriptions may be refilled and the duration 
of their validity.
Drug abuse versus patient need
The convention recognizes that governments have the right to impose further 
restrictions if they consider such restrictions necessary to prevent diversion and 
misuse of psychotropic substances. However, this right must be continually 
balanced against the responsibility to ensure the availability of psychotropic 
substances for medical purposes.
Obtaining a supply of buprenorphine
Reliable supply of buprenorphine is vital because interruptions to the supply 
are distressing for patients and place them at high risk of relapse to illicit opioid 
use. Although not required by the convention, most exporting countries will 
adhere to the additional voluntary control measures recommended by ECOSOC 
(see below). In practice, all importing countries should remember that they 
might encounter difficulties obtaining buprenorphine if they do not have an 
assessment (a simplified estimate of the annual requirements for a psychotropic 
substance, see below) covering the amount to be imported and an import 
authorization or ‘no objection’ certificate for each separate import.
Assessment of medical needs for buprenorphine in accordance with 
ECOSOC resolution 1993/38
National drug regulatory authorities should prepare an assessment of the 
annual requirements for buprenorphine of their country. INCB recommends that 
this assessment should be revised at least every three years. The assessment or 
its revision can be submitted at any time. The responsibility for determining the 
amounts of buprenorphine necessary to meet the medical and scientific need in 
a country rests entirely with the national governments. INCB publishes changes 
in the assessments received from governments on a monthly basis, as a guide 
to exporting countries.
The import–export system
A specific sequence of steps is specified in the convention for the import 
and export of psychotropic substances. Additional requirements have been 
recommended by ECOSOC, and they are adhered to by most governments.
1. Mandatory controls foreseen by the convention 
The convention foresees mandatory import–export authorizations only for 
substances included in Schedules I and II.
When exporting Schedule III substances, such as buprenorphine, exporters have 
to submit two copies of an export declaration to the competent authorities 
of the exporting country, and the third copy of the export declaration has 
to accompany the consignment. The government of the exporting country 
must forward the export declaration to the competent authorities of the 
importing country as soon as possible, but not later than 90 days after the 
date of the dispatch. Countries may require the importer to transmit the 
copy accompanying the consignment, duly endorsed stating the quantities 
received and the date of receipt, to the competent authorities of the importing 
country.
The export declaration must include:
the international non-proprietary name (INN) of the substance, or failing •	
such a name, the designation of the substance in the Schedule
the quantity and pharmaceutical form in which the substance is exported, •	
and, if in the form of a preparation, the name of the preparation
the name and address of the importer•	
the name and address of the exporter•	
the date of the dispatch.•	
2. Voluntary controls foreseen by ECOSOC resolutions
In accordance with ECOSOC resolution 1996/30, most governments have 
extended the import–export authorization system to Schedule III and IV 
substances, including buprenorphine. An import can only take place with the 
approval of the national drug regulatory authorities of the importing country 
and should remain within the assessment for buprenorphine established by 
the importing country. Approved export authorizations must accompany each 
consignment.
The import authorization must include:
the authorization number•	
the date it was issued•	
the authority by whom it has been issued•	
the international non-proprietary name (INN) of the substance(s), or •	
failing such a name, the designation of the substance(s) in the Schedule
the pharmaceutical form and quantity of the substance(s), and, if in the •	
form of a preparation, the name of the preparation
the name and address of the importer•	
the name and address of the exporter•	
the period of validity of the authorization.•	
The steps involved in the import–export process, in accordance with the 
recommendations of the ECOSOC resolutions
The entity wishing to import buprenorphine applies to its regulatory •	
authority for an import authorization.
The regulatory authority considers whether the entity is properly licensed •	
and whether the substance and amount are within the assessment; if 
approved, an original import authorization or ‘no objection’ certificate 
and the appropriate number of copies are issued. (One copy should be 
sent to the competent authorities of the exporting country. The original 
and one copy should go to the importer who will send the original to the 
exporter and will keep one copy for the Customs declaration. One copy 
should go to the Customs authorities of the importing country and an 
additional copy should be kept in the records of the importing country’s 
competent authority.)
The importer sends the original of the import authorization or certificate •	
to the company responsible for the export of the substance.
The exporter applies to its drug regulatory authority for an export •	
authorization.
The regulatory authority of the exporting country checks that an import •	
authorization has been issued and that the exporter is properly licensed, 
and that the assessment of the importing country is sufficient; if the 
application is approved, an export authorization is issued.
The regulatory authority of the exporting country sends a copy of the •	
export authorization to the regulatory authority of the importing country. 
Two copies should go to the exporter, one of which must accompany 
the consignment. One copy should go to the Customs authorities of the 
exporting country and an additional copy should be kept in the records of 
the exporting country’s competent authority.
The exporter ships the drugs to the importer, along with the copy of the •	
export authorization.
The consignment must pass a customs inspection.•	
The importer sends the export authorization to its regulatory authority. •	
After receiving the consignment, the importing authority shall return the 
accompanying export authorization to the regulatory authority of the 
exporting country with an endorsement certifying the amount actually 
imported.
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A7.3 Guidelines for regulation of health professionals
It is understood that regulatory requirements for physicians, nurses and 
pharmacists to dispense opioids to patients will differ from country to country. 
However, the following are general criteria that can be used to develop a 
practical system.
Legal authority. Physicians, nurses and pharmacists should be legally 1. 
empowered to prescribe, dispense and administer opioids to patients in 
accordance with local needs.
Accountability. They must dispense opioids for medical purposes only and 2. 
must be held responsible in law if they dispense them for non-medical 
purposes.
Appropriate records must be kept. If physicians are required to keep 3. 
records other than those associated with good medical practice, the extra 
work incurred should be practicable and should not impede medical 
activities. Hospitals and pharmacists must be legally responsible for safe 
storage and the recording of opioids received and dispensed. Records of 
each individual acquisition and disposal of opioids must be preserved for 
a period of not less than two years.
Reasonable record keeping and accountability provisions should not 4. 
discourage health-care workers from prescribing or stocking adequate 
supplies of opioids.
Prescriptions. Legal requirements for prescriptions vary by jurisdiction; 5. 
however, in general a prescription for opioid agonist maintenance therapy 
should specify the following:
name, address and telephone number of the prescribing doctor 
name of the pharmacy 
name and address of the patient 
date of the prescription 
preparation to be dispensed (i.e. methadone or buprenorphine) 
dose to be dispensed in milligrams (words and numbers) 
frequency of dispensing (daily, twice daily, alternate daily, three times  
a week)
start and end dates of the prescription 
whether doses are to be supervised or taken away. 
Patient access. Opioids should be available in locations that will be 6. 
accessible to as many opioid-dependent patients as possible.
Medical decisions. Decisions concerning the type of drug to be used, the 7. 
amount of the prescription and the duration of therapy are best made 
by medical professionals on the basis of the individual needs of each 
patient.
82 Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence
This annex describes weaknesses and gaps revealed by a review of the 
evidence to support treatment, conducted during the preparation of these 
guidelines.
A8.1 Gaps in the evidence
Comparisons between opioid agonist maintenance, detoxification and 
opioid antagonist approaches
Few studies comparing naltrexone treatments with opioid agonist maintenance 
treatments were found. The only randomized trial to compare methadone or 
buprenorphine with naltrexone  was conducted in  intravenous buprenorphine 
users[142]. There were no studies comparing long-acting naltrexone formulations 
to opioid agonist treatment approaches.
No studies assessed the potential benefit to populations of having more 
than one treatment available (e.g. buprenorphine and methadone, or opioid 
antagonists and opioid agonists).
No randomized trials were conducted in specific populations (e.g. young 
people, people with short histories of dependence, people who do not inject 
and pregnant women) to compare approaches based on opioid detoxification 
with approaches based on opioid agonist maintenance treatment. Although 
evidence strongly favours opioid agonist approaches, opioid detoxification 
remains the most requested treatment in many settings.
Impact of treatment on HIV transmission
Well-conducted observational studies to evaluate the impact of 
pharmacological treatment on HIV transmission would be useful, because 
most randomized trials did not collect data on HIV risk practices and HIV 
transmission. In particular, more data on the impact of buprenorphine 
treatment on HIV transmission is needed, because this treatment is 
unsupervised in many settings.
Optimal doses
Although there are sufficient studies on the optimal doses of methadone to 
make recommendations, the same is not true for buprenorphine. Research is 
also needed on the optimal doses of methadone and buprenorphine in non-
injecting drug users (e.g. opium smokers).
Supervised dosing in agonist maintenance treatment
For both methadone and buprenorphine, surprisingly little research has been 
conducted on the impact of dosing supervision on treatment outcome. This 
is a particularly important question given the widespread use of unsupervised 
buprenorphine treatment in several countries.
Antagonist treatment in different settings
There is a discrepancy between the modest benefits of oral naltrexone 
treatment in developed countries and reports from clinicians of the usefulness 
of naltrexone in developing countries. Further research on opioid antagonists in 
developing countries is needed.
Prescription opioid dependence
In many countries, the number of people with prescription opioid dependence 
now exceeds the number of people with illicit opioid dependence. More research 
is required on the use of opioid detoxification and agonist maintenance in this 
population, including the required degree of supervision.
Adolescence
The relative lack of research in young people and people with brief histories 
of opioid dependence is concerning, because this population may have the 
greatest capacity for change. More research is needed on psychosocial 
assistance, including family-based approaches, and on the relative merits of 
opioid agonist treatment and withdrawal, and antagonist treatment.
Pregnancy and breastfeeding
More research is required to establish the safety of buprenorphine and 
naltrexone for pregnant and breastfeeding women.
Outcomes of planned cessation of agonist maintenance treatment
More research is needed on when opioid agonist treatment can be stopped 
without leading to high rates of relapse. Studies comparing methods of 
cessation of agonist maintenance treatment are also required. 
Psychosocial support
More research is needed on various psychosocial approaches to treatment, 
particularly the more social approaches, such as employment and residential 
programmes.
A8.2 Methodological issues in research
Study size
Many studies are too small to adequately address the questions being asked. 
This may reflect the difficulties in funding clinical trials in this population, and 
the relatively small sizes of many treatment centres. Larger studies are required 
on most topics. In addition, many studies replicate earlier trials despite there 
remaining gaps in the evidence. Treatment networks at international levels may 
be needed to coordinate large trials to answer simple questions, a method that 
has been used in many fields of medicine in recent decades.
Study duration
The follow-up period of most studies is too short, given that opioid dependence 
is a chronic condition.
Study design
Most randomized trials considered in this review did not use intention-to-treat 
analyses, and many did not document allocation concealment. Although it is 
difficult to blind study participants in studies of psychoactive medication, greater 
consideration should be given to the use of blinding in outcome assessment 
and in the statistical analysis.
Outcome measures
Intention-to-treat analysis includes both “in treatment” and “out of treatment” 
patients. Most calculations assume that all people who drop out of treatment 
return to baseline levels of drug use. In reality, some people will start another 
form of treatment and other people will no longer require treatment. Although 
treatment retention is an important proxy measure in the absence of other 
relevant outcomes, continuous retention in treatment and treatment status at 
follow-up should be regarded as a measure of exposure to the intervention, 
rather than as a health outcome.
Studies should instead focus on drug use, related risk behaviours (e.g. injection, 
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sexual activity that could lead to disease transmission) and health outcomes. 
Health outcomes should include measures of psychological health and well-
being, function or dysfunction, quality of life, mortality and, where appropriate, 
specific health conditions (e.g. HIV, hepatitis C, sexually transmitted diseases).
Given that developments are taking place in pharmacogenetics research, 
consideration should be given to the storage of blood samples for such analysis 
from clinical trial participants, with their consent. 
The impact of drug use beyond the individual (e.g. family, carers and society) 
should also be considered. Data for social cost estimates (e.g. criminal activity, 
health-care use, income and receipt of government benefits) are lacking for 
many settings. Cost-effectiveness and cost–benefit analyses are also possible if 
the cost of treatment is measured.
A8.3 Programmatic and systems research
Most research on treatments for opioid dependence has used the individual 
patient as the unit of analysis. There is significant variability in the conduct 
of treatment for opioid dependence worldwide. Greater emphasis on the 
treatment programme and the treatment system may improve the capacity of 
treatment systems to become more efficient and effective. Suggested research 
topics include the choice of treatment settings (e.g. primary care), dosing 
mechanisms and integration with other treatment systems (e.g. HIV treatment 
programmes).
From a public health perspective, the highest priority is to reduce the gap 
between the number of people with opioid dependence and the number with 
access to effective treatments.
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Objective Opiate Withdrawal Scale (OOWS)
Observe the patient during a 5 minute observation period then indicate a score for each of the opioid withdrawal signs listed below (items 1-13). Add the scores for each item to obtain the total score
Date
 Time
1 Yawning 
0 = no yawns 
1 = ≥ 1 yawn
2 Rhinorrhoea 
0 = < 3 sniffs 
1 = ≥ 3 sniffs
3 Piloerection (observe arm) 
0 = absent 
1 = present
4 Perspiration 
0 = absent 
1 = present
5 Lacrimation 
0 = absent 
1 = present
6 Tremor (hands) 
0 = absent 
1 = present
7 Mydriasis 
0 = absent 
1 = ≥ 3 mm
8 Hot and cold flushes 
0 = absent 
1 = shivering / huddling for warmth
9 Restlessness 
0 = absent 
1 = frequent shifts of position
10 Vomiting 
0 = absent 
1 = present
11 Muscle twitches 
0 = absent 
1 = present
12 Abdominal cramps 
0 = absent 
1 = holding stomach
13 Anxiety 
0 = absent 
1 = mild - severe
TOTAL SCORE
Source: Handelsman et al 1987[325]
Annex 10 Opioid withdrawal scales
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Subjective Opiate Withdrawal Scale (SOWS)
In the column below in today’s date and time, and in the column underneath, write in a number from 0-4 corresponding to how you feel about each symptom RIGHT nOW.  
Scale: 0 = not at all 1 = a little 2 = moderately 3 = Quite a bit 4 = extremely
Date
Time
Symptom Score Score Score Score Score Score
1 I feel anxious
2 I feel like yawning
3 I am perspiring
4 My eyes are teary
5 My nose is running
6 I have goosebumps
7 I am shaking
8 I have hot flushes
9 I have cold flushes
10 My bones and muscles ache
11 I feel restless
12 I feel nauseous
13 I feel like vomiting
14 My muscles twitch
15 I have stomach cramps
16 I feel like using now
TOTAL
Source: Handelsman et al 1987[325]
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Clinical Opiate Withdrawal Scale (COWS)
For each item, circle the number that best describes the patient’s signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is 
increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score.
Patient’s name:_____________________            Date and Time ____/_____/____:__________ 
Reason for this assessment:___________________________________________________________
Resting Pulse Rate:_________beats/minute
Measured after patient is sitting or lying for one minute 
0  pulse rate 80 or below
1  pulse rate 81-100
2  pulse rate 101-120
4  pulse rate greater than 120
GI Upset: over last ½ hour
0 no GI symptoms
1  stomach cramps
2  nausea or loose stool
3  vomiting or diarrhea
5  Multiple episodes of diarrhea or vomiting
Sweating: over past ½ hour not accounted for by room temperature or patient activity.
0  no report of chills or flushing
1  subjective report of chills or flushing
2  flushed or observable moistness on face
3  beads of sweat on brow or face
4  sweat streaming off face
Tremor observation of outstretched hands
0  no tremor
1  tremor can be felt, but not observed
2  slight tremor observable
4  gross tremor or muscle twitching
Restlessness Observation during assessment
0  able to sit still
1  reports difficulty sitting still, but is able to do so
3  frequent shifting or extraneous movements of legs/arms
5  Unable to sit still for more than a few seconds
Yawning Observation during assessment
0  no yawning
1  yawning once or twice during assessment
2  yawning three or more times during assessment
4  yawning several times/minute
Pupil size
0  pupils pinned or normal size for room light
1  pupils possibly larger than normal for room light
2  pupils moderately dilated
5  pupils so dilated that only the rim of the iris is visible
Anxiety or Irritability
0  none
1  patient reports increasing irritability or anxiousness
2  patient obviously irritable anxious
4  patient so irritable or anxious that participation in the assessment is difficult
Bone or Joint aches If patient was having pain previously, only the additional component 
attributed to opiates withdrawal is scored
0  not present
1  mild diffuse discomfort
2  patient reports severe diffuse aching of joints/ muscles
4  patient is rubbing joints or muscles and is unable to sit still because of discomfort
Gooseflesh skin
0  skin is smooth
3  piloerrection of skin can be felt or hairs standing up on arms
5  prominent piloerrection
Runny nose or tearing Not accounted for by cold symptoms or allergies
0  not present
1  nasal stuffiness or unusually moist eyes
2  nose running or tearing
4  nose constantly running or tears streaming down cheeks 
Total Score ________
The total score is the sum of all 11 items
Initials of person 
completing Assessment:   _____________
Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal
Source: Wesson and Ling 2003[326]
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Modified Finnegan Scale
This scale is used for the measurement of neonatal abstinence syndrome due to neonatal opioid withdrawal.
Date and Time in Hours
System Signs and Symptoms Score
N
eonatal W
ithdraw
al Scoring Chart (Term
 infants)
Ce
nt
ra
l N
er
vo
us
 S
ys
te
m
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is
tu
rb
an
ce
s
High-Pitched Cry 2
Continuous High-Pitched Cry 3
Sleeps<1 hour after feeding 3
Sleeps<2 hours after feeding 2
Sleeps>3 hours after feeding 1
Mild Tremors Disturbed 1
Mod-Severe Tremors Disturbed 2
Mild Tremors Undisturbed 3
Mod-Severe Tremors Undisturbed 4
Increased Muscle Tone 2
excoriation (specify area) 1
Myoclonic Jerks 3
Generalised Convulsions 5
M
et
ab
ol
ic
/V
as
om
ot
or
/
Re
sp
ir
at
or
y 
D
is
tu
rb
an
ce
s
Fever (37.3ºC-38.3ºC) 1
Fever (38.4ºC and higher) 2
Frequent Yawning (>3.4 times) 1
nasal Stuffiness 1
Sneezing (>3-4 times) 1
nasal Flaming 2
Respiratory Rate > 60/min 1
Respiratory Rate >60/min with retractions 2
G
as
tr
oi
nt
es
ti
na
l 
D
is
tu
rb
an
ce
s
excessive sucking 1
Poor Feeding 2
Regurgitation 2
Projectile Vomiting 3
loose Stools 2
Watery Stools 3
Mas Score:41 
Total Score
Scorer's Initials
Source: Finnegan 1980.[327]
Neonatal Abstinence Syndrome Scoring Chart
Guidelines for Neonatal Abstinence Syndrome (NAS) Scoring
Score 1 for each of the following (except 1).
High pitched cry: 1. Score 2 if a cry is high-pitched at its peak, score 3 if a 
cry is high-pitched throughout.
Sleep: 2. Consider total amount of time baby was asleep between feeds.
Tremors: 3. This is a scale of increasing severity, and only one score should 
be made from the four categories. Undisturbed sleep means when the 
baby is asleep or at rest in a cot.
Increased muscle tone: 4. Score if the baby has a generalised muscle tone 
greater than the upper limit of normal.
Excoriation: 5. Score if skin excoriation occurs more than three to four 
times in 30 minutes.
Nasal flaring: 6. Score if nasal flaring is present without other evidence of 
airways disease.
Respiratory rate: 7. Score if respiratory rate of greater than 60 per minute 
is present without other evidence of airways disease.
Excessive sucking: 8. Score if the baby sucks more than average.
Poor feeding: 9. Score if the baby is very slow to feed or takes inadequate 
amounts.
Regurgitation: 10. Score only if the baby regurgitates more frequently than 
usual in newborn infants. 
Modifications for prematurity are mainly necessary in the sections on sleeping, 
e.g. a baby who needs three-hourly feeds can only sleep at most 2.5 hours 
between them. Scoring should be 1 if the baby sleeps less than two, 2 if sleeps 
less than one hour, and 3 if the baby does not sleep between feeds. Many 
premature babies require tube feeding. Babies should not be scored for poor 
feeding if tube feeding is customary for their period of gestation.
If the baby has three consecutive scores averaging more than eight (8), the child 
should be treated for NAS.
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Substance Primary mechanism of 
action 
Behavioural effects Tolerance Withdrawal Effects of prolonged 
use
ethanol Increases activity of GABA-A receptors Sedation
Impaired memory
Motor incoordination
Anxiolysis
Metabolic tolerance occurs due 
to enzyme induction 
Behavioural tolerance develops 
through learning
Tolerance also develops 
through changes to GABA-A 
receptor 
Shaking, perspiration, 
weakness, agitation, 
headache, nausea, vomiting
Seizures
Delirium tremens
Altered brain function and 
morphology 
Cognitive impairments
Decreased brain volume
Hypnotics and 
sedatives
Benzodiazepines: facilitate GABA’s 
opening of GABA-A chloride channel
Barbiturates: bind to a specific site 
on the GABA ionophore and increase 
chloride conductance
Sedation 
Anaesthesia
Motor incoordination
Cognitive impairments
Memory impairment
Develops rapidly to most 
effects (except anticonvulsant) 
due to changes in GABA-A 
receptor
Anxiety, arousal,
restlessness, insomnia, 
excitability, seizures
Memory impairment
nicotine nicotinic cholinergic receptor agonist 
Increases sodium inflow through the 
channel, causing depolarization 
Arousal, increased attention; 
concentration and memory; decreased 
anxiety, decreased appetite, stimulant-
like effects
Tolerance develops through 
metabolic factors, as well as 
receptor changes
Irritability, hostility, anxiety, 
dysphoria, depressed mood, 
decreased heart rate, 
increased appetite
Health effects due to smoking 
are well-documented 
Difficult to dissociate effects of 
nicotine from other components 
of tobacco
Opioids Mu and delta opioid receptor agonists euphoria, analgesia, sedation, 
respiratory depression
Short-term and long-term 
receptor desensitization 
Adaptations in intracellular 
signalling mechanisms
Watering eyes, runny 
nose, yawning, sweating, 
restlessness, chills, cramps, 
muscle aches
long-term changes in opioid 
receptors and peptides 
Adaptations in reward, learning, 
stress responses
Cannabinoids CB1 receptor agonists Relaxation, increased sensory 
awareness, decreased short-term 
memory, motor incoordination, 
analgesia, antiemetic and antiepileptic 
effects, increased appetite
Develops rapidly to most 
effects
Rare, perhaps due to long 
half-life of cannabinoids
Cognitive impairments, risk of 
relapse and exacerbation of 
mental illness
Cocaine Monoamine (dopamine, 
norepinephrine, serotonin) transporter 
blocker (increases monoamines in 
synaptic cleft)
Increased alertness, energy, motor 
activity, feelings of competence; 
euphoria, anxiety, restlessness, 
paranoia
Perhaps short-term acute 
tolerance
not much, except “post-
high down”
Cognitive deficits, Abnormalities 
on PeT with orbitofrontal 
cortex Impaired motor function 
Decreased reaction times eeG 
abnormalities
Cerebral ischaemia, infarcts, 
haemorrhages
Amphetamines Increased release of dopamine 
from nerve terminals via dopamine 
transporter
not dependent upon action potentials
Inhibits monoamine oxidase (MAO)
Increased alertness, arousal, energy, 
motor activity, speech, self-confidence, 
concentration, feelings of well-being; 
decreased hunger, increased heart 
rate, increased respiration, euphoria
Develops rapidly to behavioural 
and physiological effects
Fatigue, increased appetite, 
irritability, emotional 
depression, anxiety 
Sleep disturbances, anxiety, 
decreased appetite, increased 
blood pressure; decreased 
brain dopamine, precursors, 
metabolites and receptors
ecstasy Blocks serotonin reuptake Increased self-confidence, empathy, 
understanding, sensations of intimacy, 
increased communication, euphoria, 
increased energy
May develop in some 
individuals
nausea, muscle stiffness, 
headache, loss of appetite, 
blurred vision, dry mouth, 
insomnia, depression, 
anxiety, fatigue, difficulty 
concentrating
neurotoxic to brain serotonin 
systems, leads to behavioural 
and physiological consequences
Volatile solvents Most likely GABA-A receptor mediated Dizziness, disorientation, euphoria, 
light-headedness, increased 
mood, hallucinations, delusions, 
incoordination, visual disturbances, 
anxiolysis, sedation
Some tolerance develops 
(difficult to estimate)
Increased susceptibility to 
seizures
Changes in dopamine receptor 
binding and function
Decreased cognitive function 
Psychiatric and neurological 
sequelae 
Hallucinogens Varies:
lSD: serotonin autoreceptor agonist
PCP: nMDA glutamate receptor 
antagonist
Atropinics: muscarinic cholingergic 
receptor antagonists
Increased heart rate, blood pressure, 
body temperature; decreased 
appetite, nausea, vomiting, motor 
incoordination, papillary dilatation, 
hallucinations
Tolerance develops rapidly to 
physical and psychological 
effects
no evidence Acute or chronic psychotic 
episodes, flashbacks or re-
experiencing of drug effects long 
after drug use
Source: WHO 2004[9]
Annex 11 Summary of characteristics of selected psychoactive 
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Specific cautions regarding the use of methadone and 
buprenorphine
Intoxicated or sedated patients 
Methadone and buprenorphine should not be given to patients showing signs 
of intoxication or sedation, due to the risk of sedative overdose. The risks of 
methadone and buprenorphine use in opioid-dependent patients who are 
frequently intoxicated with sedatives such as alcohol and benzodiazepines, 
needs to be balanced against the benefits of treatment. 
Severe hepatic/renal dysfunctions 
The metabolism and elimination of methadone and buprenorphine may be 
affected by either hepatic or renal dysfunction in which case the dose or dosing 
frequency should be adjusted accordingly. 
Respiratory insufficiency
In patients with respiratory insufficiency, methadone and buprenorphine may 
reduce the respiratory drive. 
Psychosis
In patients with active psychosis the risks and benefits of methadone and 
buprenorphine need to be carefully considered.
Methadone maintenance treatment
Induction
The initial daily dose of methadone should depend on the level of neuroadaptation 
to opioids. It should generally not be more than 20 mg, except in cases of 
higher tolerance to opioids, and even then should not be more than 30 mg. 
For people with low or uncertain levels of tolerance to opioids, the initial daily 
dose should be 10–15 mg. Caution should be exercised with initial methadone 
doses more than 20 mg daily. Observing patients 2–3 hours after their dose 
enables the best assessment of the degree of tolerance to opioids. If patients 
have significant opioid withdrawal symptoms 2–3 hours after their dose of 
methadone, then they should be given an additional 5–10 mg methadone and 
a corresponding increase in their next daily dose. If patients are sedated after 
their dose of methadone, then the next daily dose should be reduced (and the 
patient monitored until they are no longer sedated, or treated for overdose, if 
necessary).
Patients should be observed each day prior to dosing. Patients who are sedated 
or intoxicated should not be given further doses methadone until the sedation 
has abated.
Precautions for commencing methadone include: high-risk polydrug use, mental 
illness, low levels of neuroadaptation to opioids (i.e. recent incarceration), and 
significant concomitant medical problems. 
Stabilization
Once patients are taking opioid agonist maintenance treatment without 
intoxication or significant withdrawal symptoms, the aim is to titrate the 
methadone dose to its most effective level. The daily dose of methadone should 
then be increased by 5–10 mg every few days, as needed, to reduce cravings 
for opioids, and illicit opioid use. The dose should not be increased by more 
than 20 mg per week.
Patients should be reviewed prior to each dose increase. 
The average effective dose of methadone is 60–120 mg. 
Switching from buprenorphine to methadone
Commence methadone 24 hours after the last dose of buprenorphine. 
From buprenorphine doses of 8 mg daily and above, commence with 30 mg 
methadone daily. From buprenorphine doses of 4-8 mg daily, commence with 
20-30 mg methadone daily. With buprenorphine doses below 4 mg daily, 
commence with less than 20 mg methadone daily.
Missed methadone doses
If one of two doses are missed the patient can be maintained on the same 
methadone dose. 
If three doses are missed the next methadone dose should be reduced by 25% 
to adjust for the possible reduction in tolerance. If it is well tolerated, doses can 
return to previous dose levels. If four doses are missed the next dose should be 
reduced by 50% to adjust for the potential reduction in tolerance. If the dose 
is well tolerated doses can be increased over several days to previous levels. 
If more than four doses are missed, patients should resume induction from 
baseline. 
Frequency of doses
Methadone can be administered daily for most patients. In approximately 
30% of patients, methadone does not produce effects that are evenly 
sustained over 24 hours. This can also occur in pregnancy and when 
methadone is used in combination with medications that increase its 
metabolism. In such cases methadone can be administered twice a day, 
dividing the dose in two. When it is too difficult to pick up the medication 
twice a day, or when take-home doses are not suitable, then buprenorphine 
should be considered. Increasing the dose of methadone will increase the 
duration of action to some extent, but the main determinant is the rate of 
metabolism of methadone.
Reducing dosage and stopping treatment. 
The decision to discontinue therapy with methadone should be made as part 
of a comprehensive treatment plan. Evidence suggests that it is associated 
with a risk of relapse to illicit opioid use and patients should be informed of 
these risks. Research is lacking on factors predicting successful withdrawal 
from agonist maintenance, however these may include a brief drug-use history 
prior to opioid agonist maintenance, no previous treatments prior to opioid 
agonist treatment, current employment, stable accommodation, cessation of 
illicit opioid use, cessation of other drug use (including cannabis), and a positive 
change of social and physical environment since starting treatment.
The daily dose can be generally reduced by up to 2.5 to 5 mg per week without 
severe opioid withdrawal symptoms. Patients should be reviewed frequently 
during dose reductions and adjustments to the dose made in accordance with 
clinical need.
Methadone for opioid detoxification
Commence with 10-20 mg methadone daily, according to the severity of 
dependence and degree of tolerance to opioids. Reduce the daily methadone 
dose by 1–2 mg per day. Patients will continue to experience mild opioid 
withdrawal symptoms in the week after methadone is ceased.
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Buprenorphine maintenance treatment
Induction
An adequate maintenance dose, titrated to clinical effectiveness, should be 
achieved as rapidly as possible to prevent undue opioid withdrawal symptoms 
due to inadequate dosage. 
Prior to induction, consideration should be given to the nature of opioids being 
used (i.e. long or short-acting), the time since last opioid use, and the degree or 
level of opioid dependence (i.e. opioid tolerance).
Patients taking street heroin (or other short-acting opioids). When treatment starts, the 
dose of buprenorphine should be taken at least six hours after the patient last 
used opioids, or when the early signs of withdrawal appear. The recommended 
starting dose is 4 mg buprenorphine on day 1, with a possible additional 4 mg 
depending on the individual patient’s requirement. 
Patients on methadone. Before starting treatment with buprenorphine, the 
maintenance dose of methadone should be reduced to 30 mg/day. The first 
dose of buprenorphine should be taken at least 24 hours after the patient last 
used methadone. The initial 4 mg buprenorphine induction dose should ideally 
be administered when withdrawal signs are evident. 
Precautions for commencing buprenorphine include: high-risk polydrug use, 
mental illness, low levels of neuroadaptation to opioids (i.e. recent incarceration), 
and significant concomitant medical problems. 
Stabilization
The dose of buprenorphine should be increased progressively according to the 
clinical effect in the individual patient. It is recommended to use 8–24 mg daily, 
the daily dose should not exceed 32 mg. The dosage is adjusted according to 
reassessments of the clinical and psychological status of the patient. 
Less than daily dosing with buprenorphine
After a satisfactory period of stabilization has been achieved the frequency of 
dosing may be decreased to dosing every other day at twice the individually 
titrated daily dose. For example, a patient stabilized to receive a daily dose of 8 mg 
may be given 16 mg on alternate days, with no medication on the intervening 
days. However, the dose given on any one day should not exceed 32 mg. 
In some patients, after a satisfactory period of stabilization has been achieved, 
the frequency of dosing may be decreased to three times a week (for example on 
Monday, Wednesday and Friday). The dose on Monday and Wednesday should be 
twice the individually titrated daily dose, and the dose on Friday should be three 
times the individually titrated daily dose, with no medication on the intervening 
days. However, the dose given on any one day should not exceed 32 mg. 
Transfer to methadone
Commence methadone 24 hours after the last dose of buprenorphine. 
From buprenorphine doses of 8 mg daily and above, commence with 30 mg 
methadone daily. From buprenorphine doses of 4–8 mg daily, commence with 
20–30 mg methadone daily. With buprenorphine doses below 4 mg daily, 
commence with less than 20mg methadone daily. 
Reducing dosage and stopping treatment
The decision to discontinue therapy with buprenorphine should be made as 
part of a comprehensive treatment plan. Studies suggest that it is associated 
with a risk of relapse to illicit opioid use and patients should be informed of 
these risks. Research is lacking on factors predicting successful withdrawal 
from opioid agonist maintenance; however, these factors may include a 
brief drug-use history before opioid agonist maintenance, no previous 
treatments before opioid agonist treatment, current employment, stable 
accommodation, cessation of illicit opioid use, cessation of other drug use 
(including cannabis), and a positive change of social and physical environment 
since starting treatment.
The daily dose of buprenorphine can generally be reduced by up to 4–8 mg 
per week without severe opioid withdrawal symptoms. Patients should be 
reviewed frequently during dose reductions and adjustments to the dose made 
in accordance with clinical need. 
Buprenorphine for opioid detoxification
Different dose schedules have been used for detoxification from opioids using 
buprenorphine. One suggested schedule is:
Day 1 6 mg•	
Day 2 10 mg +/- 2 mg•	
Day 3  10 mg +/- 2 mg•	
Day 4 8 mg +/- 2 mg•	
Day 5 4 mg.•	
Alpha 2 adrenergic agonists for opioid detoxification
Alpha adrenergic agonists can cause significant hypotension and bradycardia 
and should not be the treatment of choice for the management of opioid 
withdrawal in elderly patients and patients with coronary insufficiency, 
ischaemic heart disease, bradycardia, cerebrovascular disease, pregnancy and 
breastfeeding. It is recommended to monitor the pulse and blood pressure when 
using clonidine, and to withhold or reduce the dose if the patient experiences 
symptoms of reduced circulation (e.g. dizziness on standing) or if the pulse or 
the blood pressure become too low (e.g. pulse less than 50 bpm, blood pressure 
less than 90/60 mmHg).
Clonidine
In the management of opioid withdrawal, clonidine is generally 
administered in doses of up to 100–300 mcg, three or four times daily, up 
to a maximum of 10–17 mcg/kg/day, reducing after the first two days and 
finishing by day 4 or 5. In an inpatient or residential setting, the initial dose 
should be in the range of 1–2 mcg/kg, with subsequent doses adjusted 
accordingly.
In outpatient settings, where blood pressure is not being monitored, lower 
doses should be used, with maximum daily doses of 450–900 mcg, according 
to the patient’s weight and severity of opioid withdrawal. 
Lofexidine
Initially the dose is 0.4–0.6 mg twice daily, increasing as necessary and tolerated 
to a maximum of 2.4 mg daily, in 2–4 divided doses. Treatment should be for 
7–10 days, followed by a gradual withdrawal of 2–4 days. 
Guanfacine
Initially the dose should be 0.25 to 0.5 mg per day, increased as necessary and 
tolerated to 1-2 mg daily (in 1–4 divided doses) for 3–5 days then tapering over 
2–3 days. 
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Other treatments for opioid withdrawal
Many different medications can be used in combination with alpha-2 agonists 
to manage specific symptoms of opioid withdrawal (e.g. benzodiazepines for 
anxiety and insomnia, anti-emetics for nausea and vomiting, and paracetamol 
and non-steroidal anti-inflammatory drugs [NSAIDs] for muscle aches). Detailed 
guidance on the use of these medications is beyond the scope of these 
guidelines.
Patients with diarrhoea, vomiting and excessive sweating can become 
significantly dehydrated and occasionally aggressive fluid replacement may be 
required. 
Naltrexone treatment
Induction phase
Naltrexone commences after detoxification and after the patient has been free 
of opioids for 7 days (for short-acting opioids) or 10 days (for methadone). 
This should be verified at least by a negative urine drug screen and also by a 
negative naloxone challenge test, if in doubt. The standard maintenance dose 
is 50 mg orally per day. If patients experience gastrointestinal side effects, 
these may be helped by reducing the dose to 25 mg naltrexone for a few 
days. 
Maintenance phase
If patients use heroin on a day that they have taken naltrexone, they can 
continue to take naltrexone the next day. 
If a patient misses a day of naltrexone and takes heroin or other opioids, they 
should either recommence naltrexone at the earliest opportunity or wait 7 days 
and recommence as per normal induction. If they recommence naltrexone 
straight away they will experience a reduced withdrawal syndrome. To predict 
the severity of the withdrawal syndrome, patients can be given a naloxone 
challenge. Alpha-2 adrenergic agonists can be used to manage the withdrawal 
symptoms that occur. 
If a patient misses more than one day of naltrexone and takes heroin or other 
opioids, they may experience severe opioid withdrawal upon naltrexone 
recommencement and patients should be advised to wait 7 days or alternatively 
to consider opioid agonist maintenance therapy. 
There is no good evidence on the optimal duration of treatment. It is recommended 
that this be individually determined according to the specific clinical situation. 
Naltrexone can be ceased without a withdrawal syndrome. Commencing 
opioid agonist maintenance therapy from naltrexone should proceed with great 
caution because the tolerance to opioids will be very low. 
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Abstinence
Refraining from drug use. A person taking prescribed methadone but no illicit 
opioids would still be described as abstinent. The term “abstinence” should not 
be confused with the term “abstinence syndrome”, which refers to withdrawal 
syndrome.
Agonist maintenance therapy, opioid
Treatment of drug dependence by prescribing a substitute drug to which the 
patient is cross-dependent and cross-tolerant. Examples of agonist maintenance 
therapies are methadone and buprenorphine to treat heroin dependence, and 
nicotine gum to replace tobacco smoking. The goals of agonist maintenance 
therapy are to eliminate or reduce use of a particular substance (especially if it 
is illegal), reduce the harm and health risks of a particular method of substance 
administration (e.g. risk of disease from needle-sharing) and reduce the social 
consequences of drug dependence. Agonist maintenance therapy can last from 
several months to more than 20 years, and is often accompanied by other 
treatment (e.g. psychosocial treatment). It is sometimes distinguished from 
tapering-off therapy. (See opioid withdrawal syndrome.)
Bloodborne diseases
Diseases such as HIV and hepatitis B and C, which are spread by blood-to-blood 
contact (e.g. needle sharing).
Convention on Psychotropic Substances, 1971
The Convention on Psychotropic Substances, 1971 is the second of the 
international drug control treaties, supplementing the Single Convention on 
Narcotic Drugs, 1961. It aims to control psychotropic substances, as defined 
under this convention, and to prevent their abuse. The Convention outlines a 
number of responsibilities for parties. The International Narcotics Control Board 
(INCB), which submits its reports to the Economic and Social Council (ECOSOC) 
through the Commission on Narcotics Drugs (CND) is responsible for monitoring 
the compliance by governments with the 1971 Convention, ensuring on the one 
hand that psychotropic substances are available for medical and scientific use, 
and on the other hand that diversion from licit sources to illicit traffic does not 
occur. Buprenorphine is listed in the Convention on Psychotropic Substances.
Dependence
As a general term, the state of needing or depending on something or someone 
for support or to function or survive. As applied to opioids, implies the need for 
repeated doses of a drug to feel good or to avoid feeling bad. 
In 1964, a World Health Organization (WHO) Expert Committee introduced 
the term “dependence” to replace addiction and habituation. The term can 
generally be used with reference to dependence on any psychoactive drugs 
(e.g. drug dependence, chemical dependence, substance dependence), or with 
specific reference to a particular drug or class of drugs (e.g. opioid dependence). 
Although ICD-10 has a specific definition for dependence, described in terms 
applicable across drug classes, the symptoms of dependence will vary for each 
specific drug.
Dependence often refers to both the physical and psychological elements of 
drug dependence. More specifically, psychological or psychic dependence refers 
to the experience of impaired control over drug use (including cravings and 
compulsions to use drugs) while physiological or physical dependence refers 
to tolerance and withdrawal symptoms (see neuroadaptation). However, in 
biologically oriented discussion, dependence is often used to refer only to 
physical dependence.
Dependence or physical dependence is also used in a narrower sense in 
the psychopharmacological context, to refer solely to the development of 
withdrawal symptoms on cessation of drug use.
Detoxification
The process of an individual being withdrawn from the effects of a psychoactive 
substance. When referring to a clinical procedure, detoxification refers to a 
withdrawal process that is carried out in a safe and effective manner, minimizing 
the withdrawal symptoms. The facility where this takes place may be called a 
detoxification or “detox” centre.
Harm reduction
In the context of alcohol or other drugs, harm reduction (or harm minimization) 
describes policies or programmes that focus directly on reducing the harm 
resulting from the use of alcohol or drugs. The term is used particularly to refer 
to policies or programmes that aim to reduce the harm without necessarily 
changing the underlying drug use; examples include needle and syringe 
exchanges to counteract needle sharing among heroin users, and self-inflating 
airbags in automobiles to reduce injury in accidents, particularly as a result of 
drink–driving. Harm-reduction strategies cover a wider range of activities than 
simple reduction of supply and demand.
Harmful use of opioids
A pattern of psychoactive substance use that is causing damage to health (ICD-
10, code F11.1). The damage may be physical (e.g. in the cases of hepatitis from 
the self-administration of injected psychoactive substances) or mental. Harmful 
use often, but not always, has adverse social consequences; social consequences 
alone, however, are not sufficient to justify a diagnosis of harmful use.
The term was introduced in ICD-10 and replaced “non-dependent use” as a 
diagnostic term.
Narcotic drug
Narcotic drugs are the substances included in Schedules I and II of the Single 
Convention on Narcotic Drugs, 1961, (see below), whether natural or synthetic. 
Methadone is a narcotic drug.
Neuroadaptation
The changes in neurones associated with both tolerance and the appearance of 
withdrawal syndrome. Individuals can exhibit neuroadaptation without showing 
the cognitive or behavioural manifestation of dependence. For example, surgical 
patients given opioid substances to relieve pain may sometimes experience 
withdrawal symptoms but may not recognize these symptoms or have any 
desire to continue taking drugs.
Opiate
One of a group of alkaloids derived from the opium poppy (Papaver somniferum), 
with the ability to induce analgesia, euphoria, and, in higher doses, stupor, 
coma, and respiratory depression. The term excludes synthetic opioids.
Opioid
The generic term applied to alkaloids from the opium poppy (Papaver 
somniferum), their synthetic analogues, and compounds synthesized in the 
body. All of these substances interact with the same specific receptors in the 
brain, have the capacity to relieve pain and produce a sense of well-being 
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(euphoria). The opium alkaloids and their synthetic analogues also cause stupor, 
coma and respiratory depression in high doses.
Opium alkaloids and their semisynthetic derivatives include morphine, 
diacetylmorphine (diamorphine, heroin), hydromorphine, codeine and 
oxycodone. Synthetic opioids include levorphanol, propoxyphene, fentanyl, 
methadone, pethidine (meperidine) and the agonist–antagonist pentazocine. 
Endogenously occurring compounds with opioid actions include the endorphins 
and enkephalins.
The most commonly used opioids (such as morphine, heroin, hydromorphine, 
methadone and pethidine) bind preferentially to the μ-receptors; they produce 
analgesia, mood changes (e.g. euphoria, which may change to apathy or 
dysphoria), respiratory depression, drowsiness, psychomotor retardation, slurred 
speech and impaired concentration, memory and judgement.
Physical consequences of opioid use (mostly resulting from intravenous 
administration) include hepatitis B, hepatitis C, HIV, septicaemia, endocarditis 
(inflammation of the inner layer of the heart), pneumonia and lung abscess, 
thrombophlebitis (blood clots causing vein inflammation) and rhabdomyolysis 
(breakdown of muscle fibres). Psychological and social impairment is common, 
reflecting the illicit nature of non-medical opioid use.
Opioid, endogenous
Any of the naturally occurring brain neuropeptides, which include at least two 
major groups–the enkephalins and the endorphins. Both can interact with 
opiate-binding sites (receptors) and thus may modulate the perception of pain. 
Endorphins also appear to modulate mood and responses to stressful stimuli 
(see opioid).
Opioid intoxication 
A condition that follows the administration of opioids, resulting in disturbances 
in the level of consciousness, cognition, perception, judgement, affect, behaviour 
or other psychophysiological functions and responses. These disturbances are 
related to the acute pharmacological effects of, and learned responses to, 
opioids. With time, these disturbances resolve, resulting in complete recovery, 
except where tissue damage or other complications have arisen.
Intoxication depends on the type and dose of opioid, and is influenced by 
factors such as an individual’s level of tolerance. Individuals often take drugs 
in the quantity required to achieve a desired degree of intoxication. Behaviour 
resulting from a given level of intoxication is strongly influenced by cultural and 
personal expectations about the effects of the drug.
Acute intoxication is the ICD-10 term for intoxication of clinical significance 
(F11.0). Complications may include trauma, inhalation of vomitus, delirium, coma 
and convulsions, depending on the substance and method of administration.
Opioid overdose
The use of opioids in amounts that produce acute adverse physical or mental 
effects. Deliberate overdose is a common method of suicide. In absolute 
numbers, overdoses of licit opioids tend to be more common than those of illicit 
opioids. Overdose may produce transient or lasting effects, or death; the lethal 
dose of a particular opioid varies with the individual and with circumstances.
Opioid-use disorders
A group of conditions associated with the use of opioids. In ICD-I0, section 
F11.0–9 (“Mental and behavioural disorders due to psychoactive substance 
use (opioids)”) contains a wide variety of disorders of different severity and 
clinical form, all having in common the use of opioids, which may or may not 
have been medically prescribed. The clinical states that may occur include acute 
intoxication, harmful use, dependence syndrome, withdrawal syndrome (or 
withdrawal state), withdrawal state with delirium, psychotic disorder, late-onset 
psychotic disorder and amnesic syndrome.
Opioid withdrawal syndrome
Over time, morphine and its analogues induce tolerance and neuroadaptive 
changes that are responsible for rebound hyperexcitability when the drug is 
withdrawn. The withdrawal syndrome includes craving, anxiety, dysphoria, 
yawning, sweating, piloerection (gooseflesh), lacrimation (excessive tear 
formation), rhinorrhoea (running nose), insomnia, nausea or vomiting, diarrhoea, 
cramps, muscle aches and fever. With short-acting drugs, such as morphine or 
heroin, withdrawal symptoms may appear within 8–12 hours of the last dose 
of the drug, reach a peak at 48–72 hours, and clear after 7–10 days. With 
longer acting drugs, such as methadone, onset of withdrawal symptoms may 
not occur until 1–3 days after the last dose; symptoms peak between the third 
and eighth day and may persist for several weeks, but are generally milder than 
those that follow morphine or heroin withdrawal after equivalent doses.
Psychosocial intervention
Any non-pharmacological intervention carried out in a therapeutic context at 
an individual, family or group level. Psychosocial interventions may include 
structured, professionally administered interventions (e.g. cognitive behaviour 
therapy or insight oriented psychotherapy) or non-professional interventions 
(e.g. self-help groups and non-pharmacological interventions from traditional 
healers).
Psychotropic substance
Psychotropic substances are the substances, natural or synthetic, or any natural 
material in Schedules I, II, III or IV of the Convention on Psychotropic Substances, 
1971, (see above). Among others, buprenorphine and benzodiazepines are 
psychotropic substances.
Single Convention on Narcotic Drugs, 1961
The Single Convention on Narcotic Drugs, 1961 (as amended by the 1972 
Protocol) is the main international drug control treaty. Replacing a number of 
previous conventions, it aims to limit the cultivation, production, manufacture 
and use of narcotic drugs to medical and scientific purposes, while ensuring 
their availability for such purposes. The convention lists a number of narcotic 
drugs, and outlines the responsibilities of parties with regard to the production, 
manufacture, distribution and use of these drugs in their countries. The INCB, 
which submits its reports to ECOSOC through the CND, is responsible for 
monitoring the compliance of governments with the provisions of this treaty. 
Methadone is listed in the Single Convention on Narcotic Drugs, 1961.
Tolerance
A decrease in response to a drug dose that occurs with continued use. If an 
individual is tolerant to a drug, increased doses are required to achieve the 
effects originally produced by lower doses. Both physiological and psychosocial 
factors may contribute to the development of tolerance. Physiological factors 
include metabolic and functional tolerance. In metabolic tolerance, the body 
can eliminate the substance more readily, because the substance is metabolized 
at an increased rate. In functional tolerance, the central nervous system is less 
sensitive to the substance. An example of a psychosocial factor contributing 
to tolerance is behavioural tolerance, where learning or altered environmental 
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constraints change the effect of the drug. Acute tolerance refers to rapid, 
temporary accommodation to the effect of a substance following a single dose. 
Reverse tolerance, also known as sensitization, refers to a condition where the 
response to a substance increases with repeated use. Tolerance is one of the 
criteria of the  dependence syndrome.
Withdrawal syndrome (abstinence syndrome, withdrawal reaction, 
withdrawal state)
A group of symptoms of variable clustering and degree of severity that 
occur on cessation or reduction of use of a psychoactive substance that has 
been taken repeatedly, usually for a prolonged period or in high doses (ICD-
10 code F1x.3). Withdrawal syndrome may be accompanied by signs of 
physiological disturbance. It is one of the indicators of dependence syndrome, 
and is the defining characteristic of the psychopharmacological definition of 
dependence.
The onset and course of withdrawal syndrome are time limited and relate to 
the type of substance and dose being taken immediately before cessation 
or reduction of use. Typically, the features of withdrawal syndrome are the 
opposite of acute intoxication.
Opioid withdrawal is accompanied by rhinorrhoea (running nose), lacrimation 
(excessive tear formation), aching muscles, chills, piloerection (gooseflesh) and, 
after 24–48 hours, muscle and abdominal cramps. Drug-seeking behaviour is 
prominent and continues after the physical symptoms have abated.
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The Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid 
Dependence review the use of medicines such as methadone, buprenorphine, naltrexone 
and clonidine in combination with psychosocial support in the treatment of people 
dependent on heroin or other opioids. Based on systematic reviews of the literature and 
using the GRADE approach to determining evidence quality, the guidelines contain specific 
recommendations on the range of issues faced in organizing treatment systems, managing 
treatment programmes and in treating people dependent on opioids. 
Developed in collaboration with internationally acclaimed experts from the different 
regions of the globe, the Guidelines for the Psychosocially Assisted Pharmacological 
Treatment of Opioid Dependence should be of interest to policy makers, programme 
managers, and clinicians everywhere who seek to alleviate the burden of opioid 
dependence.
